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AIDP acute inflammatory demyelinating polyneuropathy
AMAN acute motor axonal neuropathy
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ASC antibody-secreting cell
AU arbitrary unit
BALF bronchoalveolar lavage fluid
BBB blood-brain barrier
BBE Bickerstaff brain stem encephalitis
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Btk Bruton tyrosin kinase
Btk– mice partially B cell-deficient mice (see Chapter 3)
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CD cluster of differentiation
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CLN cervical lymph node
CNS central nervous system
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DC dendritic cells
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General introduction and outline of the thesis
INTRODUCTION TO MYCOPLASMA PNEUMONIAE
Pneumonia is the single largest infectious cause of death in children worldwide, and 
caused by a large number of infectious agents, including viruses, bacteria, and fungi.1 
Streptococcus pneumoniae and Mycoplasma pneumoniae are the two major bacterial causes 
of pneumonia in hospitalized children.2,3 Over the past three decades, S. pneumoniae 
conjugate vaccines have markedly reduced the incidence of pneumococcal pneumonia.4 
Th is thesis focuses on M. pneumoniae that was recently reported as the most common 
bacterial cause of community-acquired pneumoniae (CAP) in hospitalized children in 
the U.S. (Figure 1).5
Figure 1. Pathogens detected in U.S. children with community-acquired pneumonia (CAP) requiring hos-
pitalization (2010–2012).
*For detection method see Jain et al.5 Darker and lighter shading in the bar graph indicates single and 
co-pathogen detection, respectively. Proportions of detections (single and co-detection) by age group are 
depicted on the pie graphs. Abbreviations: AdV, adenovirus; CoV, coronavirus; Flu, infl uenza A or B virus; 
HMPV, human metapneumovirus; HRV, human rhinovirus; M.pn., M. pneumoniae; PIV, parainfl uenza virus; 
RSV, respiratory syncytial virus; S.pn., S. pneumoniae. Reproduced with permission from Jain et al.,5 Copy-
right Massachusetts Medical Society.
M. pneumoniae infection: respiratory tract disease and extrapulmonary 
manifestations
Th e clinical entity of “atypical” pneumonia was recognized in the 1930s many years be-
fore M. pneumoniae was discovered.6 Th e term separated this entity of pneumonia from 
Chapter 1
14
classical pneumococcal pneumonia due to its lack of response to available antibiotics 
and the distinct clinical presentation without typical lobar pneumonia and a less severe 
disease course. That is why the term “walking pneumonia” has been introduced to denote 
this mild form of pneumonia.
It was in a patient with “atypical” pneumonia in 1944, where M. pneumoniae was first 
isolated from sputum in tissue culture by Eaton et al.7 At that time, it was believed to be a 
virus because it was resistant to penicillin and sulfonamides and passed through bacteria-
retaining filters. Experiments with Marine recruits and adult prisoners demonstrated that 
the so-called Eaton agent caused lower respiratory tract infections (LRTIs) in humans.8,9 
In 1963, it was first cultured on cell-free medium and classified as M. pneumoniae.10,11 
Today we know that mycoplasmas are prokaryotes that lack a cell wall and represent 
the smallest self-replicating organisms (Figure 2). With a size of 816,394 base pairs, the 
genome of M. pneumoniae is at least five times smaller than that of Escherichia coli.13 The 
absence of a cell wall and the specialized attachment organelle facilitate close contact 
with the host respiratory epithelium, which supplies the bacterium with the necessary 
nutrients for its growth and proliferation.
M. pneumoniae causes both upper respiratory tract infections (URTIs) and LRTIs, with 
CAP as the major burden of disease. Although M. pneumoniae infections are generally 
?????
Figure 2. M. pneumoniae morphology in vitro.
Scanning electron micrograph of M. pneumoniae strain Mac (subtype 2), performed by Steve Gschmeissner 
(Bedford, UK). Reproduced with permission from Meyer Sauteur et al.,12 Frontiers.
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mild and self-limiting, patients of every age can develop severe and fulminant disease.14 
M. pneumoniae can also cause extrapulmonary manifestations that affect almost every 
organ.15
Epidemiology
M. pneumoniae is transmitted by respiratory droplets through close contact. The in-
cubation period can be as long as 1 to 3 weeks. Outbreaks have been reported within 
families, schools, universities, institutions, camps, and military bases. Family members 
of index patients with acute respiratory infection and detection of M. pneumoniae in the 
upper respiratory tract (URT) were found positive in 15% by polymerase chain reaction 
(PCR).16 Thereof, 75% were <16 years of age and 44% did not develop any respiratory 
symptoms. At universities, the largest outbreak within 35 years in the U.S. was observed 
during September 1–December 4, 2012, where a total of 83 CAP cases were identified 
among students, and 12 out of 19 tested cases (63%) were positive for M. pneumoniae by 
real-time PCR.17
Outbreaks appear mainly during M. pneumoniae epidemics that occur in 3–7 year 
cycles, in addition to a background endemic pattern.18 Data on the most recent epidemic 
in Europe (2015/2016) have not been published yet; however, the epidemic before had 
a peak incidence in Finland of 145/100,000 cases in 2011.19,20 The cyclic occurrence of 
epidemics may be facilitated by a decreasing herd immunity and different M. pneumoniae 
genotypes circulating in the human population.18 The two major circulating genotypes, or 
subtypes, of M. pneumoniae are indicated as subtype 1 and 2. Differences between these 
subtypes in the amino acid sequence of the major adhesion protein P1 are believed to play 
a role in the epidemiology of infections with M. pneumoniae.21,22 The differences between 
the 169 kDa P1 proteins of subtype 1 and 2 isolates were found to be concentrated in 
two specific amino acid stretches within the protein. These regions are encoded by two 
DNA elements within the P1 gene, i.e., repetitive elements RepMP2/3 and RepMP4. 
The RepMP2/3 and RepMP4 are not unique to the P1 gene, but are also found at other 
sites within the bacterial genome.23 Homologous recombination events between these 
repetitive elements, which are similar to each other, but not identical, may form the basis 
of antigenic variation of the P1 protein of M. pneumoniae.21 While such recombination 
events may induce antigenic variation within subtype 1 or subtype 2 strains, M. pneu-
moniae strains cannot switch from one subtype to the other, as the entire set of RepMP 
elements found in one subtype differs significantly from those found in the other subtype. 
Moreover, changes in the proportion of the two subtypes of M. pneumoniae were not 
observed between 2003–2012 in Europe.19
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Infection
Respiratory disease
Although CAP is the major burden of disease, milder clinical presentations of M. pneu-
moniae respiratory infections may be much more common than CAP. These include acute 
bronchitis and URTIs.24,25 M. pneumoniae could be detected by PCR and/or serology in 
24% of non-streptococcal pharyngitis cases.25
It is estimated that 3–10% of children with M. pneumoniae respiratory infection develop 
CAP and that <5% of CAP cases are severe enough to require hospitalization.3 Between 
1963–1975, M. pneumoniae was detected by culture of respiratory specimens and/or a 
4-fold rise in complement fixation test (CFT) in 15–20% of radiologically confirmed CAP 
cases in Seattle, U.S.26 In subsequent etiological studies, M. pneumoniae accounted for 
4–39% of the isolates identified by PCR and/or serology in children with CAP admitted to 
the hospital.2,27-29 M. pneumoniae was first reported as the most common bacterial cause 
of CAP in children requiring hospitalization in a U.S. multicenter study from 2011–2012 
in Nashville and Salt Lake City.5 In this study, M. pneumoniae could be detected by PCR 
in 178 (8%) out of 2179 cases with CAP, whereas S. pneumoniae was found in 79 (4%) 
cases. Co-existence of M. pneumoniae with other pathogens was found in 28% of the 
patients.5
Manifest URTIs and/or LRTIs with M. pneumoniae occur at all ages.26 Recent obser-
vations have indicated that M. pneumoniae has also a relatively high prevalence in the 
respiratory tract of children <5 years.28,30 M. pneumoniae CAP, however, was reported to 
be most frequent among school-aged children from 5–15 years of age, with a decline after 
adolescence and tapering off in adulthood.26 This notion was corroborated in the recent 
CAP study in the U.S., where M. pneumoniae was detected significantly more frequent in 
children ≥5 years of age than in younger children (19% vs. 3%; Figure 1).5
In addition to the presentation at school-age, children with CAP due to M. pneumoniae 
have been found to present with a significantly longer duration of fever compared to 
other children with CAP.31 Other symptoms that may be associated with M. pneumoniae 
CAP are the absence of wheeze and the presence of chest pain.32 However, there is still 
a paucity of high quality data regarding clinical signs and symptoms associated with M. 
pneumoniae infections. A recent Cochrane review32 therefore concluded that the absence 
or presence of individual clinical symptoms or signs cannot be used to help clinicians 
accurately diagnose M. pneumoniae in children and adolescents with CAP.
Pathogenic effects in the respiratory tract may be caused by M. pneumoniae either 
directly (by active infection), indirectly (by infection-induced immune mechanisms), or 
both (Figure 3).33 M. pneumoniae causes direct injury through the generation of activated 
oxygen. A potential candidate protein of M. pneumoniae that may be involved in causing 
direct damage to the respiratory tract is a pertussis toxin-like protein termed community-
acquired respiratory distress syndrome (CARDS) toxin.34,35 A recombinant version of the 
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CARDS toxin has been shown to bind with high affinity to surfactant protein A and to 
exhibit mono-ADP ribosyltransferase and vacuolating activities, which causes disruption 
of the respiratory epithelium in animal models.34
In addition to the direct damage resulting from infection by M. pneumoniae, the im-
munological response following infection generates inflammatory reactions that may 
cause pulmonary and extrapulmonary symptoms. More severe symptoms of CAP have 
been observed in older children and adolescents.3 This suggests that the age-dependent 
magnitude and nature of inflammatory responses in childhood may be a major factor 
contributing to the development of M. pneumoniae-associated disease, similar to what is 
observed e.g. in infectious mononucleosis or rheumatic fever. In fact, the severity of M. 
pneumoniae CAP in children was closely associated with increased concentrations of in-
terleukin (IL)-8 and IL-18 in acute phase serum and pleural fluid samples.36 In addition, 
it has been demonstrated that cell-mediated immunity contributes to the pathogenesis of 
Acute infection
Extrapulmonary
manifestations
Direct injury
Cytotoxic
effects
Respiratory
epithelium
Blood vessels
Antibodies and cells
specific for M. pneumoniae
M. pneumoniae adherence to erythrocytes
or carriage by antigen-presenting cells
Dissemination
Pneumonia
Immunomodulation
Antigenic
variation
Intracellular
localization
M. pneumoniae
Inflammation Invasion
Chronic infection Carriage
Figure 3. Proposed pathogenic states of M. pneumoniae at the respiratory tract.
Acute infection: M. pneumoniae attaches to the respiratory surfaces, resides mostly extracellular, and pro-
duces direct injury by a variety of local cytotoxic effects. Furthermore, it can induce inflammatory responses 
that result in pneumonia, and even cause extrapulmonary manifestations. The detection of M. pneumoniae 
at extrapulmonary sites (by culture and PCR) as well as intracellular in epithelial cells (in vitro) suggests that 
M. pneumoniae may be able to invade the host. Chronic infection and carriage: antigenic variation, im-
munomodulation, and intracellular localization are hypothesized ways to achieve chronic disease state or 
carriage. Reproduced with permission from Meyer Sauteur et al.,33 Wolters Kluwer Health.
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M. pneumoniae CAP, as it was shown that the severity of CAP correlated positively with 
the size of a cutaneous induration following intradermal injection of M. pneumoniae an-
tigens.37 This study from 1971 described 20 patients with CAP, of which 19 were children 
4–15 years of age, diagnosed by a significant rise in antibody titers against M. pneumoniae 
with CFT. The strongest skin reactions were seen in patients with severe CAP.
Asthma
M. pneumoniae and other “atypical” bacteria have long been implicated in the patho-
genesis of asthma.38 There are many studies that have addressed this issue in the recent 
past. In an observational study on children and adults with asthma, M. pneumoniae 
infection was diagnosed in 9% of children with asthma (n=24/256) and was found more 
frequent in patients with chronic asthma (14%) than in those with asthma exacerbations 
(7%; p=0.10).39 The diagnosis of M. pneumoniae infection in this study was performed 
by PCR and/or serology. Another recent study diagnosed M. pneumoniae in children 
with acute asthma (64%, n=34/53) and refractory asthma (65%, n=17/26), as well as in 
healthy controls (56%, n=36/64), but did not find significant differences between these 
three groups.40 The high detection rates reported in this study were obtained using novel 
diagnostic methods (CARDS toxin enzyme-linked immunosorbent assay [ELISA] and 
CARDS gene-specific PCR).40 In a recent Taiwanese study,41 1591 children and adults 
with M. pneumoniae infection, diagnosed by positive immunoglobulin (Ig) M or 4-fold 
IgG titer increase, but without prior asthma history were included from 2000–2008 and 
followed until the diagnosis of asthma or the end of 2011. Compared to matched 6364 
patients without M. pneumoniae infection, the cumulative incidence of asthma was 
significantly higher in the M. pneumoniae cohort than in the control cohort (p<0.0001). 
Patients with M. pneumoniae infection were at higher risk of having early-onset asthma 
(age at asthma diagnosis <12 years) and late-onset asthma (age at asthma diagnosis ≥12 
years). These most recent findings suggested that M. pneumoniae can induce airway 
inflammation and contribute to incident asthma. Interestingly, exposure to recombinant 
CARDS toxin resulted in an allergic-type inflammatory response and airway hyperreac-
tivity in mice and baboons.42,43
Extrapulmonary manifestations
Apart from respiratory tract infections (RTIs), M. pneumoniae can cause extrapulmonary 
manifestations in almost every organ, including the skin and the hematologic, cardiovas-
cular, musculoskeletal, and nervous systems.15 These manifestations may be caused either 
by direct local effects of M. pneumoniae, after dissemination of the bacteria throughout 
the body, or indirect effects, such as autoimmune reactions (Figure 3). The most frequent 
manifestations are diseases of the dermatologic and nervous system.
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Skin manifestations occur in up to 25% of all M. pneumoniae infections, including 
mainly non-specific exanthems, urticaria, and (less commonly) erythema nodosum. 
There are also rare but distinct pediatric M. pneumoniae-associated skin disorders such 
as erythema multiforme, Stevens-Johnson syndrome, and a rare but distinct disorder 
with prominent mucous membrane involvement denominated as M. pneumoniae-
associated mucositis (MPAM).44,45 This condition was first described by Fuchs in 1876,46 
and therefore also referred to as Fuchs syndrome.47 We previously reviewed all published 
MPAM cases45: 32 patients with MPAM were identified, with a median age of 13.5 years at 
presentation (range 3–38 years, 23 children or young adolescents ≤18 years). All patients 
presented with prodromal respiratory symptoms with a median duration of 7 days, and 
pneumonia was found in chest radiograph in 79%. Oral lesions were present in all cases, 
ocular lesions in 97%, and urogenital lesions in 78%. There were no skin lesions in 69%. 
Although 12% of the patients were admitted to the intensive care unit, no one suffered 
from long-term sequelae.
Encephalitis and Guillain-Barré syndrome (GBS) constitute the most common and 
severe neurologic manifestations, where M. pneumoniae infection is established in up 
to 10% and 15% of patients, respectively.48,49 Encephalitis is a disorder of the central 
nervous system (CNS), which presents with an altered mental status in most cases.50 
GBS is predominantly a disease of the peripheral nervous system (PNS) and manifests 
mainly as acute neuromuscular paralysis (polyneuropathy).51 Encephalitis can be caused 
by both direct infection and an immune-mediated process,50 while GBS is considered 
the prototype of a postinfectious immune-mediated disorder.51 M. pneumoniae expresses 
adhesion proteins and glycolipids that share structural homology with a variety of host 
cells (molecular mimicry) and may induce cross-reactive antibodies.3 Antibodies against 
M. pneumoniae have been found to cross-react with galactocerebroside (GalC) in en-
cephalitis and GBS patients.52,53 GalC is a major glycolipid antigen in the myelin sheath 
of both the PNS and CNS neurons.54 In this thesis, we investigated the role of antibodies 
against M. pneumoniae in the pathogenesis of encephalitis and GBS (Part 2).
M. pneumoniae carriage
Like many other respiratory pathogens, M. pneumoniae can be carried asymptomatically 
in the respiratory tract (Figure 3).55 Recent studies have demonstrated that asymptomatic 
carriage of M. pneumoniae is highly prevalent. Detection rates of M. pneumoniae DNA 
in the respiratory tract of healthy children without respiratory symptoms were 21% 
in a Dutch study (2008–2011, Rotterdam, The Netherlands)56 and 56% in a U.S. study 
(2009–2011, San Antonio, U.S.).40 Longitudinal sampling of M. pneumoniae-positive 
asymptomatic children demonstrated that M. pneumoniae can be present in the URT 
without causing disease, for up to 4 months.56 The prevalence of M. pneumoniae in the 
URT of asymptomatic children varied considerably between years and seasons. For 
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example, asymptomatic carriage rates of 3% and 58% were reported in the spring of 
2009 and the summer of 2010, respectively.56 These data suggest that carriage follows 
an epidemic pattern. It is tempting to speculate that this fluctuation in prevalence is 
related to the cyclic epidemics of M. pneumoniae infections. Apart from M. pneumoniae, 
children were found to simultaneously carry many pathogens in their nose and throat.56 
These pathogens included the bacteria S. pneumoniae, Staphylococcus aureus, Moraxella 
catarrhalis, and Haemophilus influenzae, and the viruses influenza virus A, human meta-
pneumovirus, respiratory syncytial virus, parainfluenza virus, rhinovirus, coronavirus, 
bocavirus, and adenovirus. The simultaneous presence of two or more of these pathogens 
was detected in 56% of asymptomatic children.56
The challenge to diagnose M. pneumoniae infection
Diagnostic tests
Because the mere presence of M. pneumoniae in the URT is neither indicative nor pre-
dictive for respiratory disease, the routine diagnostic procedures to detect acute RTIs 
with M. pneumoniae need to be reconsidered. An overview of diagnostic tests with their 
advantages and drawbacks is shown in Chapter 6.
Current guidelines57,58 recommend PCR and single-sample serological tests to diagnose 
M. pneumoniae infections. The sensitivity of specific serological tests depends on the 
time point of the first serum sample and on the availability of paired sera collected ≥2 
weeks apart to evaluate seroconversion and/or ≥4-fold antibody titer increase as “gold 
standard”.59 Specific serum IgM can be detected within 1 week after initial infection and 
about 1–2 weeks before IgG.60 Reinfection in adults can lead directly to an IgG response 
and may lack production of IgM. Specific serum IgA rises, peaks, and decreases earlier 
than IgM, but is less frequently detected (only in 2% of PCR-positive children with symp-
tomatic RTI).56 Cross-reactions with other pathogens and non-infectious diseases have 
been described for CFT and particle agglutination assay, but also some ELISAs lack the 
required sensitivity and specificity.61 Further, it is intriguing that the detection of specifc 
IgM, as well as IgG and IgA by ELISA could not discriminate between the M. pneumoniae 
PCR-positive asymptomatic and symptomatic groups of children.56 Thus, it is question-
able whether or not a positive result in these tests actually indicates the etiological role 
of M. pneumoniae in all cases. Clinicians therefore need to be aware of the implications 
and clinical significance of a positive PCR and/or serology test result for M. pneumoniae.
Clinical assessment
While diagnostic tests may not be reliably predictive for a symptomatic M. pneumoniae 
infection, the clinical assessment of this entity is being revisited. The British Thoracic 
Society (BTS) guidelines57 recommend that bacterial pneumonia should be considered in 
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children when there is persistent or repetitive fever >38.5°C together with chest recession 
and a raised respiratory rate. A chest radiograph is not a routine investigation in children 
thought to have CAP. In fact, the radiographic presentation of “atypical” pneumonia due 
to M. pneumoniae is extremely variable. Bilateral, diffuse interstitial infiltrates are com-
mon, pleural effusions can occur, but none of the radiographic findings associated with 
M. pneumoniae CAP are specific.62
A fast-and-frugal clinical decision tree provided a rapid probability estimate of the 
cause of CAP in 253 children (1 months–16 years; 1997–1999, Zurich, Switzerland).31 
M. pneumoniae infection was diagnosed in 13% (n=32) of these children by PCR in 
respiratory specimens and serology (seroconversion and/or 4-fold rise in antibody titer). 
Compared with other children with CAP, patients with M. pneumoniae were older and 
had a longer duration of fever (p<0.001). Asking the simple question regarding the age 
of the child and the duration of fever allowed identification of the following group at 
high risk for CAP due to M. pneumoniae: children with CAP who have had fever >2 
days and who were >3 years of age. The decision tree placed 72% of all patients with 
M. pneumoniae infection into the high-risk group. These simple rules may further aid 
physicians in prescribing appropriate first-line antibiotics.
Treatment and antibiotic resistance of M. pneumoniae
Antibiotics
In consequence of the diagnostic uncertainty for M. pneumoniae infections, the BTS 
guidelines57 suggest empiric macrolide treatment at any age if there is no response to 
first-line β-lactam antibiotics or in the case of very severe disease. The lack of a cell wall 
makes M. pneumoniae resistant to cell wall synthesis inhibitors such as β-lactam antibiot-
ics. Antibiotics effective against M. pneumoniae include macrolides, tetracyclines, and 
fluoroquinolones.3 Although the latter two have a good in vitro inhibitory effect against 
M. pneumoniae, tetracyclines may cause teeth discoloration3 and fluoroquinolones may 
affect the developing cartilage in young children.63 Thus, they are not recommended by 
current guidelines in young children; the age limit for tetracyclines is ≥8 years, while that 
of fluoroquinolones is adolescence with skeletal maturity.58 The occurrence of arthropathy 
due to fluoroquinolones, however, is uncertain, and all musculoskeletal adverse effects 
reported in the literature had been reversible following withdrawal of treatment.63 The 
protein synthesis inhibitors of the macrolide class have a more favorable side effect profile 
and are therefore the first-line antibiotics for M. pneumoniae infections in children.58
Although antibiotics are effective against M. pneumoniae in vitro,64 there is lack of 
evidence on their in vivo efficacy. Observational data indicated that children with CAP 
due to M. pneumoniae have a shorter duration of symptoms and fewer relapses when 
treated with an antibiotic active against M pneumoniae.3,65 A recent Cochrane review59 
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evaluated seven studies on the effectiveness of antibiotic treatment for M. pneumoniae 
LRTIs in children. However, the diagnostic criteria, the type and duration of treatment, 
inclusion criteria, and outcome measures differed significantly, making it difficult to 
draw any specific conclusions – although one trial suggested that macrolides may be 
efficacious in some cases.66 It is clear that studies on the efficacy of antibiotics rely on a 
correct diagnosis of M. pneumoniae infections. Given the aforementioned shortcomings 
of current diagnostic tests, conclusions on the efficacy of antibiotic treatment will have 
to be re-examined.
Antibiotic resistance
Since 2000, the extensive macrolide use led to an alarming worldwide increase in the 
prevalence of macrolide-resistant M. pneumoniae (MRMP) strains.64 Resistance is based 
on specific point mutations in domain V of the 23S rRNA (at positions 2063, 2064, and 
2617), which reduce the affinity of macrolides to the large subunit (50S) of the bacterial 
ribosome.64 MRMP has been observed during macrolide treatment as a result of antibi-
otic selective pressure.67-69 To date, macrolide resistance has been detected on a worldwide 
scale. MRMP had developed in Asia,70 where MRMP rates have risen as high as 97% in 
China.71 MRMP has now also been reported from North America and Europe, and we 
recently reported the first MRMP infection in a child in Switzerland (Figure 4).72
The clinical relevance of macrolide resistance in hospitalized children with CAP may 
be a longer duration of symptoms.73,82,83 Zhou et al.83 found that an increase in MRMP 
may also have serious clinical consequences in children, leading to more severe radiologi-
cal findings of CAP and even an increase in extrapulmonary manifestations. In this study, 
hospitalized children with CAP due to MRMP developed more often extrapulmonary 
disease than children with CAP caused by macrolide-sensitive strains (30% vs. 10%; 
p=0.03).83 These manifestations included skin diseases and nervous system complica-
tions in 18% and 7%, respectively, of the MRMP-infected children. Serum inflammatory 
cytokine levels (INF-γ, IL-6, and IP-10) were higher in patients infected with MRMP 
than in patients infected with macrolide-sensitive strains.84 This suggests that the higher 
and more persistent inflammatory stimulation by MRMP may increase the possibility of 
severe lung lesions and extrapulmonary complications.
Vaccines
Apart from the discovery of novel antibiotics against M. pneumoniae, the development of 
vaccines against M. pneumoniae may play a crucial role in the control and/or eradication 
of this pathogen. While previous attempts to produce vaccines on the basis of inactivated 
bacteria resulted in limited efficacy against pneumonia and various adverse effects,85 
the recent use of recombinant proteins as potential vaccines was found to be promising. 
Specifically, the immunization of mice with a recombinant peptide encompassing the 
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C-terminal part of the immunodominant P1 protein (RP14) induced strong mucosal and 
systemic antibody responses against M. pneumoniae as well as reduced lung inflamma-
tion.86 In another study, it was shown that immunization of guinea pigs with a chimeric 
protein consisting of RP14 and the P30 adhesion protein of M. pneumoniae resulted in 
a robust antibody response, and, subsequently, in lower bacterial loads in the respira-
tory tract.87 These studies showed that vaccination indeed present a future alternative 
to antibiotics in the combat against M. pneumoniae (Chapter 3). Development of a M. 
pneumoniae-specific vaccine for high-risk individuals such as young children and elderly 
people may help to reduce morbidity from pneumonia and secondary complications 
as well as reduce horizontal transmission. Furthermore, the development of antibiotic-
resistant strains will be reduced.
Figure 4. Worldwide macrolide-resistant M. pneumoniae (MRMP) rates.
Actual MRMP rates are punctually depicted in pie charts (in black) over the world map.12 Asia: Japan (2011): 
87% (n=176/202),73 South Korea (2011): 63% (n=44/70),70 China (2012): 97% (n=31/32),71 Israel (2010): 30% 
(n=9/30);74 North America: U.S. (2012–2014): 13% (n=12/91),75 Canada (2010–2012): 12% (n=11/91);76 Eu-
rope: The Netherlands (1997–2008): 0% (n=0/114),77 Germany (2003–2008): 1% (n=2/167),78 France (2005–
2007): 10% (n=5/51),79 Italy (2010): 26% (n=11/43),67 Scotland (2010–2011): 19% (n=6/32),80 Switzerland 
(2011–2013): 2% (n=1/50),72 England and Wales (2014–2015): 9% (n=4/43).81 Reproduced with permission 
from Meyer Sauteur et al.,12 Frontiers.
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INTRODUCTION TO ANTIBODY RESPONSES
B cell responses are of crucial importance for the host defense against multiple pathogens 
and have a variety of functions during the development of immune responses to infection. 
While B cells are known to be involved in clearance of M. pneumoniae from the lungs, 
their role in M. pneumoniae carriage and M. pneumoniae-associated extrapulmonary 
disease is unknown.
Role of B cells in defense against pathogens
B cells produce antibodies after being triggered and activated by antigen and having 
undergone differentiation into antibody-secreting cells (ASCs). Antibody-mediated 
immunity is achieved by binding of antibodies to the surface of pathogens resulting in 
(i) neutralization (inhibiting growth), (ii) opsonisation (phagocytic recognition), (iii) 
complement activation (deposition of complement and subsequent lysis), (iv) tagging 
(destruction through antibody-dependent cell-mediated cytotoxicity), (v) coating (pre-
vention of bacterial adherence), and (vi) agglutinating (more effective recognition and 
mechanical clearance).88
B cell development
B lymphocytes develop in bone marrow (and in fetal liver during gestation), independent 
of antigen contact, from a multipotent progenitor cell to an immature B cell (Figure 5).89 
The different developmental stages of B cell development (pro-B cell, pre-B cell, and im-
mature B cell) are determined by the functional rearrangement of the Ig heavy and light 
chain segments of the B cell receptor (BCR) genes (see below).
Defects in early B cell development result in agammaglobulinemias, which are rare 
antibody deficiencies characterized by low numbers or absence of B cells, marked hypo-
gammaglobulinemia, and increased susceptibility to infections (see below).89
B cells leave the bone marrow (primary lymphoid organ) at the transitional B cell stage 
and complete their final development into mature B cells in the periphery (secondary 
lymphoid organs).89 Mature B cells can be divided into three major subsets: follicular 
B cells, marginal zone B cells, and B-1 cells.90 Follicular B cells are the dominant subset 
and they are located in the lymphoid follicles of the spleen and lymph nodes. Marginal 
zone B cells, by contrast, border on the marginal sinus of the spleen, where they are ide-
ally located to encounter blood-borne pathogens and particulate antigens. B-1 cells are 
located mostly in the peritoneal and pleural cavities and at mucosal sites, which facilitates 
their surveillance of the tissues that are the most susceptible to environmental pathogens. 
B-1 cells produce non-specific antibodies (natural antibodies) that are synthesized early 
in the immune response and are predominantly of the isotype IgM.91 They can be distin-
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guished by their recognition of self-antigens and those with repetitive epitopes such as 
carbohydrates.
Defects in later stages of B cell differentiation result in diseases with different degrees of 
disrupted antibody production, e.g., class switch recombination (CSR) defects, common 
variable immunodeficiency (CVID), and specific antibody deficiencies.89
B cell activation
T cell-dependent
After BCR stimulation by antigen, marginal zone and follicular B cells become activated 
B cells and migrate to the border of the follicle.92 At this site the activated B cells receive 
signals from antigen-specific CD4+ T cells (e.g., via CD40 and various cytokine receptors) 
(Figure 6), which trigger proliferation of B cells. Subsequently, B cells either migrate out 
of the follicle and become short-lived ASCs (plasmablasts) or migrate into the follicle and 
Figure 5. Overview of B cell development and defects causing antibody deficiency.
(A) Antigen-independent B cell development, through (i) VDJH rearrangement of the IgM (μ) heavy chain 
(by which the pre-BCR is assembled together with components of the surrogate light chains VpreB and λ5 
and signaling molecules Igα and Igβ) and (ii) VJL rearrangement of the IgM (μ) light chain (by which the 
BCR is formed). (B) Antigen-dependent B cell differentiation, after which B cells exit the germinal centers 
of secondary lymphoid organs as antibody-secreting plasma cells or memory B cells. Abbreviations: BCR, 
B cell receptor; BLNK, B cell linker protein; BTK, Bruton tyrosine kinase; CSR, class switch recombination; 
CVID, common variable immunodeficiency; HC, heavy chain; Ig, immunoglobulin; LC, light chain; LRRC8, 
leucine-rich repeat containing 8 protein. Reproduced with permission from Fried et al.,89 American Society 
for Microbiology.
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become long-lived plasma cells or memory B cells.90 In the germinal center (GC), the 
site where CSR and somatic hypermutation (SHM) occurs, follicular B cells proliferate 
and undergo CD4+ T cell-dependent affi  nity-maturation. Cells that receive CD4+ T cell 
signals exit the GC as long-lived plasma cell or memory B cell.90 Failure to receive signals 
from CD4+ T cells results in apoptosis. Long-lived plasma cells reside in survival niches 
in the bone marrow, even aft er the antigen has been eliminated, and continuously secrete 
protective antibodies of a given specifi city. Reactivation by antigen leads to diff erentiation 
of memory B cells into plasmablasts that are competent to become long-lived plasma 
cells.90
T cell-independent
Non-protein antigens (lipo-/polysaccharides, glycolipids, and nucleic acids) stimulate 
B cell responses in the absence of helper T cell activation (thymus-independent [TI] 
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Figure 6. B cell diff erentiation in response to antigen in secondary lymphoid organs.
Abbreviations: Bcl-6, B cell lymphoma 6 protein; BCR, B cell receptor; Blimp-1, B lymphocyte maturation 
protein-1; Ig, immunoglobulin; swIg, isotype switched Ig. Reproduced with permission from Taylor et al.,92 
Elsevier.
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antibody responses) as they cannot be presented to CD4+ T cells in the context of major 
histocompatibility complex (MHC) molecules.92 Th ere are two classes of TI antigens (i.e., 
TI-1 and TI-2). TI-1 antigens (e.g., bacterial lipopolysaccharide or nucleic acids) can trig-
ger B cell activation through their Toll-like receptor (TLR).93 TI-2 antigens (e.g., bacterial 
polysaccharides or glycolipids) extensively crosslink BCRs and deliver a prolonged and 
persistent signal to the B cell, transmitted via Bruton tyrosin kinase (Btk).94 TI antibody 
responses are characterized by a fast production of lower-affi  nity antibodies with limited 
isotype switching.
B cell receptor and antibodies
Th e BCR is located on the outer surface of B cells and is composed of a membrane-bound 
Ig molecule (mature naïve B cells: IgM, IgD; memory B cells: IgM, IgG, IgA, or IgE) 
and a signal transduction moiety (Igα/Igβ heterodimer, CD79) (Figure 5). Apart from 
the presence of the integral membrane domain, the Igs of the BCR are identical to their 
secreted soluble forms (i.e., antibodies).
VDJ recombination
Th e Ig molecule consists of paired heavy chains (IgH) and light chains (IgL). Both IgH 
and IgL contain variable (V) and constant (C) regions (Figure 7). Th e amino-terminal V 
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Figure 7. Overview of formation and structure of antibodies.
Reproduced with permission from Trück (https://ora.ox.ac.uk/objects/uuid:4bbccd8c-febd-4713-a97b-
d6a8a08e3979).
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region of IgH is encoded by variable (VH), diversity (DH), and joining (JH) gene segments 
on chromosome 14. The V region of IgL contains only variable (VL) and joining (JL) gene 
segments. There are two types of IgL in humans, kappa (κ) and lambda (λ), which are 
determined by the CL region. Only one type of IgL (κ or λ) is present in a particular 
antibody. Genes encoding the V region of IgL are located on chromosome 2 (κ) and 
chromosome 22 (λ), respectively. V regions of both IgH (VH, DH, and JH) and IgL (VL 
and JL) form the antigen-binding part of the antibody (Fragment antigen-binding, Fab).89
During B cell development in bone marrow, initial diversity is generated by VDJ 
recombination. Gene rearrangement follows a sequential order, starting with recombina-
tion of the VH, DH (IgH only), and JH gene segments of the IgH locus, followed by VL and 
JL rearrangement of the IgL locus. In addition to randomly assembling different V to D 
to J segments, which form the basis of antibody function to bind foreign antigen, further 
diversity develops by random removal and addition of nucleotides at the recombination 
sites (junctional diversity).
B cell receptor (BCR)
Productive IgM (μ) heavy chain recombination leads to the formation of the pre-BCR, 
which is covalently associated with an IgL-like molecule called the surrogate light chain.95 
The expression of the pre-BCR induces progression from the pro-B cell stage to the pre-B 
cell stage (Figure 5).96 Immature B cells subsequently express a BCR.97
In the absence of the μ heavy chain the pre-BCR cannot be formed, resulting in a block 
in B cell development at the pro-B cell stage. This is shown in μMT mice that have an 
inactivating mutation of the membrane exon of the IgM (μ) heavy chain gene.98 μMT 
mice were used in Chapter 2 to investigate the outcome of M. pneumoniae infection and 
carriage in the absence of mature B cells.
BCR signals are directly linked to B cell survival via Btk (Figure 5), through activation 
of the transcription factor nuclear factor (NF)-κB.99-101 Mutations in the Btk gene result in 
X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) 
in mice.102 The resulting pre-B cell developmental block is almost complete in XLA, but 
limited in xid. Btk– mice, which we used in Chapter 3, have severely reduced (>50%) 
mature B cells, absent B-1 cells, and low serum IgM and IgG3 levels.103,104 Despite being 
less in numbers, the mature B cells in Btk– mice show normal T cell-dependent antibody 
responses to model antigens.94 Moreover, the lack of Btk in B cells makes these mice 
hyporesponsive to certain TI antigens.94
Class switch recombination (CSR) and somatic hypermutation (SHM)
Contact with antigen and T cells in peripheral lymphoid organs initiate further diversi-
fication of antibodies through CSR for the acquisition of different Ig isotypes, SHM for 
increased antigen specificity, and selection of B cells for improved antigen binding.105
Ch
ap
te
r 1
29
General introduction and outline of the thesis
The GCs are the primary sites for CSR, SHM, and B cell memory and plasma cell gen-
eration (Figure 6). CSR targets the CH region, which is organized by distinct exon clusters 
in the order Cμ, Cδ, Cγ, Cε, and Cα. CSR results in DNA replacement of the expressed 
CH exon cluster (e.g., Cμ for IgM) with Cγ for IgG, Cα for IgA, or Cε for IgE. The antigen-
binding V region is unaltered after CSR. IgM and IgD is generated not through CSR, but 
through alternative splicing of the primary (germline) transcripts encoded by the Cμ and 
Cδ genes.
SHM inserts point mutations into the V region of IgH and IgL at a high rate to provide 
structural substrate for positive selection of higher affinity antibodies by antigen.
Immunoglobulin (Ig) isotypes
Ig classes or isotypes have distinct tissue distribution and efficacy against different types 
of pathogens. IgM (pentamer or hexamer, 960 kDa) proteins have a large size and can-
not pass the vascular endothelium into the extravascular space, whereas IgG (monomer, 
subclasses IgG1–4, 150 kDa), IgE (monomer, 200 kDa), and IgA (monomer or dimer, 
subclasses IgA1–2, 320 kDa) molecules can be distributed systemically to tissues. During 
infections in humans, IgM is part of the primary immune response, mediates complement 
activation, and is effective against most microbial pathogens (high avidity for antigens 
with repetitive patterns), whereas IgE is effective against large extracellular parasites, 
and IgA predominates in the combat against mucosal pathogens. The expressed subclass 
(IgG1–4) of the IgG isotype depends on the signals that pathogens provide to dendritic 
cells and/or B cells.105
Antibody-mediated (autoimmune) disease
B and T cells are rendered non-reactive to self by central tolerance in bone marrow (B 
cells) or thymus (T cells) and by peripheral tolerance in secondary lymphoid organs. 
Negative selection eliminates avid B and T cells reactive with self-antigens in bone mar-
row and thymus, respectively.106 Autoimmune diseases are a diverse group of disorders 
characterized by abnormal immune reactivity in association with autoreactive B and T 
cell responses. Multiple factors are thought to contribute to the development of immune 
response to self, including genetic susceptibility, environmental factors, and hormonal 
milieu.107 Of all environmental factors infectious pathogens have the most potential to 
trigger autoimmunity. There are several mechanisms through which pathogens can initi-
ate or perpetuate autoimmunity (Figure 8).
Microbial antigens sometimes resemble self and therefore trigger BCRs and T cell re-
ceptors (TCRs). Such cross-reactions underlie the concept of molecular mimicry, which 
is defined as dual recognition of structures of a microorganism and host by a single BCR 
or TCR.108 Hence, molecular mimicry is a potential mechanism by which infections can 
trigger cross-reactive antibodies or T cells that cause autoimmune disease, e.g., acute 
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rheumatic fever and GBS. We also investigated if M. pneumoniae epitopes trigger the 
production of antibodies that react with host antigens (glycolipids) and cause disease 
(encephalitis and GBS) (Part 2).
A
C
B
D
Figure 8. Autoimmune mechanisms triggered by infections.
(A) Molecular mimicry: Microbial structures share similarity in amino acid sequence or structure to self-
antigen. As a result of cross-reactivity, leading to the activation of naïve, autoreactive T cells specific to the 
corresponding self-molecule, the immune response can eventually turn toward the self-peptide/-tissue. (B) 
Protein changes and cryptic antigens: Infection causes tissue injury (cell death, oxidative stress, free radical 
production, and reparative changes) and proteins that are usually recognized as self can become antigenic 
and induce an autoimmune response. In addition, proteins that are normally sequestered and shielded 
from immune recognition (“cryptic”) can be exposed to the immune system. These antigens become acces-
sible to (self-reacting) T cells as they had not been presented appropriately to induce central and periph-
eral tolerance. (C) Superantigens: Superantigens are proteins produced by a variety of microorganisms, or 
virus-infected cells that can bind a TCR irrespective of its antigenic specificity, resulting in the activation of 
a large number of T cells of different antigenic specificity, thus behaving as a potent immune-stimulating 
molecule. (D) Bystander activation: Infection can result in enhanced processing and presentation of self-
antigens, which induces the expansion and/or spreading of the immune response toward different self-
antigens (“epitope spreading”). Abbreviations: APC, antigen-presenting cell; Mø, macrophage; Th, T helper 
cell. Reproduced with permission from Sfriso et al.,107 John Wiley and Sons.
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HYPOTHESES, OBJECTIVES, AND AIMS
Despite the often described benign nature of M. pneumoniae infections, cases of fulmi-
nant pneumonia14 and/or severe extrapulmonary manifestations3 have been reported. In 
light of the global increase in antibiotic resistance of M. pneumoniae, other strategies in 
the combat against M. pneumoniae are needed. Vaccination may be a promising alterna-
tive to antibiotics. However, to develop optimal approaches to vaccination against M. 
pneumoniae it is critical to understand the immune mechanisms that may contribute to 
protection and/or immunopathology. In particular, it is important to clarify the role of B 
cells and antibodies in M. pneumoniae carriage and M. pneumoniae-associated disease as 
(i) no data exists regarding humoral immunity against M. pneumoniae carriage, and (ii) 
antibody-mediated pathogenesis has been suggested in extrapulmonary diseases.
Hypotheses
Overall
We hypothesized that antibodies to M. pneumoniae protect against pulmonary infection 
but trigger extrapulmonary nervous system disease.
1. Antibody responses to M. pneumoniae: protecting against disease
We hypothesized that antibodies to M. pneumoniae are essential for resolution of pulmo-
nary infection but are not effective in clearing carriage from the URT. Given its essential 
role in protection against disease the detection of B cell responses may be a diagnostic 
indicator for pulmonary infection.
2. Antibody responses to M. pneumoniae: triggering disease
We hypothesized that antibodies against galactocerebroside (GalC), a major myelin gly-
colipid of both the PNS and CNS, are critical for development of nervous system disease 
following M. pneumoniae infection, and investigated whether encephalitis and GBS after 
this type of preceding infection presented with distinct clinical features and outcome.
Aims and objectives
Overall
To determine the role of antibodies to M. pneumoniae in respiratory tract carriage, pul-
monary infection, and extrapulmonary nervous system disease.
1. Antibody responses to M. pneumoniae: protecting against disease
– To develop a C57BL/6 mouse model for M. pneumoniae infection and carriage, which 
resembles the human situation;
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– To investigate the role of antibodies in carriage and clearance of M. pneumoniae from 
the respiratory tract of mice;
– To determine which antigenic structures of M. pneumoniae are recognized by specific 
antibodies in mice and children;
– To investigate if specific B cell responses (antibodies and/or antibody-secreting cells 
[ASCs]) differentiate M. pneumoniae infection from carriage, and thereby optimize 
current PCR-based diagnostic testing.
2. Antibody responses to M. pneumoniae: triggering disease
2.1 Encephalitis
– To investigate the role of antibodies to M. pneumoniae in pathogenesis and diagnosis 
of childhood encephalitis;
– To assess the intrathecal antibody response to M. pneumoniae in children with en-
cephalitis;
– To identify potential myelin targets of antibodies to M. pneumoniae in childhood 
encephalitis;
– To evaluate the presence of pediatric M. pneumoniae-associated encephalitis in a 
national prospective surveillance study;
2.2 Guillain-Barré syndrome
– To determine the relation of M. pneumoniae with GBS in a large case-control study, 
the first study in both adults and children;
– To assess clinical features and outcome in adult and pediatric GBS triggered by M. 
pneumoniae;
– To investigate the antibody response to M. pneumoniae in a series of children with 
severe and complicated disorders within the GBS spectrum after M. pneumoniae 
infection;
– To identify potential myelin targets of antibodies to M. pneumoniae in adult and 
pediatric patients with GBS triggered by M. pneumoniae;
– To demonstrate cross-reactivity of anti-GalC antibodies found in adult and pediatric 
patients with M. pneumoniae GBS;
– To determine the role of anti-GalC antibodies in serum and cerebrospinal fluid (CSF) 
in adult and pediatric GBS.
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OUTLINE
This thesis contains two general parts, i.e., Part 1 on protective antibody responses and 
Part 2 on antibody responses triggering disease. Part 1 contains studies about kinetics 
and targets of M. pneumoniae-specific antibodies following M. pneumoniae infection 
in mice and children. Chapter 1 introduces current knowledge about M. pneumoniae 
and B cell responses. In Chapter 2 we describe the role of B cells and antibodies in M. 
pneumoniae respiratory tract carriage and infection in a newly developed mouse model. 
This mouse model provided an excellent tool to study M. pneumoniae-specific immune 
responses in the URT, which has not been addressed in previous in vivo studies. In 
Chapter 3, target structures of M. pneumoniae-specific antibodies are determined and 
the contribution of such particular antibodies in protecting against RTI is described. In 
Chapter 4 we investigated specific B cell responses (antibodies and ASCs) as diagnostic 
indicator for pulmonary infection in children and evaluated its potential to optimize M. 
pneumoniae diagnosis.
In Part 2, the focus is shifted from the respiratory tract (protecting antibody response) 
towards the nervous system (disease-triggering or pathogenic antibody response). 
Part 2.1 addresses the extrapulmonary CNS manifestation encephalitis. Chapter 5 
describes first the intrathecal antibody response to M. pneumoniae in encephalitis pa-
tients. Chapter 6 is a review that discusses the role of antibodies in pathogenesis and 
diagnosis of M. pneumoniae-associated encephalitis. Based on the discussion in Chapter 
6, potential myelin targets of antibodies to M. pneumoniae, including GalC, were assessed 
in encephalitis in Chapter 7. As final step of Part 2.1 about encephalitis, Chapter 8 pres-
ents epidemiological and clinical data of M. pneumoniae-associated encephalitis and its 
pathogenesis in a national prospective surveillance study.
Part 2.2 is about the PNS manifestation GBS. Chapter 9 describes a first case series of 
children with severe and complicated disorders within the GBS spectrum after infection 
with M. pneumoniae, presenting clinical data, outcome, and antibody responses to M. 
pneumoniae. Chapter 10 covers our primary case-control study, the first study in both 
adults and children, in which we determine the relation of M. pneumoniae with GBS in a 
large number of cases. This study also investigated whether GBS after this type of preceding 
infection presents with characteristic clinical features, outcome, and antibody responses 
to glycolipids, including GalC. At the end of Part 2.2, Chapter 11 and Chapter 12 present 
data about intrathecal antibodies to GalC in patients of the case-control study (Chapter 
10) and the case series (Chapter 9).
Finally, in Chapter 13, the overall findings and implications of the studies described in 
this thesis are discussed. Chapter 14 provides a summary of the thesis.
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ABSTRACT
Background
Carriage of Mycoplasma pneumoniae in the nasopharynx is considered a prerequisite for 
pulmonary infection. It is interesting to note that M. pneumoniae carriage is also detected 
after infection. Although B cells are known to be involved in pulmonary M. pneumoniae 
clearance, their role in M. pneumoniae carriage is unknown.
Methods
In this study, we show in a mouse model that M. pneumoniae persists in the nose after 
pulmonary infection, similar to humans.
Results
Infection of mice enhanced M. pneumoniae-specific immunoglobulin (Ig) M and IgG 
levels in serum and bronchoalveolar lavage fluid. However, nasal washes only contained 
elevated M. pneumoniae-specific IgA. These differences in Ig compartmentalization cor-
related with differences in M. pneumoniae-specific B cell responses between nose- and 
lung-draining lymphoid tissues. Moreover, transferred M. pneumoniae-specific serum Igs 
had no effect on nasal carriage in B cell-deficient μMT mice, whereas this enabled μMT 
mice to clear pulmonary M. pneumoniae infection.
Conclusions
We report the first evidence that humoral immunity is limited in clearing M. pneumoniae 
from the upper respiratory tract.
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INTRODUCTION
Mycoplasma pneumoniae is a frequent cause of childhood community-acquired pneu-
monia (CAP) worldwide,1 and currently is the most commonly detected bacterial cause 
of CAP in hospitalized children in the U.S.2 We and others observed that besides causing 
upper respiratory tract (URT) and lower respiratory tract (LRT) infections, M. pneu-
moniae is also carried in the URT of asymptomatic children.3-7 Carriage is considered a 
prerequisite for infection.3,8-10 Interestingly, carriage also occurs following symptomatic 
infection.11 Several studies in humans demonstrated the presence of M. pneumoniae in 
the nasopharynx up to eight months after respiratory tract infection.3-7
B cells are of crucial importance for the host defense against multiple pathogens, as B 
cell activation can result in the production of specific immunoglobulins (Igs) that neu-
tralize the pathogen.12 Following an initial M. pneumoniae respiratory tract infection M. 
pneumoniae-specific IgM is detectable in serum within one week, and increased amounts 
of M. pneumoniae-specific IgG can be found from two weeks postinfection (p.i.).13,14 M. 
pneumoniae-specific IgA is produced early after infection and its levels both peak and 
decrease earlier than IgM or IgG.15 Indeed, B cells are known to be involved in pulmonary 
mycoplasma clearance.16-20 Furthermore, patients with hypogammaglobulinemia are at 
greater risk for M. pneumoniae pulmonary disease and/or extrapulmonary manifesta-
tions.21-25 It is likely that carriage of M. pneumoniae by these patients make them suscep-
tible to the development of symptomatic M. pneumoniae infection.
In contrast to the known important role of B cells in clearance of a pulmonary infection, 
limited knowledge exists on the role of B cells in the control of M. pneumoniae carriage 
in the URT. Therefore, we set out to determine whether humoral immunity contributes 
to clearance of M. pneumoniae carriage from the URT. Since this is difficult to study in 
human subjects, we further developed a C57BL/6 mouse model to study M. pneumoniae 
(strain M129) infections and the role of humoral immunity on control of these infections.
METHODS
Mice
C57BL/6 mice were purchased from Charles River Laboratories and used at 8–12 weeks 
of age. μMT transgenic mice (C57BL/6×FVB×129)26 were bred and housed in the animal 
facilities of the Erasmus MC under specific pathogen-free conditions. All experiments 
were approved by the Animal Experiments Committee of the Erasmus MC, Rotterdam, 
The Netherlands.
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Bacteria
M. pneumoniae reference strain M129 (subtype 1, ATCC 29342) was cultured at 37°C/5% 
CO2 in SP4 medium (pH 7.8–8.0) for 72 hours and concentrated in fresh SP4 medium 
to 1×109–10 colony-forming units (CFUs)/ml (Supplementary Data). To track M. pneu-
moniae, bacteria were labeled with 10 μM carboxyfluorescein diacetate succinimidyl ester 
(CFSE) according to the manufacturer’s instructions (Molecular Probes).
M. pneumoniae infection and carriage mouse model
Mice were inoculated intranasally with 1×109 CFU of M129 diluted in 50 μl SP4 medium. 
Control mice were inoculated with 50 μl SP4 medium. On indicated days after M. pneu-
moniae inoculation, body weight was measured and mice were sacrificed. Lung washes 
and nasal fluid samples (washes and brushes) were collected. Cells from lungs, lymph 
nodes, and nasal passages (mucosa and nasal-associated lymphoid tissue [NALT]27) were 
isolated. Detailed methods for sample procedures are included in Supplementary Data.
Serum transfer
Sera were collected and pooled from wild-type (WT) and μMT mice on day 14 p.i., 
diluted with PBS (1:1.3), and 200 μl was injected intravenously into each WT and μMT 
recipient mice at day 15, 16, and 22 p.i. One week after the last serum transfer, recipient 
mice were sacrificed. Sera were devoid of M. pneumoniae as confirmed by a negative PCR 
for M. pneumoniae.28
M. pneumoniae quantification
The presence of M. pneumoniae was detected either by PCR28 or culture of bronchoalveo-
lar lavage fluids (BALFs) and nasal fluid samples (100 μl undiluted and 10-fold diluted) 
on SP4 agar plates at 37°C. Suspensions of spleen, liver, and immersed cotton swabs of 
articular surfaces were processed in a similar fashion.
M. pneumoniae phagocytosis and killing
M. pneumoniae M129 was incubated with sera from infected WT mice. As control, sera 
from uninfected mice were used. Murine RAW 264.7 macrophages were incubated with 
the respective bacteria for 20 min, washed, and at time point 0 and 180 min, cells were 
lysed to determine bacterial load (CFU/105 RAW cells) by culture on SP4 agar plates.
Histopathology scoring
Histopathology scoring (HPS) of lung sections was performed without knowledge of the 
treatment or time after infection of mice. The modified HPS system29 assigns values from 
0 to 10 by grading immune cell infiltrates in alveoli and bronchi for distribution, severity 
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of inflammation, presence of necrosis, and presence of perivascular, peribronchial, and 
peribronchiolar cuffing (Supplementary Data).
Quantification of antibodies
Total antibody concentrations (μg/ml) and M. pneumoniae-specific antibodies (arbitrary 
units [AU]/ml) were quantified by ELISA as described in Supplementary Data.
IgA ASC ELISpot
The frequency of M. pneumoniae-specific and total IgA-producing antibody-secreting 
cells (ASCs) in mediastinal lymph nodes (MLNs), cervical lymph nodes (CLNs), and 
nasal passages was measured by enzyme-linked immunospot (ELISpot) assay using a 
commercially available kit (Mabtech), as described in Supplementary Data.
Flow cytometry
Aliquots of single-cell suspensions were incubated with appropriate dilutions of anti-
bodies for 30 min on ice. Cells were subsequently analyzed using a FACS Canto II (BD 
Biosciences) and FlowJo 10 software (Tree Star). Monoclonal antibodies and the gating 
strategy are described in Supplementary Figure S1.
Cytokine analysis
Cytokines were measured in BALF and nasal lavage fluid by a multiplex fluorescent-
bead-based immunoassay (Procarta multiplex, eBioscience).
Statistical analysis
R software environment (version 3.4.0) and GraphPad Prism (version 5.01) were used 
for statistical analysis. The Welch’s t-test, Mann-Whitney U test, Kruskal-Wallis test with 
post hoc Dunn’s multiple comparisons test of selected pairs, Fisher exact test or χ2 test 
were used to determine statistical significance. Family-wise error rates were controlled 
using the Holm-Bonferroni Method. Association between paired samples was tested 
using the Pearson product-moment correlation coefficient. Statistical significance was 
defined as p<0.05.
RESULTS
M. pneumoniae persists in the nose after pulmonary infection
To unravel the role of B cells in M. pneumoniae pulmonary infection and nasal carriage, 
we further developed a mouse model for M. pneumoniae infection using the M. pneu-
moniae reference strain M129 (subtype 1) in C57BL/6 mice.30-32 Intranasal inoculation of 
anaesthetized C57BL/6 mice with 1×109 CFU of M. pneumoniae M129 resulted in a mean 
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relative body weight loss of 4% within three days (Figure 1A). Aft er two weeks, infected 
mice returned to their initial weight and from then on were comparable to control mice, 
which did not lose weight at any time point. BALF cultures of infected mice, but not 
control mice, were positive for M. pneumoniae with the highest median bacterial load of 
3×104 CFU/ml on day three p.i. (Figure 1B). Bacterial loads in BALF gradually declined 
within two weeks, and were undetectable at four weeks aft er infection. In contrast to 
the lung, M. pneumoniae persisted in the nose. During the fi rst two weeks of infection, 
median bacterial loads were 5–9×104 CFU/ml, and at day 42 p.i., M. pneumoniae was still 
detected in the nasal lavage fl uid of 5 out of 6 mice, with a median bacterial load of 6×102 
CFU/ml (Figure 1C). Th e only mouse in which M. pneumoniae was not detected in the 
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Figure 1. M. pneumoniae persists in the nose after pulmonary infection.
C57BL/6 WT mice were infected intranasally with 1×109 CFU M. pneumoniae M129 (black circles) or mock-
infected with SP4 medium (white circles). (A) Body weight changes were monitored at indicated time 
points p.i. and expressed as percentage of body weight at day 0; the mean ± SD of each group (n=6–16 
mice/time point) is shown. *p<0.05 and ***p<0.001 (Welch’s t-test with Holm-Bonferroni method correc-
tion). (B–C) Bacterial loads as CFU/ml in BALF and nasal lavage fl uid; values are expressed as median with 
interquartile range (IQR). (D–E) Immunofl uorescent images of lung and nasal sections of C57BL/6 WT mice 
(n=3 mice/time point) at indicated time points after intranasal inoculation with 1×109 CFU CFSE-labeled M. 
pneumoniae M129 (image: 200× magnifi cation; inset 630× magnifi cation).
49
Ch
ap
te
r 2
The role of B cells in carriage and clearance of Mycoplasma pneumoniae from the respiratory tract of mice
nasal lavage fluid at day 42 p.i. did show a positive culture for M. pneumoniae when nasal 
brush samples were analyzed (data not shown).
These findings were corroborated using CFSE-labeled M. pneumoniae M129: CFSE-
labeled bacteria were detected on the bronchial epithelium and in alveoli forming islets 
in the lungs at day one p.i. (Figure 1D). The loss of fluorescence from the lungs of infected 
mice at day three p.i. likely resulted from bacterial replication, as high bacterial loads were 
detected in the lungs at this same time point (Figure 1B) and CFSE signals are reduced 
two-fold at each bacterial division.33 This was confirmed when sections were incubated 
with an anti-M. pneumoniae antibody: M. pneumoniae was detected in the lungs both at 
day one and day three p.i. (data not shown). By contrast, CFSE-labeled M. pneumoniae 
was detected on the nasal respiratory epithelium at both time points analyzed, without an 
apparent loss of fluorescence intensity between these time points (Figure 1E). In contrast 
to previous studies showing invasion and intracellular survival of M. pneumoniae in 
vitro,34,35 we did not observe CFSE-labeled M. pneumoniae within respiratory epithelial 
cells (Supplementary Figure S2).
Specific IgG antibodies in serum and BALF coincide with clearance of 
M. pneumoniae from the lungs
To define the course of pneumonia following infection with M. pneumoniae and identify 
immune mechanisms that contribute to pulmonary clearance, we examined pulmonary 
inflammation by HPS as well as immune cells and antibodies in BALF at the indicated 
time points after inoculation of mice with M. pneumoniae. Pulmonary inflammation, 
demonstrated by both inflammatory infiltrates and necrosis in HPS (Figure 2A) and 
increased BALF leukocytes (Supplementary Figure S3A), was most severe on day three 
p.i., and resolved at day 28 p.i. At day three p.i., the infected lungs showed pulmonary 
consolidation at gross pathology and histopathology showed thickened alveolar septa 
characterized by infiltration of inflammatory infiltrates and presence of perivascular 
and peribronchiolar cuffing (Figure 2B). Using flow cytometry, we detected a major 
influx of granulocytes, monocytes, and dendritic cells (DCs) into BALF at day three p.i. 
(Supplementary Figure S3B), which corroborated the inflammation seen histologically at 
that time point (Figure 2). Additionally, increased numbers of CD4+ and CD8+ T cells, 
natural killer (NK) cells, and B cells were detected in infected lungs, albeit at much lower 
frequencies than observed for the innate immune cells (Supplementary Figure S3C).
Since B cells only marginally infiltrated the lungs, we evaluated the systemic and local 
humoral immune response against M. pneumoniae. Both M. pneumoniae-specific IgM 
and IgG were detected in serum from day seven p.i. (Figure 3A). While specific IgM levels 
declined after day 28 p.i., specific IgG persisted at high levels. Further analysis revealed 
that both IgG1 and IgG2a subclasses were present in the M. pneumoniae-specific IgG 
pool (Figure 3B), which indicates neutralizing and complement-dependent killing of M. 
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pneumoniae. Indeed, we found that the serum of M. pneumoniae-infected WT mice had 
the capacity to opsonize M. pneumoniae resulting in enhanced internalization and killing 
of the bacteria by macrophages in vitro (Figure 3C).
Notably, M. pneumoniae-specific IgG levels in the nasal lavage fluid were far below 
those detected in BALF on day 42 (Figure 4A). The opposite was seen for specific IgA: the 
levels were highly increased in nasal lavage fluid but not in BALF. Total IgG and IgA levels 
were similar in BALF and nasal lavage fluid (Supplementary Figure S4). ELISpot analysis 
revealed that M. pneumoniae-specific IgA ASCs were present in CLN and nasal passages 
seven days p.i., with highest numbers in CLN (Figure 4B). In contrast and in line with 
the data obtained by ELISA, M. pneumoniae-specific IgA ASCs were not present in MLN.
This prompted us to investigate the activation and expansion of B cells in the CLN 
and MLN that drain the URT and LRT, respectively. B cell expansion and activation was 
observed in both MLNs and CLNs, but not in peripheral (inguinal) lymph nodes (PLNs), 
which indicates that M. pneumoniae infection induced a B cell response only locally and 
not systemically (Figure 4C and 4D). It is interesting to note that the expression levels 
of CD86 were higher on B cells in MLN than on those in CLN (Figure 4E). Notably, 
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Figure 2. M. pneumoniae is characterized by alveolar and bronchiolar immune cell infiltrates at day 3 p.i.
C57BL/6 WT mice were M. pneumoniae-infected (black bars) or mock-infected (white bars). (A) HPS for mice 
at indicated time points p.i.; bars represent the median ± IQR of each group (n=6 mice/time point). *p<0.05 
(Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test). (B) Representative lung paraffin sec-
tions from M. pneumoniae-infected and control mice on day 3 p.i., stained with H&E (image: 50× magnifica-
tion; inset: 200× magnification).
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increased numbers of CD86+ B cells were still found in CLN, but not in MLN, on day 28 
p.i., albeit not signifi cant from controls. Together, these fi ndings demonstrate a distinct 
diff erence in the B cell response to M. pneumoniae between LRT and URT lymphoid 
tissues.
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Figure 3. M. pneumoniae-specifi c serum antibodies have neutralizing capacities.
(A–B) M. pneumoniae-specifi c antibody levels as AU in serum of M. pneumoniae-infected (black circles) and 
control treated (white circles) C57BL/6 WT mice (n=6–16 mice/group per time point): (A) M. pneumoniae-
specifi c IgM, IgG, and IgA at indicated time points p.i.; (B) M. pneumoniae-specifi c IgG subclasses IgG1 and 
IgG2a at day 42 p.i. Dots represent individual mice, and the horizontal line in each graph represents the 
median. (C) M. pneumoniae was incubated with sera from infected (dark gray box) or uninfected (light gray 
box) C57BL/6 WT mice or with medium (white box) and subsequently co-cultured with RAW cells for 20 
minutes. After washing, phagocytosis and killing of M. pneumoniae was determined based on the number 
of CFU/105 RAW cells recovered. The box represents the lower and upper quartiles, and the median is shown 
as a line across the box. Whiskers extend to the maximum or minimum values within 1.5 times the IQR 
above and below the 3rd and 1st quartile, respectively. *p<0.05 and **p<0.01 (A: Kruskal-Wallis test with 
post hoc Dunn’s multiple comparisons test; B: Mann-Whitney U test).
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Figure 4. Differential B cell activation in upper versus lower respiratory tract.
(A) Analysis of M. pneumoniae-specific IgG and IgA antibody levels (AU/ml) in BALF and nasal lavage fluid 
at 42 days p.i. (IgG) and 28 days p.i. (IgA) of M. pneumoniae- and mock-infected C57BL/6 WT mice (n=4–6 
mice/group per time point). (B) Analysis of M. pneumoniae-specific and total IgA ASCs in MLNs, CLNs, and 
nasal passages at 7 days p.i. of M. pneumoniae-infected C57BL/6 WT mice (n=3–6 mice). (C) Number of 
CD19+MHCII+ B cells in MLNs, CLNs, and PLNs of C57BL/6 WT mice. (D–E) CD86+ B cell numbers (D) and 
mean fluorescence intensity (MFI) as ratio to medium controls (E) in MLNs and CLNs of C57BL/6 WT mice. 
Bars and horizontal lines indicate the median and dots individual mice. *p<0.05 and **p<0.01 (A: Mann-
Whitney U test; B–E: Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test).
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B cells are essential for pulmonary clearance of M. pneumoniae and affect 
M. pneumoniae carriage
To further evaluate the contribution of B cells to protective immunity against M. pneu-
moniae, we assessed whether bacterial replication in the URT and LRT is altered in μMT 
mice. Similar to WT mice, an initial body weight loss at day three p.i. was measured in 
μMT mice. Yet, while infected WT mice were back at their initial weight within two 
weeks and from then on continued to gain weight, the weight of μMT mice remained 
lower than that of WT mice at all time points analyzed (Figure 5A). Interestingly, while 
M. pneumoniae was no longer detectable in BALF of WT mice at day 28 p.i., bacteria 
were still detectable at day 42 in μMT mice, albeit at relatively low levels (Figure 5B). 
In the absence of antibodies mycoplasma is suggested to be more prone to disseminate 
extrapulmonary,16-18 however, spleen, liver, and articular surfaces of μMT and WT mice 
on day 14 and 28 p.i. were negative for M. pneumoniae by culture and PCR (data not 
shown).
In line with the long-term presence of M. pneumoniae in the lungs of μMT mice, both 
the HPS of alveoli (Figure 5D) and the lung leukocyte number (Figure 5E) of μMT mice 
was higher than those of WT mice on day three p.i. Moreover, in comparison with WT 
mice, the lungs of μMT mice showed even increased numbers of leukocytes on day 42 p.i. 
(Figure 5E and 5F).
Interestingly, also significantly reduced control of bacterial replication was noted in 
the URT of μMT mice (Figure 5C). M. pneumoniae was detected in nasal lavage fluid of 
all μMT mice and the median bacterial loads remained at similar levels from day 14 to 
42 p.i. (2×104 CFU/ml), while median bacterial loads in WT mice decreased from 4×104 
to 6×102 CFU/ml during this time period. In the absence of B cells, significantly higher 
levels of the proinflammatory mediators IL-6 and monocyte chemoattractant protein 
(MCP)-1 were detected in nasal lavage fluid of μMT mice at day 3 p.i. (Figure 5G).
Serum transfer from WT infected mice to infected μMT mice controls bacterial 
replication only in the lungs
To specifically examine the contribution of the IgG and IgM antibodies in serum to clear-
ance of bacteria from the nose, we passively immunized μMT mice with serum from 
infected WT mice. Therefore, donor and recipient mice were both intranasally inoculated 
with 1×109 CFU of M. pneumoniae M129. Two weeks later, when recipient WT and μMT 
mice still had similar median levels of bacterial loads in the lungs (Figure 5B), donor 
serum was transferred (Figure 6A). As shown in Figure 6B, μMT mice were only able to 
control M. pneumoniae replication in the lungs upon transfer of serum from infected WT 
mice, as indicated by the similar bacterial load in the lungs of μMT and WT mice at day 
28 p.i. Transfer of μMT serum, however, did not reduce M. pneumoniae loads in the lungs 
of infected μMT recipient mice; pulmonary M. pneumoniae loads in these μMT recipients 
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were similar to those of untreated controls at day 28 p.i. (Figure 6B). Moreover, these 
findings were corroborated by the detection of M. pneumoniae-specific IgG in the BALF 
of four out of six μMT recipient mice two weeks after WT serum transfer (Figure 6D). M. 
pneumoniae persisted in the lungs of the two μMT recipient mice, whose BALF did not 
contain M. pneumoniae-specific IgG after serum transfer (Figure 6E).
By contrast, the bacterial loads in the nose were comparable for all recipient μMT mice 
(with a median of 2×104 CFU/ml), irrespective of the specific source of the serum (Figure 
6C). The median concentration of M. pneumoniae-specific and total IgG in nasal lavage 
fluid of infected μMT mice after serum transfer was 5 AU/ml and 0.005 μg/ml, respectively, 
at day 28 p.i. Notably, there was no significant difference between M. pneumoniae-specific 
IgG levels in BALF and nasal lavage fluid of μMT mice receiving WT serum (median 6 
vs. 5 AU/ml). In addition to nasal lavage fluid and BALF, M. pneumoniae-specific and 
total IgG antibodies were also detected in serum of μMT mice after WT serum transfer 
(Supplementary Figure S5).
DISCUSSION
In this study, we show M. pneumoniae persistence after infection in a further developed 
mouse model for M. pneumoniae infection.30-32 B cells in lung-draining MLNs become 
activated and expand early after M. pneumoniae infection, resulting in elevated levels of 
M. pneumoniae-specific IgM and IgG antibodies in serum and BALF. This B cell activation 
in MLNs may be key to clear the infection as shown by our observations in μMT mice, 
in which M. pneumoniae infection leads to chronic pulmonary disease, characterized 
by failure to thrive, more severe pneumonia, and long-lasting innate and adaptive com-
pensatory immune cell infiltrates, due to bacterial persistence in the lungs. Conversely, 
μMT mice do clear M. pneumoniae infections in the lungs when passively immunized 
Figure 5. B cell-deficient μMT mice show limited pulmonary clearance of M. pneumoniae and higher nasal 
carriage rates.
C57BL/6 WT mice (black circles) and μMT mice (gray squares) were infected intranasally with M. pneumoni-
ae. Control mice (white circles) received SP4 medium alone. (A) Body weight changes were monitored at 
indicated time points p.i. and expressed as percentage of body weight at day 0; the mean ± SD of each 
group is shown (n=6–13 mice/time point). (B–C) Bacterial loads as CFU/ml in BALF and nasal lavage fluid; 
values are expressed as median with IQR. (D) HPS for mice at indicated time points p.i.; the mean ± SD 
of each group (n=6–7 mice/time point) is shown. (E) Absolute number of leukocytes in lungs at differ-
ent days p.i. (F) Numbers of lung granulocytes (Ly6G+CD11bhiCD11c-), monocytes (CD11bhiLy6G-CD11c-), 
CD4+ T cells (CD3+CD4+), and CD8+ T cells (CD3+CD8+). (G) IL-6, monocyte chemoattractant protein (MCP)-1, 
macrophage inflammatory protein (MIP) 1β, and tumor necrosis factor (TNF)-α in nasal lavage fluids of M. 
pneumoniae-infected WT and μMT mice were determined by multiplex fluorescent-bead-based immunoas-
say. Median levels with IQR are shown. *p<0.05 and *p<0.01 (A: Welch’s t test with Holm-Bonferroni method 
correction; B–C: Mann-Whitney U test with Holm-Bonferroni method correction; D–F: Kruskal-Wallis test 
with post hoc Dunn’s multiple comparisons test; A–C: μMT vs. infected WT mice).
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with serum from infected WT mice. Additionally, we showed that the induced antibodies 
enhance phagocytosis and killing by macrophages in vitro, which suggests that they can 
contribute to resolve M. pneumoniae infections in vivo.
In contrast to the lungs, B cells in the nose-draining CLN did not become activated by 
the presence of M. pneumoniae. As the draining lymph nodes are the major sites of B cell 
induction following RTI,36 the observed differences in B cell expansion and activation 
between the nose-draining CLN and lung-draining MLN suggest a different control of 
bacterial replication in the URT compared to that in the LRT. Indeed, M. pneumoniae 
persisted in the nose of WT mice while the bacterium was cleared from the lungs during 
the course of infection. Importantly, these data mimic the findings in humans, where 
M. pneumoniae is carried in the URT of children up to eight months after symptomatic 
infection.3-7 The observed difference in B cell responses between LRT and URT lymphoid 
tissues is in line with the low levels of M. pneumoniae-specific IgG and IgM in the nasal 
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Figure 6. Adoptive transfer of wild-type (WT) serum allows B cell-deficient μMT mice to control M. pneu-
moniae infection in the lungs.
(A) Experimental setup of the serum transfer experiment (n=6 mice/group). (B–C) Bacterial loads as CFU/ml 
in BALF and nasal lavage fluid of WT and μMT mice. (D) M. pneumoniae-specific IgG levels (AU/ml) in BALF 
of WT and μMT mice. (E) Correlation between M. pneumoniae-specific IgG and bacterial load in BALF of μMT 
mice that were untreated or passively immunized with WT serum. The p value is indicated in the graphs 
(B–D: Mann-Whitney U test; E: Pearson product-moment correlation coefficient).
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lavage fluid. It is unlikely that M. pneumoniae-specific IgG does not reach the URT, as 
total IgG levels were similar in nasal lavage fluid and BALF, and we observed comparable 
bacterial loads in the URT of WT mice as in that of Btk– mice, which have reduced pe-
ripheral B cell numbers (data not shown). In contrast to M. pneumoniae-specific IgG, M. 
pneumoniae-specific IgA was more abundant in nasal lavage fluid than in BALF of M. 
pneumoniae-infected mice. While this has not been shown before for bacterial infections, 
similar observations were made in influenza virus-infected mice.37 The vast majority 
of ASCs in the URT (NALT) of such mice were found to produce IgA, whereas B cell 
responses in the LRT (lungs) mainly generated IgG and IgM.38 In fact, we also detected 
M. pneumoniae-specific IgA ASCs in CLN and nasal passage, but not in MLN, which is 
in line with observations from Hodge and Simecka,39 showing mycoplasma-specific IgA 
ASCs in nasal passages but not in the lungs from mice following nasal immunization. 
Furthermore, these data also corroborate our findings on the presence of IgA in nasal 
washes but not in BALF. Detection of M. pneumoniae-specific IgA-producing ASCs in 
the nasal passage, albeit at lower numbers than in CLN, may indicate that some of the 
activated B cells have migrated into the nasal passage.
The locally induced immune responses upon M. pneumoniae carriage in the URT and 
infection of the LRT are distinct. We show that M. pneumoniae-specific IgG controls M. 
pneumoniae in the lungs and does not impact on carriage in the URT. By contrast, M. 
pneumoniae-specific IgA and IgA ASCs in the URT affect M. pneumoniae carriage, but 
do not mediate complete resolution of the bacteria. Using μMT mice and serum transfer 
studies we further assessed the relative roles of immunity in the URT and LRT of M. 
pneumoniae infected mice. Transfer of WT immune serum, containing M. pneumoniae-
specific IgG, controlled M. pneumoniae pulmonary infection in lungs of μMT mice but 
did not lead to a reduction of M. pneumoniae loads in the nose. Together, these observa-
tions demonstrate the importance of local immunity. Yet, why IgA cannot clear bacterial 
carriage in the URT is unknown.40 M. pneumoniae is not known to possess IgA protease 
activity.41 Also, increasing local specific IgA responses by immunization did not lead to a 
corresponding reduction of mycoplasma bacterial loads in the nose,39 which suggests that 
enhancing IgA responses alone does not control carriage in the URT.
Our observation that M. pneumoniae infections are more severe – and chronic – in 
μMT mice may resemble the findings in patients that suffer from B cell deficiencies,42 
such as common variable immunodeficiency, X-linked agammaglobulinemia, or hypo-
gammaglobulinemia, who have been reported to be at increased risk for M. pneumoniae 
pulmonary disease and/or extrapulmonary manifestations, e.g., arthritis.21-25 It can be 
speculated that if these patients experience M. pneumoniae infections, they may benefit 
from intravenous immunoglobulin (IVIg) treatment, as our data demonstrate that ad-
ministration of serum containing M. pneumoniae-specific IgG protected μMT mice from 
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pulmonary M. pneumoniae infections. In fact, high amounts of M. pneumoniae-specific 
IgG can be detected in commercial human IVIg preparations.43
While the M. pneumoniae mouse model provides a useful tool to investigate the im-
munological processes involved in controlling infection of the lungs and carriage in the 
nose, the use of the human pathogen M. pneumoniae instead of M. pulmonis44 can be a 
limitation of our study considering the genomic differences between these pathogens.45
CONCLUSIONS
Together, we show for the first time that, like in humans, M. pneumoniae is carried in the 
URT of mice after symptomatic infection. In addition, we demonstrate that B cells and M. 
pneumoniae-specific antibodies are crucial for M. pneumoniae clearance in the lungs of 
mice, but are limited in clearing M. pneumoniae from the URT. These novel aspects of M. 
pneumoniae-host interactions will aid the understanding of M. pneumoniae pathogen-
esis and promote the development of M. pneumoniae-targeting vaccines to prevent the 
progress of M. pneumoniae pulmonary disease in individuals that carry M. pneumoniae.
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SUPPLEMENTARY DATA
METHODS
Bacteria
M. pneumoniae reference strain M129 (subtype 1, ATCC 29342) was cultured at 37°C/5% 
CO2 in SP4 medium (1.4% Difco PPLO broth [Becton Dickinson, Sparks, MD, USA] 
supplemented with 0.15% Difco TC Yeastolate, UF [Becton Dickinson], 1.4% glucose, 
20% horse serum, 0.02 mg/ml phenol red, 1000 U/ml penicillin, 500 U/ml polymyxin B, 
3 μg/ml amphotericin B, and 5 μg/ml voriconazole; pH 7.8−8.0) for 72 hours, harvested, 
washed and concentrated in fresh SP4 medium to 1×109 CFU/ml. Aliquots were stored 
at −80°C until use.
M. pneumoniae infection and carriage mouse model
At indicated time points, mice were sacrificed and BALF samples were obtained by flush-
ing the lungs 2 times with 1 ml of PBS containing 0.5 mM EDTA. The same tracheal 
puncture was used to flush the nasal cavity 2 times with 0.2 ml PBS containing 0.5 mM 
EDTA. All BALF and nasal lavage fluid samples were kept on ice until further processing. 
Next, the lungs were removed and right lung lobes were cut into grain size pieces and 
incubated in PBS supplemented with 20 μg/ml Liberase-TL (Roche Diagnostics GmbH, 
Manheim, Germany) and 2 U/ml DNase I (Sigma, St. Louis, MO, USA) for 30 min at 
37°C. Lung cell suspensions were passed through a 100 μm gauze (BD Falcon, Franklin 
Lakes, NJ, USA). Erythrocytes in single cell suspensions of lungs and LNs were lysed with 
ACK lysis buffer. Subsequently, the immune composition was analyzed by flow cytometry 
upon staining with specific antibodies. The left lobes of the lungs were placed in 4% PFA 
for 24 h, washed in 70% ethanol, dehydrated in series of alcohols, and embedded in 
paraffin. The heads of mice were placed in acetic acid-zinc-formalin for 24 h, washed 
in distilled water for 30 min, decalcified in Gooding and Stewart’s decalcification fluid 
(10% formic acid and 5% formaldehyde) for 6 h, before being processed and embedded 
in paraffin similar as for lung tissue. Four μm-thick paraffin-embedded sections were 
stained with H&E.
M. pneumoniae quantification
To analyze the presence and amount of M. pneumoniae ex vivo, 100 μl of undiluted and 
10-fold diluted BALF and nasal lavage fluid were cultured on SP4 agar plates at 37°C. 
Sample suspensions of homogenized spleen and liver tissue, as well as from immersed 
cotton swabs of articular surfaces, were processed in a similar fashion. Quantification was 
performed by counting CFUs. Alternatively, the presence of M. pneumoniae was detected 
using quantitative PCR as previously described.28
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Quantification of antibodies
Detection of total antibody concentration
Concentrations of IgM, IgG, and IgA were determined in serum, BALF or nasal lavage 
fluids by sandwich ELISA. In brief, diluted sera or lavage fluids were added in duplicate 
onto 96-well polystyrene plates (Corning Costar, Corning, NY, USA) that were pre-
coated with polyvalent rabbit anti-mouse IgM (1000 ng/ml), goat anti-mouse IgG (2200 
ng/ml) or goat anti-mouse IgA (350 ng/ml). The bound antibodies in sera and lavage 
fluids were detected by addition of horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse IgM, goat anti-mouse IgG or goat anti-mouse IgA. Binding was visualized using 
tetramethylbenzidine (TMB; Sigma) as substrate and optical density was measured at 650 
nm with a VersaMax ELISA microplate reader (VersaMax, Molecular Devices, Sunnyvale, 
CA, USA). The results were analyzed by microplate data collection and analysis software 
(VersaMax). Purified mouse IgM, IgG or IgA were used as standard. All antibodies and 
standards were obtained from Thermo Scientific (Waltham, MA, USA).
Detection of M. pneumoniae-specific antibodies
For assessment of specific antibodies against M. pneumoniae, 96-well half-area polysty-
rene plates (Corning Costar) were coated o/n at 4°C with 10 μg whole cell lysates of M. 
pneumoniae M129 in 100 mM sodium carbonate-bicarbonate buffer (pH 9.6) containing 
1 M urea. The next day, non-specific binding was blocked by incubation with PBS/1% 
BSA (Sigma) for 2 h at RT. The samples were diluted in PBS/0.1% BSA (1:100 and 1:300 
for IgM; 1:50 and 1:100 for IgG; 1:10 and 1:30 for IgA) and 100 μl were incubated in 
duplicate o/n at 4°C. Bound antibodies were detected by HRP-conjugated antibodies as 
described above. The same Ig isotype standards as for the detection of the total antibody 
concentration was used to determine the AU of antibodies against M. pneumoniae M129 
as follows. At a given optical density value in the linear range, the reciprocal dilutions of 
the serum samples were divided by the reciprocal dilution of the standard antibodies.
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Supplementary Figure S1. Flowcytometric gating strategy for innate and adaptive immune cells in lung 
tissue.
The following anti-mouse monoclonal antibodies were used: PerCP-Cy5.5-conjugated anti-CD19 (clone 
1D3; eBioscience) and anti-Ly-6G (1A8; BD Biosciences), APC-conjugated anti-CD4 (RM4-5; BD Biosciences) 
and anti-CD11c (HL3; BD Biosciences), PE-conjugated anti-CD8a (53-6.7; Biolegend, San Diego, CA, USA) 
and anti-SiglecF (E50-2440; BD Biosciences), biotinylated anti-CD3e (145-2C11; Biolegend) and anti-Ly-6C 
(AL-21; BD Biosciences), APC-Cy7-conjugated anti-MHCII (M5/114.15.2; Biolegend), PE-Cy7-conjugated 
anti-NK1.1 (PK136; Biolegend) and anti-CD11b (M1/70; BD Biosciences), and BV510-conjucated anti-CD5 
(53-7.3; BD Biosciences) and anti-CD19 (1D3; BD Biosciences). The secondary antibody was FITC-conjugated 
streptavidin (Biolegend). Controls included isotype controls (Biolegend and eBioscience), single positive, 
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and unstained cells. Dead cells were excluded using the live/dead fi xable dead cell stain kit (Pacifi c blue 
dye, Invitrogen) and tandem dyes were protected with stabilizing fi xative (BD Biosciences). Gating strategy: 
viable single cells were analyzed by excluding dead cells. Subsequently, single cells were gated (FSC-W 
and FSC-H) and viable single innate cells or lymphocytes were analyzed by gating on the basis of FSC-A 
and SSC-A. Granulocytes and monocytes were identifi ed as Ly6G+CD11bhiCD11c- and CD11bhiLy6G-CD11c-, 
respectively; alveolar macrophages as SiglecFhiCD11chi and DCs as CD11c+MHCII+ (excluding lymphocytes 
by CD4 and CD19 negativity); CD3 positivity discerned CD4+ and CD8a+ T cells (CD3+CD4+ and CD3+CD8a+ 
cells) from NK1.1+CD3- NK cells; additionally, CD3-CD19+MHCII+ B cells were distinguished.
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Supplementary Figure S2. Immunofl uorescent images of lung and nasal sections of mice infected with 
CFSE-labeled M. pneumoniae and of controls.
Experimental setup as described in the legend to Figure 1D–E: (A) Lung sections. (B) Nasal sections. Im-
ages at 200× magnifi cation of C57BL/6 mice at indicated time points after intranasal administration of SP4 
medium (control), 1×109 CFU of M. pneumoniae (M129), and 1×109 CFU of CFSE-labeled M. pneumoniae 
(CFSE-M129) (n=3 mice/group/time point). The vertical line in the scheme of the nasal cavity indicates the 
anterior surface of the frontal nasal tissue blocks, which were selected for microscopic examination (inset 
indicates the location for images).
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Supplementary Figure S3. Immune cells and pro-inflammatory mediators in BALF during M. pneumoniae 
infection in WT mice.
Experimental setup as described in the legend to Figure 1 (n=6–16 mice/group/time point): (A) Absolute 
leukocyte number in BALF at indicated time points p.i. (B–C) Frequency of innate (B) and adaptive (C) im-
mune cell subsets in BALF. (D) IL-6, MCP-1, MIP1β, and TNF-α levels in BALF. Data are expressed as median 
(with IQR). *p<0.05, **p<0.01, ***p<0.001 (Mann-Whitney U test).
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Supplementary Figure S4. Kinetics of antibodies in serum, BALF, and nasal lavage fluids of M. pneumoniae-
infected mice.
Experimental setup as described in the legends to Figure 3 and 4: (A) Total serum concentrations of IgM, 
IgG, and IgA at indicated time points p.i. (B) Total IgG and IgA concentrations in BALF and nasal lavage fluid 
at day 42 p.i. (IgG) and day 28 p.i. (IgA), respectively. Data are expressed as median (with IQR). *p<0.05, 
**p<0.01 (Mann-Whitney U test).
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Supplementary Figure S5. Specific and total antibodies in serum and BALF of WT and μMT mice after 
serum transfer.
Experimental setup as described in the legend to Figure 6: (A–B) M. pneumoniae-specific and total IgM, IgG, 
and IgA in serum. (C) M. pneumoniae-specific IgA in BALF. (D) Total IgG and IgA in BALF. The horizontal line 
represents the median. The absolute median value is specified above for μMT mice without serum transfer 
and μMT mice receiving WT serum. The p value is indicated in the graphs (Mann-Whitney U test).
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INTRODUCTION TO ENCEPHALITIS
Encephalitis is a severe neurologic disorder characterized by inflammation of the brain 
parenchyma.1 It results in substantial morbidity and mortality worldwide. The clinical 
diagnosis is complicated as the symptoms and signs are similar to many other serious 
neurological diseases. There are many infectious and immune-mediated etiologies, but 
specific causes are identified in only about 50% of the cases.
Clinical definition
Encephalitis is defined as inflammation of the brain parenchyma associated with neu-
rologic dysfunction.2 Pathologic examination and testing of brain tissue are considered 
to be the “gold standard” diagnostic test. Because of the risk of invasive neurosurgical 
procedures, the clinical definition of encephalitis is based on selected clinical, labora-
tory, electroencephalographic, and neuroimaging features in most cases. Current clinical 
diagnostic criteria for encephalitis are listed in Table 1. The clinical definition is viewed 
to be complementary to the etiological definition, since diagnosis of an infection with an 
organism that is strongly associated with encephalitis would confirm a clinical diagnosis 
of encephalitis.1
Table 1. Diagnostic criteria for encephalitis and encephalopathy of presumed infectious or autoimmune 
etiology.
Major criterion (required):
Patients presenting to medical attention with altered mental status (defined as decreased or altered level of 
consciousness, lethargy or personality change) lasting 24 h with no alternative cause identified.
Minor criteria (2 required for possible encephalitis; 3 required for probable or confirmed* encephalitis):
-  Documented fever ≥38°C (within the 72 h before or after presentation);
-  Generalized or partial seizures not fully attributable to a preexisting seizure disorder;
-  New onset of focal neurologic findings;
-  CSF WBC count ≥5/mm3;
-  Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior 
studies or appears acute in onset;
-  Abnormality on EEG that is consistent with encephalitis and not attributable to another cause.
Abbreviations: CSF, cerebrospinal fluid; EEG, electroencephalogram; WBC, white blood cell. Table adapted 
from Venkatesan et al.1
* Confirmed encephalitis requires one of the following: (1) pathologic confirmation of brain inflammation 
consistent with encephalitis; (2) defined pathologic, microbiologic, or serologic evidence of acute infection 
with a microorganism strongly associated with encephalitis from an appropriate clinical specimen;3 or (3) 
laboratory evidence of an autoimmune condition strongly associated with encephalitis.7
Etiological definition
The most commonly demonstrated etiology in encephalitis is infection, predominantly 
caused by viruses. However, defining the causal relationship between a microbe and en-
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cephalitis is complex.3 Over 100 different infectious agents may cause encephalitis, often 
as one of the rarer manifestations of infection. Further, the failure to identify a pathogen 
does not exclude the diagnosis. In fact, a higher proportion of studies with children 
compared to with adults had 50% of cases with unknown etiology (62% vs. 20%).4
The “gold standard” techniques to detect causative infectious agents in encephalitis 
depend on brain biopsy material. Because this is not possible in most cases, there exists a 
hierarchy of sample locations to attribute causality (Figure 1).3
BRAIN*
Organism within
CNS ± intrathecal
specific
immune response
Organism in sterile
site† ± specific
immune response 
Organism carriage
 and evidence of specific immune
response
Organism carriage – detection in non-
sterile site and no specific immune response
Increased
likelihood of 
being causative
agent
Figure 1. Hierarchy of diagnostic tests for defining causal relationship between a pathogen and the syn-
drome encephalitis.
*Hierarchy not relevant for all bacteria and viruses, e.g., rabies virus. †Normally sterile site: blood, cerebro-
spinal, joint, pleural, or pericardial fluid. Reproduced with permission from Granerod et al.,3 Cambridge 
University Press.
Specific etiologies
The multiple etiologies in pediatric encephalitis of a recent study are shown in Table 2. 
Overall, Mycoplasma pneumoniae infection is reported in 5–10% of pediatric encephalitis 
patients.5,6 In this thesis, we investigate the association of M. pneumoniae with pediatric 
encephalitis (Chapter 5–8).
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Table 2. Etiology of pediatric encephalitis.
Etiology of encephalitis Total
n %
Infectious 49 30
-  Enterovirus 20 12
-  M. pneumoniae 11 7 
-  Herpes simplex virus 9 5 
-  Cytomegalovirus 3 2 
-  other* 6 4 
Infection-associated encephalopathy 13 8
-  Influenza virus 5 3
-  Rotavirus 5 3 
-  Acute necrotizing encephalopathy** 3 2 
Immune-mediated or autoantibody-associated 56 34
-  Acute disseminated encephalomyelitis (ADEM) 35 21
-  N-methyl-D-aspartate receptor (NMDAR) antibody 10 6 
-  Voltage-gated potassium channel complex (VGKC-complex) antibody 7 4 
-  Dopamine D2 receptor antibody 4 2 
Unknown 46 28
Total 164 100
Table about etiology of pediatric encephalitis in Australia, 1998–2010, adapted from Pillai et al.8
* Group A Streptococcus (n=1), adenovirus (n=1), Epstein-Barr virus (n=1), parainfluenza virus 3 (n=1), par-
vovirus B19 (n=1), varicella zoster virus (n=1);
** Associated infections in 2 of 3 patients.
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ABSTRACT
The pathogenesis of Mycoplasma pneumoniae encephalitis is not established. We report, 
for the first time, the case of a patient with severe Bickerstaff brain stem encephalitis in 
whom we detected intrathecal production of M. pneumoniae-specific antibodies, con-
trasting the findings in another patient with less severe encephalitis in whom we detected 
intrathecal M. pneumoniae DNA but no specific antibodies. Our observations suggest 
that intrathecal M. pneumoniae-specific antibody responses may contribute to a more 
severe course of M. pneumoniae encephalitis.
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INTRODUCTION
Mycoplasma pneumoniae is a leading cause of encephalitis in children.1 The paucity of 
reports on M. pneumoniae isolation from or detection in the central nervous system 
(CNS) favors the hypothesis that M. pneumoniae-associated encephalitis is caused by 
an immune-mediated inflammation.2 The inflammation may be induced by molecular 
mimicry between M. pneumoniae and neuronal cell components.3
We recently reported on the case of a 15-year-old girl with self-limiting M. pneumoni-
ae-associated encephalitis showing microbial CNS invasion but no intrathecal specific 
antibody responses (Table 1: Case 1). Therefore, we speculated that intrathecal antibody 
responses might be present in more severe M. pneumoniae-associated encephalitis.4 Here, 
we report on a contrasting case of a patient with M. pneumoniae-associated encephalitis 
with neurologic sequelae who indeed showed detectable intrathecal specific antibody 
responses.
Table 1. Microbiological and clinical data for two patients with confirmed M. pneumoniae-associated en-
cephalitis.
Diagnosis Case 14 Case 2
Meningoencephalitis Bickerstaff brain stem 
encephalitis
Age (years) and sex 15, F 9, M
Prodromal respiratory symptoms (duration) Cough and fever (2 weeks) Cough and runny nose (3 
weeks)
Pulmonary infiltrate (chest radiograph) Yes Yes
White blood cell count (4.5–13.5×109/l) 11.7×109/l (neutrophils 79%) 6.8×109/l (neutrophils 70%)
C-reactive protein (<10 mg/) 2.7 mg/l 4.0 mg/l
Clinical findings
GCS score 15 5
Symptoms Neck pain, headache, diplopic 
images, and irritability
Meningism, ataxia, 
ophthalmoplegia, hemiplegia, 
and coma
Magnetic resonance imaging Normal Brain stem encephalitis
Electroencephalography Normal Mild diffuse and moderate focal 
slowing (right hemisphere and 
occipitotemporal)
CSF
White blood cells (0–5 cells/μl) 39 cells/μl (95% mononuclear) 11 cells/μl
Protein (150–450 mg/l) 200 mg/l 320 mg/l
Glucose (2.5–4.2 mmol/l) 3.7 mmol/l (blood: 5.3 mmol/l) 3.0 mmol/l (blood: 5.0 mmol/l)
M. pneumoniae real-time PCR
Pharyngeal swab Negative Positive
CSF Positive Negative
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CASE PRESENTATION
A 9-year-old boy was admitted in November 2012 to our hospital with a 3-week history of 
respiratory symptoms followed by headache and drowsiness (Table 1: Case 2). He mani-
fested meningism, ataxia, ophthalmoplegia, left-sided hemiplegia, and eventually coma 
within 24 hours. The analysis of cerebrospinal fluid (CSF) revealed 11 white blood cells/
μl, normal protein and glucose concentrations, and no growth in conventional bacterial 
cultures. Magnetic resonance imaging (MRI) showed pronounced brain stem encepha-
litis that worsened within 1 week (Figure 1). Because M. pneumoniae DNA was detected 
by real-time polymerase chain reaction (PCR) from a pharyngeal swab, we searched for 
intrathecal M. pneumoniae-specific antibodies. Indeed, we detected intrathecal specific 
antibody synthesis of three-isotype immunoglobulin (Ig) reaction according to Reiber5 
with dominant IgM response, as observed in neuroborreliosis5: index (cutoff 1.5) was 15.5 
(IgM), 7.2 (IgG), and 5.4 (IgA), respectively. In addition, antigen-specific immunoblot-
ting of CSF and serum IgG revealed positive responses in CSF against highly specific M. 
pneumoniae adhesion proteins P1 and P90 (insufficient CSF to test for IgM and IgA). M. 
pneumoniae was not detectable by PCR in CSF. Chest radiograph showed left-sided para-
cardial opacities. Other investigations for an infective cause were negative, including PCR 
for herpes simplex virus types 1 and 2, enterovirus, and Epstein-Barr virus in CSF; PCR 
for influenza A/B of a pharyngeal swab; and serology for Borrelia burgdorferi. Metabolic 
analysis included normal arterial blood gas, blood lactate level (1.3 mmol/l), and am-
monia (24 μmol/l). The empirical treatment with ceftriaxone and acyclovir was changed 
to intravenous doxycycline (4 mg/kg once daily for 7 days), and the patient additionally 
Table 1. Microbiological and clinical data for two patients with confirmed M. pneumoniae-associated en-
cephalitis. (continued)
Diagnosis Case 14 Case 2
Meningoencephalitis Bickerstaff brain stem 
encephalitis
M. pneumoniae-specific antibodies
M. pneumoniae ELISA (serum) (≤11 U/mL) IgM: 31.7, IgG: 15.5, IgA: 40.7 
U/ml
IgM: 67.0, IgG: 48.7, IgA: 34.3 
U/ml
Intrathecal antibody synthesis No Yes
Reiber index5 (cutoff: 1.5) – IgM: 15.5, IgG: 7.2, IgA: 5.4
Treatment and outcomes
Treatment Azithromycin PO (5 days) Doxycycline IV (7 days)
IVIg (1 g/kg once)
Prednisolone IV (5 days)
Sequelae No Yes
Abbreviations: CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; GCS, Glasgow Coma 
Scale; Ig, Immunoglobulin; IV, intravenous; PCR, polymerase chain reaction; PO, orally.
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received intravenous Ig (1 g/kg body weight once) and prednisolone (2 mg/kg twice daily 
for 5 days). The patient had to be intubated for 4 days. After 2 weeks, he was discharged 
into rehabilitation with mild residual ataxia, ophthalmoplegia, and hemiparesis.
DISCUSSION
Ophthalmoplegia and ataxia with disturbance of consciousness together with MRI find-
ings of brain stem encephalitis lead to the diagnosis of Bickerstaff brain stem encephalitis 
(BBE)6 that is considered a parainfectious autoimmune disorder similar to Miller Fisher 
syndrome and Guillain-Barré syndrome.7 All three disorders have been associated with 
M. pneumoniae infection but only two cases of BBE associated with M. pneumoniae infec-
tion have been reported.8,9 Nevertheless, the criteria to diagnose M. pneumoniae CNS 
infection10 were fulfilled in our case for the first time in BBE. Possible reasons for the 
negative PCR in CSF may be “spontaneous” clearance of M. pneumoniae from CSF as 
in our previous case4 or absent influx of CSF to the active inflammation site in the brain 
stem. The latter may be reflected by the low pleocytosis in our and the reported BBE 
cases.8,9 An alternative explanation could be that the pathogen may have been immuno-
logically cleared from the CNS. We detected an immune response, however, when the 
patient was symptomatic. This suggested that the mere infection process without immune 
reaction did not cause any symptoms that, in turn, is in line with M. pneumoniae not 
to harm or destroy cells.4 Notably, the late-onset disease, defined as the onset of CNS 
symptoms more than 1 week after the onset of respiratory symptoms,11 is consistent with 
the negative PCR in CSF1,11 and further supports an immune-mediated process.12 Thus, 
if clearance took place, then immunity was involved, and the immune reaction may have 
also caused immune-mediated symptoms. Anti-ganglioside GQ1b antibodies, frequently 
Figure 1. Magnetic resonance imaging findings in the brain of a 9-year-old boy with extensive Bickerstaff 
brain stem encephalitis during M. pneumoniae infection.
(A) Sagittal, (B) coronal, and (C) axial anatomy with T2-weighted cranial magnetic resonance imaging show-
ing hyperintensity and generalized edema of the brain stem with craniocaudal extension from crus poste-
rior of capsula interna to the pons.
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detected in BBE (in up to 68%6,7), were not detectable in our patient. Anti-GM1, anti-
GD1a, and anti-GD1b antibodies were negative, too.
This case of BBE with detectable intrathecal specific antibody responses suggests that the 
latter may contribute to augmented severity of CNS disease and supports our speculated 
immune-mediated pathogenesis of M. pneumoniae-associated encephalitis. Moreover, 
intrathecal specific antibody responses of three-isotype Ig reaction according to Reiber5 
may be essential to ascertain the diagnosis of M. pneumoniae-associated encephalitis.
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The pathogenesis of encephalitis associated with the respiratory pathogen Mycoplasma 
pneumoniae is not well understood. A direct infection of the central nervous system 
(CNS) and an immune-mediated process are discussed.1 Recent observations suggest that 
intrathecally detectable antibodies against the bacterium, which can serve to establish the 
etiology of encephalitis, may indeed mediate the disease.
M. pneumoniae is a major cause of upper and lower respiratory tract infections in humans 
worldwide, particularly in children.2,3 Up to 40% of community-acquired pneumonia in 
children admitted to the hospital are attributed to M. pneumoniae infection.4-7 Although 
the infection is rarely fatal, patients of every age can develop severe and fulminant disease. 
Apart from the respiratory tract infection, M. pneumoniae can cause extrapulmonary 
manifestations. They occur in up to 25% of manifest M. pneumoniae infections and may 
affect almost every organ, including the skin as well as the hematologic, cardiovascular, 
musculoskeletal, and nervous system.8 Encephalitis is one of the most common and severe 
complications.1 M. pneumoniae infection is established in 5–10% of pediatric encephalitis 
patients,9,10 and up to 60% of them show neurologic sequelae.10,11
It is important to early establish the cause of encephalitis in order to specifically treat 
what can be treated and to defer from unnecessary treatment. The diagnosis of M. pneu-
moniae encephalitis is challenging. The current diagnostic algorithm of the “Consensus 
Statement of the International Encephalitis Consortium”12 recommends for the diagnosis 
of M. pneumoniae infection in children with encephalitis serology and polymerase chain 
reaction (PCR) from throat samples (routine studies), and for children with positive 
results and/or additional respiratory symptoms PCR in cerebrospinal fluid (CSF) (con-
ditional studies).
However, M. pneumoniae serology and PCR in the respiratory tract cannot discern 
between colonization and infection in a clinically relevant time frame.13 The main reason 
for this is the relatively high prevalence of M. pneumoniae in the upper respiratory tract 
of healthy children (up to 56%).13,14 The demonstrated positive serological results in such 
asymptomatic PCR-positive children (positive immunoglobulin [Ig] M in 17%, IgG in 
24%, and IgA in 6% of 66 cases)13 may simply reflect one or more previous encounters 
with M. pneumoniae and are not necessarily related to the presence of M. pneumoniae 
in the respiratory tract. It is clear that this may give rise to an overestimation of the M. 
pneumoniae-related disease burden. A more reliable diagnosis of M. pneumoniae infec-
tion may be achieved by using paired patient sera in order to detect seroconversion and/
or a four-fold increase in antibody titers in addition to PCR (Table 1). However, such 
procedures are time-consuming and are, therefore, neither practicable nor useful in an 
acutely ill patient.
Chapter 6
120
Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f d
ia
gn
os
tic
 te
st
s 
fo
r M
. p
ne
um
on
ia
e.
M
et
ho
d
Te
st
Ta
rg
et
/a
nt
ig
en
A
nt
ib
od
ie
s
Sp
ec
im
en
Pe
rf
or
m
an
ce
a
Va
lu
e
Co
m
m
en
ts
D
ir
ec
t 
id
en
ti
fic
at
io
n 
of
 
M
. p
ne
um
on
ia
e
Po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
(P
CR
)
D
iff
er
en
t t
ar
ge
t 
ge
ne
s 
(e
.g
., 
P1
 
ge
ne
, 1
6S
 rD
N
A
, 
16
S 
rR
N
A
, R
ep
M
P 
el
em
en
ts
 e
tc
.)
–
Re
sp
ira
to
ry
 s
pe
ci
m
en
 
(n
as
op
ha
ry
ng
ea
l 
se
cr
et
io
n,
 p
ha
ry
ng
ea
l 
sw
ab
, s
pu
tu
m
, 
br
on
ch
oa
lv
eo
la
r 
la
va
ge
), 
ce
re
br
os
pi
na
l 
flu
id
 (C
SF
), 
ot
he
r b
od
ily
 
flu
id
s 
or
 ti
ss
ue
s
H
ig
h 
se
ns
iti
vi
ty
, 
hi
gh
 s
pe
ci
fic
ity
RD
b
- 
 Va
lid
at
io
n 
an
d 
st
an
da
rd
iz
at
io
n 
re
qu
ire
d 
fo
r r
ou
tin
e 
di
ag
no
st
ic
- 
 N
uc
le
ic
 a
ci
d 
am
pl
ifi
ca
tio
n 
te
st
s 
(N
A
AT
s)
 p
ro
vi
de
 fa
st
 re
su
lts
 (i
n 
le
ss
 th
an
 a
 d
ay
) a
nd
 m
ay
 b
e 
ea
rli
er
 
th
an
 s
er
ol
og
y 
(b
ec
au
se
 a
nt
ib
od
y 
pr
od
uc
tio
n 
re
qu
ire
s 
se
ve
ra
l d
ay
s)
Cu
ltu
re
–
–
Re
sp
ira
to
ry
 s
pe
ci
m
en
 
(s
ee
 a
bo
ve
)
Lo
w
 s
en
si
tiv
ity
, 
hi
gh
 s
pe
ci
fic
ity
A
D
- 
 Sp
ec
ia
l e
nr
ic
he
d 
br
ot
h 
or
 a
ga
r 
m
ed
ia
- 
 Is
ol
at
io
n 
ta
ke
s 
up
 to
 2
1 
da
ys
N
on
-s
pe
ci
fic
 
se
ro
lo
gi
ca
l t
es
ts
 
fo
r M
. p
ne
um
on
ia
e
Co
ld
-a
gg
lu
tin
in
 
te
st
 (“
be
ds
id
e 
te
st
”)
Er
yt
hr
oc
yt
es
 (I
 
an
tig
en
)
Co
ld
 a
gg
lu
tin
in
s 
(Ig
M
)
Se
ru
m
L o
w
 s
en
si
tiv
ity
, 
lo
w
 s
pe
ci
fic
ity
–c
- 
 Co
ld
 a
gg
lu
tin
in
s 
ta
rg
et
 th
e 
I 
an
tig
en
 o
f e
ry
th
ro
cy
te
s 
(a
lte
rn
at
iv
e 
th
eo
ry
: c
ol
d 
ag
gl
ut
in
in
s 
di
re
ct
ly
 
ta
rg
et
 M
. p
ne
um
on
ia
e 
ad
he
re
d 
to
 
er
yt
hr
oc
yt
es
)
- 
 Po
si
tiv
e 
in
 o
nl
y 
ab
ou
t 5
0%
 a
nd
 in
 
th
e 
fir
st
 w
ee
k 
of
 s
ym
pt
om
s
- 
 Le
ss
 w
el
l s
tu
di
ed
 in
 c
hi
ld
re
n
- 
 Cr
os
s-
re
ac
tiv
ity
 w
ith
 o
th
er
 
pa
th
og
en
s 
an
d 
no
n-
in
fe
ct
io
us
 
di
se
as
es
Sp
ec
ifi
c 
se
ro
lo
gi
ca
l t
es
ts
 
fo
r M
. p
ne
um
on
ia
e
Co
m
pl
em
en
t 
fix
at
io
n 
te
st
 (C
FT
)
Cr
ud
e 
an
tig
en
 
ex
tr
ac
t w
ith
 
gl
yc
ol
ip
id
s 
an
d/
or
 p
ro
te
in
s
Ig
s 
(n
o 
di
sc
rim
in
at
io
n 
be
tw
ee
n 
is
ot
yp
es
)
Se
ru
m
Se
ns
iti
vi
ty
 
an
d 
sp
ec
ifi
ci
ty
 
co
m
pa
ra
bl
e 
to
 E
IA
–c
- 
 Po
si
tiv
e 
cr
ite
ria
: 4
-fo
ld
 ti
te
r i
nc
re
as
e 
be
tw
ee
n 
ac
ut
e 
an
d 
co
nv
al
es
ce
nt
 
se
ra
 o
r s
in
gl
e 
tit
er
 ≥
1:
32
- 
 Cr
os
s-
re
ac
tiv
ity
 w
ith
 o
th
er
 
pa
th
og
en
s 
an
d 
no
n-
in
fe
ct
io
us
 
di
se
as
es
121
Ch
ap
te
r 6
Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis?
Ta
bl
e 
1.
 O
ve
rv
ie
w
 o
f d
ia
gn
os
tic
 te
st
s 
fo
r M
. p
ne
um
on
ia
e.
 (c
on
tin
ue
d)
M
et
ho
d
Te
st
Ta
rg
et
/a
nt
ig
en
A
nt
ib
od
ie
s
Sp
ec
im
en
Pe
rf
or
m
an
ce
a
Va
lu
e
Co
m
m
en
ts
Pa
rt
ic
le
 
ag
gl
ut
in
at
io
n 
as
sa
y 
(P
A
)
Ig
M
 a
nd
/o
r I
gG
Se
ru
m
Se
ns
iti
vi
ty
 
an
d 
sp
ec
ifi
ci
ty
 
co
m
pa
ra
bl
e 
to
 E
IA
–c
- 
 Se
e 
ab
ov
e
Im
m
un
o-
flu
or
es
ce
nt
 a
ss
ay
 
(IF
A
)
Ig
M
 a
nd
/o
r I
gG
Se
ru
m
Le
ss
 s
en
si
tiv
e 
an
d 
le
ss
 s
pe
ci
fic
 th
an
 
EI
A
–c
- 
 Su
bj
ec
tiv
e 
in
te
rp
re
ta
tio
n
En
zy
m
e 
im
m
un
o-
as
sa
y 
(E
IA
)
Pr
ot
ei
ns
 (e
.g
., 
ad
he
si
on
 p
ro
te
in
 
P1
) a
nd
/o
r 
gl
yc
ol
ip
id
s
Ig
M
, I
gG
,d,
e  I
gA
f
Se
ru
m
d , 
CS
Fe
,g
, o
th
er
 
bo
di
ly
 fl
ui
ds
7
M
od
er
at
e-
hi
gh
 
se
ns
iti
vi
ty
, 
m
od
er
at
e-
hi
gh
 
sp
ec
ifi
ci
ty
RD
- 
 Th
e 
se
ns
iti
vi
ty
 d
ep
en
ds
 o
n 
th
e 
tim
e 
po
in
t o
f t
he
 fi
rs
t s
er
um
 a
nd
 o
n 
th
e 
av
ai
la
bi
lit
y 
of
 p
ai
re
d 
se
ra
 (f
or
 
se
ro
co
nv
er
si
on
 a
nd
/o
r r
is
e 
in
 ti
te
r)
- 
 “G
ol
d 
st
an
da
rd
”: 
4-
fo
ld
 ti
te
r i
nc
re
as
e 
as
 m
ea
su
re
d 
in
 p
ai
re
d 
se
ra
I m
m
un
ob
lo
tt
in
g
Ig
M
, I
gG
, I
gA
H
ig
h 
se
ns
iti
vi
ty
, 
hi
gh
 s
pe
ci
fic
ity
h
A
D
- 
 Co
nfi
rm
at
or
y 
as
sa
y
A
bb
re
vi
at
io
ns
: A
D
, a
dv
an
ce
d 
di
ag
no
st
ic
 te
st
; C
FT
, c
om
pl
em
en
t fi
xa
tio
n 
te
st
; C
N
S,
 c
en
tr
al
 n
er
vo
us
 sy
st
em
; C
SF
, c
er
eb
ro
sp
in
al
 fl
ui
d;
 E
IA
, e
nz
ym
e 
im
m
un
oa
ss
ay
; I
FA
, i
m
m
u-
no
flu
or
es
ce
nt
 a
ss
ay
; I
g,
 im
m
un
og
lo
bu
lin
; N
A
AT
s, 
nu
cl
ei
c 
ac
id
 a
m
pl
ifi
ca
tio
n 
te
st
s;
 P
A
, p
ar
tic
le
 a
gg
lu
tin
at
io
n 
as
sa
y;
 P
CR
, p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 R
D
, r
ou
tin
e 
di
ag
no
st
ic
 
te
st
; R
ep
M
P, 
re
pe
at
ed
 M
. p
ne
um
on
ia
e 
D
N
A
. R
ef
er
en
ce
s:
 13
,1
9,
38
-4
6
a  Q
ua
lit
at
iv
e 
st
at
em
en
ts
 in
cl
ud
ed
 b
ec
au
se
 o
f t
he
 w
id
e 
ra
ng
e 
of
 te
st
 p
er
fo
rm
an
ce
s, 
w
hi
ch
 d
ep
en
d 
on
 th
e 
as
sa
y,
 th
e 
pa
tie
nt
 c
oh
or
t (
ch
ild
re
n 
an
d/
or
 a
du
lts
), 
th
e 
re
fe
re
nc
e 
st
an
da
rd
 (P
CR
, c
ul
tu
re
, a
nd
/o
r s
er
ol
og
y)
, t
he
 re
sp
ira
to
ry
 s
pe
ci
m
en
 (f
or
 P
CR
), 
an
d 
th
e 
tim
e 
po
in
t o
f t
he
 s
am
pl
e 
co
lle
ct
io
n 
af
te
r d
is
ea
se
 o
ns
et
 (f
or
 E
IA
); 
e.
g.
, s
en
si
tiv
iti
es
 
an
d 
sp
ec
ifi
ci
tie
s 
fo
r P
CR
40
,4
1 : 
79
–1
00
%
 a
nd
 9
6–
99
%
; I
gM
 E
IA
 (i
n 
re
la
tio
n 
to
 P
CR
)42
: 3
5–
77
%
 a
nd
 4
9–
10
0%
; I
gG
 E
IA
40
,4
2 : 
37
–1
00
%
 (n
o 
in
di
ca
tio
n 
on
 s
pe
ci
fic
ity
 b
ec
au
se
 o
f 
m
is
si
ng
 in
fo
rm
at
io
n 
on
 p
re
vi
ou
s 
M
. p
ne
um
on
ia
e 
in
fe
ct
io
ns
). 
b  
Ep
id
em
io
lo
gi
ca
l d
iff
er
en
tia
tio
n 
of
 c
lin
ic
al
 s
tr
ai
ns
 o
n 
th
e 
ba
si
s 
of
 d
iff
er
en
ce
s 
in
 th
e 
P1
 g
en
e 
by
 P
CR
 o
r i
n 
th
e 
nu
m
be
r o
f r
ep
et
iti
ve
 s
eq
ue
nc
es
 a
t a
 g
iv
en
 g
en
om
ic
 lo
cu
s 
by
 m
ul
til
oc
us
 v
ar
ia
bl
e-
nu
m
be
r t
an
de
m
-r
ep
ea
t a
na
ly
si
s 
(M
LV
A
).4
5  c
 L
ar
ge
ly
 re
pl
ac
ed
 b
y 
EI
A
. d
 K
in
et
ic
s 
of
 
an
tib
od
y 
re
sp
on
se
s i
n 
bl
oo
d:
 Ig
M
: o
ns
et
: w
ith
in
 1
 w
ee
k 
af
te
r t
he
 o
ns
et
 o
f s
ym
pt
om
s;
 p
ea
k:
 3
–6
 w
ee
ks
; p
er
si
st
en
ce
: m
on
th
s (
to
 y
ea
rs
). 
Ig
G
: o
ns
et
 a
nd
 p
ea
k:
 2
 w
ee
ks
 a
ft
er
 
Ig
M
; p
er
si
st
en
ce
: y
ea
rs
 (t
o 
lif
el
on
g)
; r
ei
nf
ec
tio
n 
in
 a
du
lts
 m
ay
 le
ad
 d
ire
ct
ly
 to
 a
n 
Ig
G
 re
sp
on
se
 in
 th
e 
ab
se
nc
e 
of
 a
n 
Ig
M
 re
sp
on
se
. I
gA
: o
ns
et
, p
ea
k,
 a
nd
 d
ec
re
as
e 
ea
rli
er
 
th
an
 Ig
M
. e
 A
nt
ib
od
y 
re
sp
on
se
s i
n 
th
e 
CN
S 
di
ffe
r f
ro
m
 b
lo
od
: T
he
re
 is
 n
o 
sw
itc
h 
fr
om
 a
n 
Ig
M
 to
 a
n 
Ig
G
 re
sp
on
se
, t
he
 p
at
te
rn
 o
f I
gM
, I
gG
, a
nd
 Ig
A
 sy
nt
he
si
s r
em
ai
ns
 ra
th
er
 
co
ns
ta
nt
 a
nd
 d
ep
en
ds
 o
n 
th
e 
ca
us
e,
 a
nd
 th
er
e 
is
 a
 lo
ng
-la
st
in
g 
an
d 
sl
ow
 d
ec
ay
 o
f i
nt
ra
th
ec
al
 a
nt
ib
od
y 
sy
nt
he
si
s.1
9  I
n 
M
. p
ne
um
on
ia
e 
en
ce
ph
al
iti
s, 
a 
do
m
in
an
t I
gM
 re
-
sp
on
se
 h
as
 b
ee
n 
ob
se
rv
ed
.20
 f  T
he
 p
re
va
le
nc
e 
of
 se
ru
m
 Ig
A
 d
et
er
m
in
ed
 b
y 
EI
A
 h
as
 b
ee
n 
sh
ow
n 
to
 b
e 
ve
ry
 lo
w
 in
 P
CR
-p
os
iti
ve
 c
hi
ld
re
n 
w
ith
 sy
m
pt
om
at
ic
 re
sp
ira
to
ry
 tr
ac
t 
in
fe
ct
io
n 
(2
.0
%
).1
3  g
 To
 o
ur
 k
no
w
le
dg
e 
no
 v
al
id
at
ed
 te
st
 a
va
ila
bl
e.
 h  
Im
m
un
ob
lo
tt
in
g 
w
ith
 a
 c
om
bi
na
tio
n 
of
 a
t l
ea
st
 5
 sp
ec
ifi
c 
M
. p
ne
um
on
ia
e 
pr
ot
ei
ns
 sh
ow
ed
 se
ns
iti
vi
tie
s 
(in
 re
la
tio
n 
to
 P
CR
) o
f 8
3%
 (I
gM
), 
51
%
 (I
gG
), 
an
d 
64
%
 (I
gA
), 
an
d 
sp
ec
ifi
ci
tie
s 
of
 9
4–
10
0%
 (I
gM
), 
98
–1
00
%
 (I
gG
), 
an
d 
93
–9
7%
 (I
gA
).4
6
Chapter 6
122
The detection rate of M. pneumoniae by PCR in CSF of M. pneumoniae encephalitis 
patients is relatively low (0–14%).9,10,15,16 Moreover, various cases with M. pneumoniae 
encephalitis in which bacterial DNA could not be detected in CSF had a more prolonged 
duration of respiratory symptoms before the onset of encephalitis (>5–7 days).10,15,17 
These cases indicate that M. pneumoniae encephalitis may represent a post-infectious 
phenomenon, which manifests after clearance of the bacteria from the CNS or respiratory 
tract by the immune system. The immune response to M. pneumoniae in the CNS or 
other sites may also contribute to the encephalitis (Figure 1).
Interestingly, a promising diagnostic marker for M. pneumoniae encephalitis has recently 
emerged from a few case studies. In one study, intrathecal synthesis of antibodies to 
M. pneumoniae was reported in 14 cases of M. pneumoniae encephalitis (74%).18 The 
intrathecal production of antibodies is generally considered a highly specific marker for 
infection of the CNS.19 All cases who underwent PCR testing (93%) indeed had a positive 
Intrathecal anti- 
body synthesis 
Invasion Infection Direct injury Inflammation 
Pneumonia 
M. pneumoniae 
Activated 
oxygen 
Dissemination 
Blood brain barrier dysfunction 
M. pneumoniae adherence to erythrocytes 
or carriage by antigen-presenting cells 
Cerebrospinal fluid 
Neuron 
Myelin antigens 
Antibodies from 
outside CNS 
Antibodies and cells 
specific for M. pneumoniae 
Respiratory 
epithelium 
Immune-mediated process 
Chemical 
mediators 
a b 
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CNS Respiratory tract 
Blood vessels 
Figure 1. Proposed schematic pathomechanisms in M. pneumoniae encephalitis.
(Left) Respiratory tract infection. M. pneumoniae resides mostly extracellular on epithelial surfaces. Its close 
association allows producing direct injury by a variety of local cytotoxic effects. Furthermore, it can induce 
inflammatory responses, elicited by both adhesion proteins and glycolipid epitopes that result in pneu-
monia. (Right) Encephalitis. Extrapulmonary disease of the central nervous system (CNS) is characterized 
by systemic dissemination with resultant direct infection and local tissue injury (a), or immune-mediated 
injury (b–c). The latter may occur as a result of cross-reactive antibodies against myelin components, e.g., 
gangliosides and galactocerebroside (GalC). These antibodies could theoretically be originated from intra-
thecal synthesis (b) or from outside the CNS (c). Figure adapted from 1; see references in the text.
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PCR targeting M. pneumoniae in CSF,18 even though it has been recently demonstrated 
that intrathecal antibody responses to M. pneumoniae but not bacterial DNA can be pres-
ent at the onset of clinical encephalitis.20 In another study, it was reported that intrathecal 
antibodies to M. pneumoniae were found to cross-react with galactocerebroside (GalC) 
in 8 out of 21 (38%) of M. pneumoniae encephalitis cases.21 All these 8 cases showed a 
negative PCR targeting M. pneumoniae in CSF. The cross-reactivity in these cases is likely 
induced by molecular mimicry between bacterial glycolipids and host myelin glycolipids, 
including GalC and gangliosides (Figure 2). Cross-reactive, anti-GalC antibodies have 
previously been detected in patients with Guillain-Barré syndrome (GBS) that suf-
fered from a preceding M. pneumoniae infection.22-26 GBS is a typical post-infectious 
immune-mediated peripheral neuropathy.27 In GBS, cross-reactive antibodies cause 
complement activation and formation of a membrane attack complex at the peripheral 
nerves, resulting in neuromuscular paralysis. Anti-GalC antibodies have been associ-
Neuron Mycoplasma pneumoniae 
Triple-layered cell membrane Tip structure 
(attachement organelle) 
Myelin bilayer 
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P30
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P90 
P1 protein (169 kDa) 
P30 protein (30 kDa) 
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N-Acetylgalactosamine (GalNAc) 
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Figure 2. Schematic structures responsible for molecular mimicry between M. pneumoniae and neuronal 
cells.
(Left) M. pneumoniae adhesion proteins and glycolipids. The immunogenic and major cytadherence pro-
teins P1 and P30 are densely clustered at the tip structure. The P1 protein47 and glycolipids, e.g., forming 
a GalC-like structure,22 elicit cross-reactive antibodies induced by molecular mimicry. (Right) Host myelin 
glycolipids, to which antibodies were found in patients with M. pneumoniae encephalitis. Glycolipids are or-
ganized in specialized functional microdomains called “lipid rafts”, and play a part in the maintenance of the 
cell membrane structure. Abbreviations: GalC, galactocerebroside; GQ1b, ganglioside quadrosialo 1b; GM1, 
ganglioside monosialo 1 (the numbers stand for the order of migration on thin-layer chromatography, and 
the lower cases for variations within basic structures). Structures of M. pneumoniae adhesion proteins and 
host glycolipids are adapted from 48 and 49, respectively. HMW, high-molecular-weight.
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ated with demyelination in patients with GBS.23,26 Moreover, these anti-GalC antibodies 
cause neuropathy in rabbits that are immunized with GalC.28 Such antibodies may also 
be involved in demyelination of central nerve cells in M. pneumoniae encephalitis, as a 
significant correlation was found between the presence of anti-GalC antibodies in the 
CSF and demyelination (p=0.026).21
Anti-GalC antibodies have not only been detected in CSF, but also in serum of M. 
pneumoniae encephalitis patients,21,24,29-31 including rates from 13% (2/15)21 to 100% 
(3/3)29, respectively. It is possible that the blood-brain barrier (BBB) can become perme-
able during inflammation, such that antibodies can cross the BBB and cause disease. As 
a consequence, the cross-reactive antibodies in the CSF of M. pneumoniae encephalitis 
patients do not necessarily have to be produced intrathecally (Figure 1).
M. pneumoniae infections may also be followed by the production of antibodies to 
gangliosides, both in patients with GBS and encephalitis. In M. pneumoniae encephalitis, 
such antibodies were directed against GQ1b32,33 or GM134 (Figure 2). Interestingly, anti-
GQ1b antibodies are associated with a distinct and severe encephalitis variant, referred 
to as Bickerstaff brain stem encephalitis.35
In conclusion, while PCR and serology may be of limited value in the diagnosis of M. 
pneumoniae encephalitis, the detection of intrathecal antibodies to M. pneumoniae, 
including cross-reactive antibodies against GalC and gangliosides, may be regarded as a 
promising new diagnostic tool.
The routine diagnostic work-up of M. pneumoniae encephalitis should therefore aim 
for the detection of M. pneumoniae antibodies in both CSF and serum, in addition to 
M. pneumoniae PCR in CSF. Intrathecal antibodies can be detected by widely accessible 
enzyme immunoassays (EIAs) or immunoblotting (Table 1), while intrathecal antibody 
synthesis can be established either by calculation of an antibody index19 or through 
parallel immunoblotting of simultaneously collected CSF and serum samples.36,37 Anti-
ganglioside antibodies can be detected routinely by some specialized laboratories, but 
their detection together with cross-reactive antibodies against GalC primarily serve for 
scientific purposes and may help to clarify M. pneumoniae antibodies’ immune target(s). 
Furthermore, their hypothesized role in the pathogenesis might provide a basis for im-
munomodulatory treatment in M. pneumoniae encephalitis.
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LETTER TO THE EDITOR
We recently reported on a 9-year-old boy with ophthalmoplegia, ataxia, left-sided 
hemiplegia, and eventually coma diagnosed as Bickerstaff brain stem encephalitis (BBE) 
following Mycoplasma pneumoniae infection.1 The etiologic diagnosis in this case was 
confirmed by the detection of an intrathecal synthesis of M. pneumoniae-specific anti-
bodies.2 Because we could not detect bacterial DNA in the cerebrospinal fluid (CSF) of 
the patient at disease onset,1 we suggested a postinfectious immune-mediated process 
that manifested after clearance of the bacteria from the central nervous system (CNS).
We here aimed to identify a potential myelin target of cross-reactive antibodies elicited 
by M. pneumoniae in this BBE case.
For the analysis, the same serum and CSF samples used for the analysis of M. pneumoni-
ae-specific antibodies taken at onset of neurologic symptoms and stored at −80°C were 
investigated.
IgM and IgG antibodies to GM1, GM2, GD1a, GD1b, GQ1b, AGM1, and galactocer-
ebroside (GalC) (all from Sigma-Aldrich, Zwijndrecht, the Netherlands) were measured 
as described previously.3,4 To determine anti-GalC antibodies, half-area 96-wells plates 
(Costar, Corning B.V. Life Sciences, Amsterdam, the Netherlands) were coated with 450 
pmol of glycolipid per well. All sera were diluted 100-fold. The optical densities (ODs) 
from uncoated (only ethanol containing wells) were subtracted from the glycolipid-
coated wells. Cutoff values were either predefined (i.e., a background-subtracted OD of 
0.2 for IgG and 0.3 for IgM) or obtained by measuring 30 healthy control sera (mean OD 
plus three times the standard deviation). Positive samples were titrated using two-fold 
serial dilution series starting at a 1:100 dilution. The titer was defined as the reciprocal of 
the highest dilution that resulted in an OD higher than the cutoff value.
Since patients with Guillain-Barré syndrome (GBS) may also produce antibodies to 
complexes of two glycolipids instead of a single glycolipid,5 we additionally tested anti-
bodies to glycolipid complexes as described previously,5 with the modification that 225 
pmol/well was used for GalC and 75 pmol/well for other glycolipids in half-area plates.
Our analysis demonstrated the isolated presence of anti-GalC IgM and IgG antibodies in 
both CSF and serum (Figure 1). In serum, the binding activity of IgG antibodies to GalC 
was inhibited by the presence of GM1, GD1a, GD1b, or GQ1b and attenuated by the 
presence of GM2 and asialo-GM1. The presence of serum antibodies against N-methyl-
D-aspartate receptor, voltage-gated potassium channel complex, and aquaporin-4 had 
previously been excluded.
To our knowledge, this is the first case of BBE with the detection of anti-GalC antibodies.
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BBE is closely related to GBS, forming a continuous spectrum.6,7 This is supported by 
immunological findings in which antibodies against the myelin glycolipid GQ1b were 
strongly associated with BBE.8 Anti-GQ1b antibodies were also found in the serum of the 
two previously reported BBE cases associated with M. pneumoniae infection.9,10
In GBS, antibodies against M. pneumoniae infection have been found to cross-react 
with the myelin glycolipid GalC.11,12 GalC is a major glycolipid antigen in the myelin of 
both the peripheral and CNS, and accounts for 32% of the CNS myelin lipid content.13 
Anti-GalC antibodies caused demyelinating neuropathy in rabbits immunized with 
GalC14 and have also been associated with demyelination in GBS,12 encephalitis,15 and 
encephalomyelitis.16 Anti-GalC antibodies were not tested in the other two BBE cases 
associated with M. pneumoniae infection.9,10
Because we detected an intrathecal antibody synthesis of M. pneumoniae-specific 
antibodies in this case and because it has been demonstrated that anti-GalC antibodies 
cross-react with M. pneumoniae,11,12 there is evidence that these anti-GalC antibodies 
were induced by M. pneumoniae. In fact, we detected anti-GalC antibodies in CSF and 
serum, although the mere presence of anti-GalC in CSF may have a pivotal role for the 
pathogenesis of BBE. However, the mechanisms of M. pneumoniae-driven antibody 
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Figure 1. Antibody profile against various glycolipids in a patient with Bickerstaff brain stem encephalitis 
following M. pneumoniae infection.
Both IgM and IgG antibodies against single glycolipids (x – Neg) and glycolipid complexes (x – y) in cerebro-
spinal fluid and serum were determined by enzyme-linked immunosorbent assay. Abbreviations: AGM1, 
asialo-GM1; GalC, galactocerebroside.
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responses within the CNS are unclear. It is also possible that during inflammation the 
blood-brain barrier (BBB) can become permeable, which would thereby enable serum 
antibodies to cross the BBB and cause disease.
In conclusion, the presence of antibodies to GalC (in absence of antibodies to GQ1b) in 
this patient may suggest that these antibodies are involved in the development of BBE. 
Their hypothesized role in the pathogenesis may provide a basis for immunomodulatory 
treatment in BBE associated with M. pneumoniae infection.
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SUMMARY
Objective
To assess the presence of Mycoplasma pneumoniae-associated encephalitis in children in 
Switzerland and its likely pathogenesis.
Methods
M. pneumoniae-associated encephalitis cases seen at a single-center during 2010–2013 
were reviewed, and the Swiss Pediatric Surveillance Unit (SPSU) prospectively conducted 
a nationwide surveillance 2013–2015. Case definition included confirmed, probable, and 
possible cases.
Results
Seven patients (median age 8.7 years, range 4.7–10.1 years) with confirmed or possible 
M. pneumoniae-associated encephalitis were observed. All patients manifested prodro-
mal respiratory symptoms over at least 5 days and five out of the six who had a chest 
radiograph, showed pulmonary infiltrates. M. pneumoniae DNA in cerebrospinal fluid 
was negative in all patients. Intrathecally synthesized M. pneumoniae-specific immuno-
globulin (IgM and IgG) were investigated and found positive in one patient (confirmed 
case). M. pneumoniae DNA in respiratory specimens and/or M. pneumoniae-specific IgM 
and IgG in serum were detected in the other six patients (possible cases). One confirmed 
and two possible cases had neurological sequelae at 4–19 months follow-up.
Conclusion
The lack of detectable M. pneumoniae DNA in cerebrospinal fluid of our encephalitis 
patients suggests a likely immune-mediated pathogenesis ignited by a respiratory inflam-
matory process including pneumonia.
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INTRODUCTION
Encephalitis is the most severe extrapulmonary manifestation of Mycoplasma pneu-
moniae infection.1 Its pathogenesis is not understood.2 Detecting M. pneumoniae in the 
central nervous system (CNS) may be most straightforward to confirm M. pneumoniae-
associated encephalitis.3 However, two large recent national encephalitis studies were 
unable to detect M. pneumoniae DNA by means of polymerase chain reaction (PCR) 
in cerebrospinal fluid (CSF) (United Kingdom, 2005–2006,4 and France, 20075). In con-
trast, another national encephalitis study reported M. pneumoniae as a possible cause, 
detected either by serology or positive PCR in respiratory specimens, in 6% (96/1570; 
US, 1998–20056), compared with two cases confirmed by PCR in CSF (0.1%). Thus, CNS 
infection or immune-mediated pathology are debated. These divergent pathogenetic 
hypotheses create uncertainty in diagnostic procedures and lead to differences in case 
definition criteria.7
We aimed to assess the presence of pediatric M. pneumoniae-associated encephalitis in 
Switzerland and its likely pathogenesis.
METHODS
Study design
Preparatory study
To evaluate whether a nationwide surveillance was worth being conducted we retrospec-
tively reviewed pediatric M. pneumoniae-associated encephalitis cases in the frame of our 
community-acquired pneumonia study at the University Children’s Hospital of Zurich8 
between July 1, 2010 and June 30, 2013.
National prospective surveillance study
Between July 1, 2013 and June 30, 2015, the Swiss Pediatric Surveillance Unit (SPSU), 
a national network of 33 hospitals,9,10 prospectively collected reports of pediatric M. 
pneumoniae-associated encephalitis. Anonymized demographic, clinical, and microbio-
logical data were sent to the SPSU central, which forwarded the forms to the principal 
investigator who verified the case definition. An outcome evaluation questionnaire was 
dispatched to the caring practitioner half a year after case presentation.
M. pneumoniae-associated encephalitis case definition
Children ≤16 years of age fulfilling (1) the clinical case definition for acute encephalitis 
(Table S1),11 and (2) the etiological case definition for acute encephalitis caused by M. 
pneumoniae,3 i.e., (2a) “confirmed” (detection of M. pneumoniae by PCR in CSF or of in-
trathecal synthesis of specific antibodies), (2b) “probable” (≥4-fold rise in specific serum 
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antibody titer), or (2c) “possible” (detection of M. pneumoniae by PCR in respiratory 
specimens and/or single raised specific serum antibody titer), were considered cases.
RESULTS
One “confirmed” and three “possible” pediatric M. pneumoniae-associated encephalitis 
cases were observed during the 3-year preparatory study and three “possible” cases dur-
ing the 2-year national prospective surveillance study (Table 1). All patients were male 
(median age 8.7 years, range 4.7–10.1). Pleocytosis was present in six cases (86%; median 
cell number 30/μl, range 8–96) and neuroimaging was consistent with encephalitis in five 
cases (71%) (Table S1). Preceding respiratory symptoms were reported in all patients (me-
dian duration 7 days, range 5–21 days) and pneumonia was radiologically confirmed in 
five of six patients (83%). M. pneumoniae DNA was detected in the respiratory specimens 
of six patients, but not in CSF, and M. pneumoniae-specific immunoglobulin (IgM and 
IgG) in serum of all five tested patients and in CSF of one tested patient. Three patients 
(43%) still had neurological signs and symptoms at 4–19 months follow-up (Table 1).
DISCUSSION
Here, we have documented for the first time the presence of pediatric M. pneumoniae-
associated encephalitis in Switzerland and gathered indications of an immune-mediated 
process.
Our three M. pneumoniae-associated encephalitis cases observed during the 2-year 
national surveillance represent an estimated yearly incidence of 0.09 cases per 100,000 
population ≤19 years of age,12 although underreporting is likely. Nevertheless, the figure 
is comparable to that in Finland, estimated after a national surveillance in 1993–1994 
(0.1 cases per 100,000).13 The incidence, however, depends on the presence or absence 
of epidemics. Indeed, we retrospectively identified four patients in a single-center over 
a prior 3-year period and three of them coincided with the M. pneumoniae epidemic in 
Europe from 2010–2011.8,14
M. pneumoniae was found as the cause of 9% (84/906; USA, 1998–200615) and 31% 
(50/159; Canada, 1994–199816) of cases of pediatric encephalitis, whereby 2% (1/62)15 
and 12% (6/50)16 of the cases, respectively, were confirmed by PCR in CSF. The yearly 
incidence of pediatric encephalitis in developed countries is about 10.5 cases per 100,000 
children.13 Since no data on pediatric encephalitis exist for Switzerland we cannot esti-
mate the relative frequency of our M. pneumoniae-associated encephalitis cases.
We found no M. pneumoniae DNA in CSF of any patient but it was present in throat 
specimens of all patients except one, and specific serum antibodies were found in all 
patients tested. This suggests that their encephalitis was likely immune-mediated follow-
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ing respiratory infection. Indeed, all patients had prodromal respiratory symptoms over 
at least 5 days. Interestingly, a recent study17 reported that M. pneumoniae-associated 
encephalitis patients with negative PCR for M. pneumoniae in CSF showed radiological 
signs of pneumonia with infiltrates on chest radiograph more frequently than patients 
with positive PCR in CSF (77% vs. 33%). We found infiltrates on chest radiograph in 83%.
Pleocytosis was present in most of our patients and neuroimaging was compatible with 
an inflammatory process in 71%. This further underscores the likelihood of an immune-
mediated pathogenesis in our M. pneumoniae-associated encephalitis cases, which was 
proven by the detection of an intrathecal antibody synthesis in one investigated patient 
(patient 4).18 Antibodies against M. pneumoniae have been shown to cross-react with 
galactocerebroside (GalC).19 GalC is a major glycolipid antigen in the myelin of both 
the peripheral and central nervous systems. We previously demonstrated, in this specific 
case, antibodies against GalC in serum and CSF,20 which suggests that these antibodies 
are involved in the development of M. pneumoniae-associated encephalitis.2 Intriguingly, 
one patient showed extensive extrapulmonary multiorgan inflammation with additional 
involvement of skin and heart (patient 1), which required prolonged anti-inflammatory 
treatment.
In conclusion, we suspect an immune-mediated process in our observed M. pneumoniae-
associated encephalitis cases. Pneumonia may be an indicator for the remote inflamma-
tory process. The association of encephalitis with M. pneumoniae may be increasingly 
established by expanding diagnostic procedures through the analysis of intrathecal anti-
bodies.
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Guillain-Barré syndrome
Parts of the introduction are published in: 
The spectrum of preceding infections in Guillain-Barré syndrome  
– beyond Campylobacter
P.M. Meyer Sauteur
A.M.C. van Rossum
B.C. Jacobs
In: GBS100 Monograph, Peripheral Nerve Society 2016;181–195 (ISBN 978-0-9975103-0-0)
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INTRODUCTION TO GUILLAIN-BARRÉ SYNDROME
Guillain-Barré syndrome (GBS) is the most common cause of acute neuromuscular 
paralysis in countries where poliomyelitis has been eliminated,1 characterized by sym-
metrical weakness of the limbs, and hyporeflexia or areflexia, which reaches a maxi-
mum severity within four weeks.2 GBS is considered the prototype of a postinfectious 
immune-mediated disorder. About two-thirds of GBS patients experience respiratory or 
gastrointestinal symptoms days to weeks before the onset of neurologic symptoms.3 A 
specific pathogen can be identified in about half of patients with GBS. Campylobacter 
jejuni accounts for around one-third of these infections.1,4
Over the last 10 years, there is accumulating evidence on the role of preceding infec-
tions and cross-reactive anti-glycolipid antibodies in the immunopathology of GBS. Most 
notably, there is now convincing evidence that C. jejuni is a potential trigger of GBS and is 
associated with the acute motor axonal neuropathy (AMAN) subtype and IgG antibodies 
against GM1, GM1b, GD1a, or GalNAc-GD1a (Figure 1).5 Much less is known about 
the role of preceding infections and the pathogenesis in the patients with GBS without a 
preceding C. jejuni infection.
Detecting a pathogen in GBS – what does it mean?
The demonstration of a causative pathogen in GBS is rather complex. First, there is 
usually a delay of days to weeks between the infection and the diagnosis of GBS. The 
detection rate of a pathogen by culture and/or polymerase chain reaction (PCR) at GBS 
onset is low.3 It is possible that the pathogen has already been cleared at the infectious site 
by the immune reaction that may have also caused GBS.
Second, demonstrating the presence of a pathogen in a GBS patient does not necessar-
ily implicate that there is an infection that triggered an immune response to the nerves. 
Many pathogens, apart from C. jejuni, persist or are carried in healthy asymptomatic 
individuals without any symptoms.6 As discussed in Chapter 1 and 4, no single diagnos-
tic test or combination of tests is capable of differentiating carriage from infection with 
respiratory pathogens, some of them also associated with GBS. Caution should be taken 
in the interpretation of such diagnostic test results, also because some serological assays 
may lack sensitivity and specificity.
Third, GBS is a highly heterogeneous disorder. Various subtypes of GBS have been 
reported that differ in their clinical, electrophysiological, and histological features (Table 
1). This applies also to the type of preceding infection. Additionally, some infections may 
have triggered the onset of disease only in a small minority of the cases.
Forth, some patients may have already received intravenous immunoglobulin (IVIg) 
before blood samples were obtained to investigate infection serology, and such serology 
may then be false positive.
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Figure 1. Immunopathogenesis of GBS.
C. jejuni lipooligosaccharides (LOS) can trigger antibodies that cross-react with gangliosides on peripheral 
nerves. Anti-ganglioside antibodies can bind to nodal axolemma (AMAN) or Schwann cells (AIDP) and acti-
vate complement followed by membrane-attack complex formation, resulting in nerve-conduction failure 
(AMAN) or vesicular degeneration with invasion of myelin by macrophages (AIDP). It is not excluded that 
for other GBS patients cross-reactive T cells or very diff erent mechanisms than cross-reaction may play a 
role in the pathogenesis. Abbreviations: AIDP, acute infl ammatory demyelinating polyneuropathy; AMAN, 
acute motor axonal neuropathy; APC, antigen-presenting cell. Reproduced with permission from van den 
Berg et al.,5 Springer Nature.
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Infectious association – or cause?
When an infectious diagnosis can be made, how sure are we that there is a causal relation-
ship between the identified pathogen and GBS?
Despite the association between many infections and GBS, the overall risk of devel-
oping GBS is very small. For example, only one in 1,000–5,000 patients with C. jejuni 
enteritis will develop GBS in the subsequent two months.7 A fact which certainly also 
applies to other infectious pathogens, where the acute disease is much more frequent 
than this severe postinfectious complication.
One of the critical steps in GBS pathogenesis is the generation of antibodies that cross-
react with specific gangliosides. It has been shown for C. jejuni that such cross-reactive 
antibodies are not produced during uncomplicated C. jejuni enteritis.5 Apart from C. 
jejuni, many other identified pathogens have also been reported in association with GBS: 
M. pneumoniae, Haemophilus influenzae, cytomegalovirus, Epstein-Barr virus, and influ-
enza virus (reviewed in 8) (Figure 2). There are even more pathogens reported in single 
GBS case reports or series. The involvement of these pathogens in GBS is less clear, and 
has not been determined in controlled larger studies.
Table 1. GBS subtypes, clinical features and anti-glycolipid antibodies.
GBS subtypes Clinical features NCS findings Antibodiesa
Acute inflammatory 
demyelinating 
polyneuropathy (AIDP)
Sensorimotor GBS, often 
combined with cranial 
nerve deficits and frequent 
autonomic dysfunction
Demyelinating 
polyneuropathy
Variousb
Acute motor axonal 
neuropathy (AMAN)
Pure motor GBS, cranial 
nerves rarely affected
Axonal polyneuropathy, 
sensory action potential 
normal
GM1a, GD1a, 
GM1b, GalNAc-
GD1a
Acute motor sensory 
axonal neuropathy 
(AMSAN)
Resembles severe AMAN, but 
sensory fibres are affected, 
leading to sensory deficits
Axonal polyneuropathy, 
sensory action potential 
reduced or absent
GM1, GD1a
Pharyngeal-cervical 
brachial variant
Prominent weakness of 
oropharyngeal, facial, neck 
and shoulder muscles
Normal in most patients GT1a, GQ1b, GD1a
Miller Fisher syndrome 
(MFS)
Ataxia, ophthalmoplegia, 
areflexia
Normal in most patients GQ1b, GT1a
Bickerstaff brain stem 
encephalitis (BBE)
Ataxia, ophthalmoplegia, 
altered level of consciousness 
(CNS variant of MFS)
Normal in most patients GQ1b, GT1a
Abbreviations: NCS, nerve conduction study. Gangliosides: GalNAc, N-Acetylgalactosamine; GD, ganglio-
side disialo; GM, ganglioside monosialo; GQ, ganglioside quadrosialo; GT, ganglioside trisialo (numbers 
stand for the order of migration on thin-layer chromatography, and lower-case letters for variations within 
basic structures). Table adapted from van den Berg et al.5
a Antibodies are predominantly IgG, but IgM and IgA antibodies have also been demonstrated;
b Association with GBS and role in pathogenesis unknown.
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Interestingly, the variety in types of preceding infection may be related to the diversity in 
clinical presentation,9 outcome,10 and also to the specifi city of antibodies to glycolipids 
(Table 2).4 Th erefore, the detection of a distinct anti-glycolipid antibody type could give 
an indication on the preceding infectious agent that triggered the antibody response.11 In 
this thesis, we focus on the role of M. pneumoniae in GBS (Chapter 9–12).
???
????
????
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??????
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???
????????????
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?????
????
Figure 2. Incidence of positive infection serology in 154 adult GBS patients.
“Other” pathogens were H. infl uenzae, infl uenza virus A/B, parainfl uenza virus, adenovirus, herpes simplex 
virus, and varicella-zoster virus. Most of GBS patients with >1 pathogen detected had positive EBV and/
or CMV serology in addition to other pathogens. Abbreviations: CJ, C. jejuni; CMV, cytomegalovirus; EBV, 
Epstein-Barr virus; MP, M. pneumoniae. Reproduced from Meyer Sauteur et al.8
Table 2. The spectrum of preceding infections in GBS.
Pathogen Detection rate (%) Anti-glycolipid antibodies Microbial 
mimic 
structure
GBS HC NC GBS Controls
Bacteria
C. jejuni 26%12,◊ 1–2% – – – – GM1-, GD1a-, 
GD3-, GT1a-
like LOS13,14
32%4,◊◊ 8%* 12%* anti-GM1 41% 
and
anti-GD1b 
29%4,◊◊
– –
57%1,◊◊ 8%* 3%* anti-GM1/
GD1a 56%1,◊◊
anti-GM1/
GD1a 6%*
anti-GM1/
GD1a 1%1*
– – – C jejuni +:
anti-GM1 
29%15,◊◊
– –
M. 
pneumoniae
5%4,# 0% 1%* M. 
pneumoniae +:
anti-GalC 
73%16,#
M. 
pneumoniae +:
anti-GalC 
58%16,#,
anti-GalC 
18%17,#
M. 
pneumoniae –:
anti-GalC 
0%16,#*,
anti-GalC 
0%17,#
GalC-like18
15%19,# 1%* 2%*
21%20,# 14% 14%
3%21,° – –
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Table 2. The spectrum of preceding infections in GBS. (continued)
Pathogen Detection rate (%) Anti-glycolipid antibodies Microbial 
mimic 
structure
GBS HC NC GBS Controls
H. influenzae 9%22,# 0% 8% H. influenzae 
+:
anti-GM1 
100% and
anti-GQ1b 
25%22,#
– – GM1-like,23
GT1a/GQ1b-
like22
7%24,# 6% 7% H. influenzae 
+:
anti-GQ1b 
and
anti-GT1a 
86%24,#
(GBS + MFS)
– –
MFS: 11%24,# 6%* 7%*
1%4,# – – – – –
Salmonella 
enterica 
species
0%25,& – – S. Paratyphi 
A +:
anti-GQ1b26,&,a
– – –
1%27,& – –
Viruses
CMV 13%4,# 0%* 2%* CMV +:
anti-GM2 
25%4,#
CMV +:
–
CMV –:
–
GM2-like, 
expressed by 
CMV-infected 
fibroblasts286%19,§ 1% 2% – – –
8%29,#
MFS: 6%29,#
0%*
0%
–
–
anti-GM2$ 
100%29,#
anti-GM2$ 
60%
anti-GM2$ 0%*
12%21,#,§ – – anti-GM2$ 
42%21,#,§
anti-GM2$ 
47%
anti-GM2$ 0%
15%30,# – – anti-GM2$ 
22%31,#
anti-GM2$ 2%* anti-GM2$ 0%*
12%32,#,§,† – –
8%33,#,§ – –
EBV 10%4,# 0%* 1%* No antibodies against known glycolipids 
detected4,21
–
4%19,# 0% 0%
1%21,# – –
2%33,#,§ – –
HSV-1/2 1%4,° – – – – – –
VZV 1%4,° – – – – – –
HZ: 
0.025%34,††
HZ: 
0.001%*
–
Influenza 
virus
(A and B)
2%4,° – – Influenza A +:
anti-GD1b35,#,a,
anti-GD1b, 
-GM1, and 
-GD1a??????
– – No structural 
homologies 
with known 
gangliosides37
3%38,° – –
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ABSTRACT
We report seven children with recent Mycoplasma pneumoniae infection and severe 
Guillain-Barré syndrome (GBS) that presented to two European medical centers from 
1992 to 2012. Severe GBS was defined as the occurrence of respiratory failure, central 
nervous system (CNS) involvement, or death. Five children had GBS, one Bickerstaff 
brain stem encephalitis (BBE), and one acute-onset chronic inflammatory demyelinating 
polyneuropathy (A-CIDP). The five patients with severe GBS were derived from an origi-
nal cohort of 66 children with GBS. In this cohort, 17 (26%) children had a severe form 
of GBS and 47% of patients with M. pneumoniae infection presented with severe GBS. Of 
the seven patients in this case series, five were mechanically ventilated and four had CNS 
involvement (two were comatose). Most patients presented with non-specific clinical 
symptoms (nuchal rigidity and ataxia) and showed a rapidly progressive disease course 
(71%). Antibodies against M. pneumoniae were detected in all patients and were found to 
be intrathecally synthesized in two cases (GBS and BBE), which proves intrathecal infec-
tion. One patient died and only two patients recovered completely. These cases illustrate 
that M. pneumoniae infection in children can be followed by severe and complicated 
forms of GBS. Non-specific clinical features of GBS in such patients may predispose a 
potentially life-threatening delay in diagnosis.
157
Ch
ap
te
r 9
Severe childhood Guillain-Barré syndrome associated with Mycoplasma pneumoniae infection: a case series
INTRODUCTION
Nervous system disease is one of the most common and severe extrapulmonary mani-
festations of infections with the respiratory pathogen M. pneumoniae.1 Preceding M. 
pneumoniae infection has been reported in 3–15% of Guillain-Barré syndrome (GBS) in 
adults2-4 and also in GBS variants5-7 and related neuropathies.8
At present, it is unclear if M. pneumoniae infections may also precipitate the devel-
opment of childhood GBS. In children, the incidence of M. pneumoniae infections is 
higher than in adults.9 Previous studies showed that the type of preceding infection may 
influence the clinical presentation and outcome of GBS.10 We present a case series of 
children who developed severe and complicated disorders within the GBS spectrum after 
infection with M. pneumoniae.
MATERIALS AND METHODS
Patients
A group of previously healthy children (≤16 years of age) was diagnosed with severe 
GBS and related disorders following a recent M. pneumoniae infection in two European 
centers from 1992 to 2012 (patient 1–6: Erasmus MC–Sophia Children’s Hospital, Rot-
terdam, The Netherlands; patient 7: University Children’s Hospital Zurich, Switzerland). 
All patients fulfilled the diagnostic criteria for GBS.11 The case definition for severe GBS 
included respiratory failure requiring mechanical ventilation, additional involvement of 
the central nervous system (CNS), and death. Total numbers for children diagnosed with 
GBS were available for Rotterdam (n=66, excluding GBS-related disorders), but not for 
Zurich. Some of the patients had previously been included in other studies.12-14 Informed 
consent was given by the parents and/or the patients if 12 years or older. The study was 
approved by the Erasmus MC medical ethics board.
M. pneumoniae diagnostics
M. pneumoniae DNA
Detection of M. pneumoniae in the respiratory tract and in cerebrospinal fluid (CSF) was 
performed by real-time polymerase chain reaction (PCR) as previously described.15
Antibodies to M. pneumoniae
A recent infection with M. pneumoniae had previously been defined by detection of im-
munoglobulin (Ig) M antibodies to M. pneumoniae.16 Patients were only included in this 
study if serum and/or CSF samples were available to confirm the serology. All serum 
samples were retested for further comparative analysis of IgM, IgG, and IgA antibodies 
to M. pneumoniae adhesion protein P1 using a commercially available enzyme-linked 
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immunosorbent assay (ELISA) (Genzyme, Virotech GmbH, Rüsselsheim, Germany). 
Test results were confirmed with a recently developed and validated line immunoblot 
containing a combination of at least five M. pneumoniae-specific proteins, including P1 
and P90.17 Where available, CSF samples were also tested. Intrathecal antibody synthesis 
was determined either by calculation of an antibody index or through parallel immunob-
lotting of simultaneously collected CSF and serum samples.18
RESULTS
We identified seven children diagnosed with severe GBS and a positive IgM serology to 
M. pneumoniae. The disease spectrum included five patients with GBS and two with GBS-
related disorders. One patient with the clinical variant Bickerstaff brain stem encephalitis 
(BBE) and one patient who at first appeared to have GBS, but was later diagnosed with 
acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP).
Excluding GBS-related disorders (BBE and A-CIDP), severe GBS occurred in 17 of the 
total cohort of 66 children (26%) diagnosed with GBS in Rotterdam. In this cohort, GBS 
after M. pneumoniae infection was classified in 47% as severe GBS (n=7, from which only 
five had residual samples and were thus included in this study).
An overview of the patient characteristics is shown in Table 1. The median age was 7.2 
years (range, 4.9–14.5 years). Most patients presented with non-specific clinical features 
at onset of disease (headache [57%], unsteady gait [43%], and pain [43%]) and at admis-
sion (nuchal rigidity [57%] and ataxia [29%]). The disease was rapidly progressive in 
most cases (Figure 1). Consistent with the case definition for severe GBS, one patient 
died, four patients had clinically defined CNS involvement, and five patients required 
mechanical ventilation.
Respiratory tract symptoms and/or fever were reported in 57% (median duration 11 
days, range, 2–21 days). M. pneumoniae DNA was detected in the respiratory tract in 
two of four (50%) patients, both with respiratory tract symptoms and infiltrates on chest 
radiograph. M. pneumoniae DNA was not observed in CSF of five tested patients. The 
detection of IgM antibodies to M. pneumoniae at the time of diagnosis could be verified 
for this study in all cases by both ELISA and immunoblotting. CSF from all patients 
showed a white blood cell count <50/μl and an increased protein concentration (“cyto-
albuminologic dissociation”). Intrathecal antibody production was demonstrated in two 
cases. Poor outcome occurred in two cases (patient 5 and 7). Two patients (29%) showed 
full recovery (GBS disability score 0).
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DISCUSSION
This study demonstrates that M. pneumoniae infection in children can precipitate a 
spectrum of severe disorders of both the peripheral and CNS. M. pneumoniae is a major 
cause of respiratory tract infections in children9 and a wide spectrum of extrapulmonary 
complications may develop, including encephalitis and GBS.1 Serology and PCR are still 
the most accurate methods to determine the involvement of M. pneumoniae in GBS.19 
Serological testing in GBS is usually based on single pretreatment samples because in-
travenous immunoglobulin may influence the test results. Some commercially available 
serological tests lack the required sensitivity and specificity.20 We therefore confirmed all 
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Figure 1. Disease course of seven children with severe GBS spectrum disease associated with M. pneu-
moniae infection.
The bars indicate the number of days at home and at various care facilities for each patient after first signs 
of disease. The vertical line through all cases at day 0 reflects the start of neurologic symptoms. “Prodrome” 
is defined as time from start of preceding symptoms of infection to start of neurologic symptoms and 
“onset” as time from start of neurologic symptoms to hospital admission. The final diagnosis is specified 
on the left. In addition, the time points of taking blood (serum), cerebrospinal fluid (CSF), and the start of 
intravenous immunoglobulin (IVIg) are assigned on top of the bars. Disease nadir defined as the time point 
of lowest GBS disability score28 is indicated with a dashed vertical line (nadir). Abbreviations: A-CIDP, acute-
onset chronic inflammatory demyelinating polyneuropathy; BBE, Bickerstaff brain stem encephalitis; ICU, 
intensive care unit; MV, mechanical ventilation; Rehab, rehabilitation center.
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IgM responses previously detected by ELISA with a highly specific immunoblot.17 These 
specific IgM responses reflect a recent activation of the immune system elicited by M. 
pneumoniae at the respiratory surface, which is essential in the context of GBS where spe-
cific preceding infections may precipitate an immune response against neural targets.10
In a considerable proportion of patients with GBS, M. pneumoniae infection was 
followed by a severe form of GBS. In patients with GBS, serum antibodies to M. pneu-
moniae have been found to cross-react with the myelin glycolipid galactocerebroside 
(GalC).21 These anti-GalC antibodies caused demyelinating neuropathy in rabbits that 
were immunized with GalC22 and have also been associated with demyelination in GBS,23 
encephalitis,24 and acute disseminated encephalomyelitis.25
Given the pathogenic role of cross-reactive antibodies in GBS,10 one might speculate 
that such antibodies would also be present in the CNS of the four patients with CNS 
involvement. Interestingly, we indeed demonstrated intrathecal synthesis of antibodies 
against M. pneumoniae in two patients with CNS involvement (BBE and GBS), which 
proves intrathecal infection.18 Both patients did also show radiological evidence of CNS 
involvement.
GBS with CNS and prominent cranial nerve involvement can present with a short 
interval from onset to nadir.26 This study additionally indicates that GBS after M. 
pneumoniae infection may present with non-specific clinical features of GBS, especially 
nuchal rigidity and ataxia. These clinical signs have already been reported in children 
with GBS.12,27 Non-specific symptoms in patient 5 led to a misdiagnosis, which had fatal 
consequences because of the rapid disease progression. The awareness of a non-specific 
presentation of severe subtypes of GBS associated with M. pneumoniae infection should 
prevent a potentially life-threatening delay in diagnosis and lead to earlier treatment.
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ABSTRACT
Objective
Guillain-Barré syndrome (GBS) is an acute postinfectious immune-mediated polyneu-
ropathy. Although preceding respiratory tract infections with Mycoplasma pneumoniae 
have been reported in some cases, the role of M. pneumoniae in the pathogenesis of GBS 
remains unclear. We here cultured, for the first time, M. pneumoniae from a GBS patient 
with antibodies against galactocerebroside (GalC), which cross-reacted with the isolate. 
This case prompted us to unravel the role of M. pneumoniae in GBS in a case-control 
study.
Methods
We included 189 adults and 24 children with GBS and compared them to control cohorts 
for analysis of serum antibodies against M. pneumoniae (n=479) and GalC (n=198).
Results
Anti-M. pneumoniae immunoglobulin (Ig) M antibodies were detected in GBS patients 
and healthy controls in 3% and 0% of adults (p=0.16) and 21% and 7% of children 
(p=0.03), respectively. Anti-GalC antibodies (IgM and/or IgG) were found in 4% of adults 
and 25% of children with GBS (p=0.001). Anti-GalC-positive patients showed more fre-
quent preceding respiratory symptoms, cranial nerve involvement, and a better outcome. 
Anti-GalC antibodies correlated with anti-M. pneumoniae antibodies (p<0.001) and 
cross-reacted with different M. pneumoniae strains. Anti-GalC IgM antibodies were not 
only found in GBS patients with M. pneumoniae infection, but also in patients without 
neurological disease (8% vs. 9%; p=0.87), whereas anti-GalC IgG was exclusively found 
in patients with GBS (9% vs. 0%; p=0.006).
Interpretation
M. pneumoniae infection is associated with GBS, more frequently in children than adults, 
and elicits anti-GalC antibodies, of which specifically anti-GalC IgG may contribute to 
the pathogenesis of GBS.
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INTRODUCTION
Guillain-Barré syndrome (GBS) is a postinfectious immune-mediated peripheral neu-
ropathy.1 First symptoms of GBS typically occur within 1 to 4 weeks after the clinical 
manifestations of a preceding infection, with Campylobacter jejuni the most frequently 
identified.2 It is hypothesized that the immune response against the infectious agent 
generates antibodies that cross-react with glycolipids present in peripheral nerves and 
nerve roots. This results in nerve damage or functional blockade of nerve conduction.
Two thirds of GBS patients report preceding symptoms of a gastrointestinal or re-
spiratory tract infection before onset of neurological symptoms.1 A common cause of 
respiratory tract infections is Mycoplasma pneumoniae, where incidence of infections is 
higher in children than adults.3 Apart from respiratory tract infections, M. pneumoniae 
can also cause nervous system disease.4,5 Preceding M. pneumoniae infection has been se-
rologically reported in adult and pediatric GBS with frequencies of 2% to 21%, compared 
with 0% to 14% in healthy adults and children and 1% to 14% in adults and children 
with neurological diseases other than GBS.2,6-9 Patients with GBS after M. pneumoniae 
infection may produce antibodies against galactocerebroside (GalC),10-14 one of the major 
glycolipids of both the peripheral nervous system and central nervous system.15 Anti-
GalC antibodies have been demonstrated to cross-react with M. pneumoniae antigens10,13 
and to cause demyelination in vitro16 and in rabbits immunized with GalC.17
However, there are several limitations in the current knowledge about the relationship 
between M. pneumoniae infections and GBS. First, to our knowledge, M. pneumoniae has 
not been isolated from patients with GBS to test for cross-reactivity with anti-glycolipid 
antibodies. Second, highly variable rates of positive M. pneumoniae serology have been 
reported in GBS. Third, there is a lack of proper case-control studies, and fourth, anti-
GalC antibodies have been also found in patients with M. pneumoniae infections without 
neurological symptoms.10,12,18
Here, we present, for the first time, an M. pneumoniae culture-positive GBS patient 
with anti-GalC antibodies that cross-reacted with the patient-derived M. pneumoniae 
strain. This prompted us to determine the relation of M. pneumoniae with GBS in a 
large case-control study, the first study in both adults and children. We hypothesized 
that anti-GalC antibodies are critical for development of GBS following M. pneumoniae 
infection and investigated whether GBS after this type of preceding infection presented 
with distinct clinical features and outcome.
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PATIENTS AND METHODS
Ethics Statement
Ethical approval for this study was granted by the institutional review board of the Eras-
mus MC (Rotterdam, The Netherlands).
Patients
The derivation set contained 462 patients with GBS (Figure 1). All patients fulfilled the 
current diagnostic criteria for GBS.19 Excluded were 165 adults and 61 children because 
there was insufficient serum available for testing, or the sample was taken after intrave-
nous immunoglobulin (IVIg) treatment or without exact information on the time point 
of collection. Further excluded were 19 adults and 4 children with either a GBS variant or 
with another diagnosis during follow-up. In total, 189 adults and 24 children (<18 years 
of age) were included (Table 1). All samples were stored at −80°C before testing.
Adult GBS cohort Pediatric GBS cohort 
373 Adults enrolled
209 RCT 1994–2000
164 Observational study 2005–2008
89 Children enrolled
5 RCT 1986–1989
13 RCT 1994–2000
6 Observational study 2005–2008
65 Other 1986–2009
208 Adults with sufﬁcient 
specimen
28 Children with sufﬁcient 
specimen
165 Adults excluded
71 No or insufﬁcient specimen
47 Specimen after IVIg
47 Not clear if pretreatment 
specimen
 
61 Children excluded
53 No or insufﬁcient specimen
8 Specimen after IVIg
 
19 Adults excluded
16 MFS
2 A-CIDP
1 Other diagnosis
4 Children excluded
1 MFS
3 A-CIDP
189 Adults included
51%
24 Children included
27%
A B
Figure 1. Enrollment flow diagram of GBS patients.
(A) Adult GBS cohort. (B) Pediatric GBS cohort. Abbreviations: A-CIDP, acute onset chronic inflammatory de-
myelinating polyneuropathy; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin; MFS, Miller 
Fisher syndrome; RCT, randomized controlled trial.
Controls
The control derivation set contained extensive separate cohorts for comparison of GBS 
patients with both the M. pneumoniae-specific enzyme-linked immunosorbent assay 
(ELISA) and the glycolipid ELISA (Table 1). In addition, 16 out of 19 M. pneumoniae-
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Table 1. Demography and origin of patients and controls for anti-M. pneumoniae and anti-GalC antibody 
testing in serum.
Anti-M. 
pneumoniae 
antibodies
n Population
(region; year)
Sex
(male),
%
Age,
median
(IQR)
Reference
Adult GBS 189 Adult GBS patients (The Netherlands, 
Belgium, Germanya; 1994–2000 and 
2005–2008)
58% 52 (37–66) 40,41
Pediatric GBS 24 Pediatric GBS patients (Rotterdam, The 
Netherlands; 1986–2009)
67% 11 (9–14) 40-42
Adult HCb 104 Adult blood donors (South Germany; 
2010–2011)
NA2 20–60b Serion GmbH, 
Würzburg, Germany 
(unpublished data)
Pediatric HCc 339 Asymptomatic children (Rotterdam, The 
Netherlands; 2009–2011)
36% 4 (1–9) 29
Pediatric NCd 36 Children with non-infectious neurological 
diseases (Rotterdam, The Netherlands; 2012):
-  Auto-immune disease 11 (31%)
-  Epilepsy 17 (47%)
-  Neuromuscular disease 2 (5%)
-  Other non-inflammatory diseases 6 (17%)
50% 7 (4–10) Erasmus MC–Sophia 
Children’s Hospital
Anti-GalC
antibodies
Adult GBS 189 See above
Pediatric GBS 24 See above
Adult NNCe 82 Non-neurologic adult patients (Rotterdam, 
The Netherlands; 2009–2013)
60% 48 (34–60) Department of Viro-
science, Erasmus MC
Pediatric 
NNCe
80 Non-neurologic pediatric patients 
(Rotterdam, The Netherlands; 2009–2014)
51% 12 (9–15) Department of Viro-
science, Erasmus MC
Pediatric NC 36f See above
Abbreviations: GalC, galactocerebroside; HC, healthy controls; Ig, immunoglobulin; IQR, interquartile range; 
NA, not available; NC, neurologic controls; NNC, non-neurologic controls.
All patients were tested with the Serion ELISA classic M. pneumoniae (Serion GmbH, Würzburg, Germany).
a Most patients were randomized in Dutch centers; the others in two Belgian centers and two German 
centers;40,41 b Adult blood donor samples taken from 2010–2011 in South Germany and collected by the 
Serion GmbH (Würzburg, Germany). Detailed information on sex and age had not been collected; c Chil-
dren without respiratory tract disease enrolled from 2009–2011 during admission for a planned elective 
surgical procedure at the short-stay department of the Erasmus MC–Sophia Children’s Hospital;29 d Children 
with non-infectious neurological diseases enrolled from January to May 2012 during routine check-ups at 
the pediatric neurology out-patient clinic of the Erasmus MC–Sophia Children’s Hospital; e In-patients and 
out-patients without neurological diseases tested for anti-M. pneumoniae antibodies at the Erasmus MC 
between 2009–2013/2014. With the exception that patients from the neurology out-patient clinics and 
the neurology wards, as well as the intensive care units were excluded, no information on disease charac-
teristics were available. The samples of these patients were stored at the department of Viroscience and 
selected for this study for M. pneumoniae-specific isotype constellations, as well as matched for sex, age, 
and isotype titers. The M. pneumoniae-specific isotype constellations are IgM+IgG- (n=22), IgM-IgG+ (n=30), 
and IgM-IgG- (n=30) for the adult NNC and IgM+IgG- (n=10), IgM+IgG+ (n=19), IgM-IgG+ (n=27), and IgM-
IgG- (n=24) for the pediatric NNC, respectively; f Sufficient serum samples for anti-GalC antibody testing 
were available in 25 (69%) of 36 patients of the pediatric NC.
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positive control samples of a prior study10 were available for further testing with the 
glycolipid ELISA.
Data collection
Clinical and laboratory data
Clinical and laboratory characteristics of GBS patients are shown in Table 2.
Table 2. Clinical and laboratory characteristics of adult and pediatric GBS patients.
Adult GBS Pediatric GBS
(n=189)a (n=24)a
Demographic characteristics
Sex (male), n (%) 110/189 (58%) 16/24 (67%)
Age, median (IQR) 52 (37–66) 11 (9–14)
Characteristics of GBS
-  Preceding respiratory symptoms, n (%) 69/186 (37%) 11/23 (48%)
-  Cranial nerve involvement, n (%) 64/188 (34%) 1/21 (5%)
-  Pain, n (%) 110/185 (59%) 14/24 (58%)
-  CSF white blood cell count/μl, median (IQR) 1 (1–3) 3 (1–3)
-  CSF protein (g/l), median (IQR) 0.70 (0.47–1.26) 0.64 (0.40–1.75)
-  Electrophysiology:
-  AIDP, n (%) 92/176 (52%) 9/15 (60%) 
-  AMAN, n (%) 6/176 (4%) NAb 
-  Equivocal, n (%) 72/176 (41%) NAb 
-  Inexcitable, n (%) 4/176 (2%) NAb 
-  Normal, n (%) 2/176 (1%) 0/15 (0%) 
-  GBS disability score at nadir, median (IQR) 4 (3–4) 4 (3–4)
-  Mechanical ventilation, n (%) 36/189 (19%) 4/23 (17%)
Specific treatment
-  IVIg, n (%) 172/189 (91%) 20/23 (87%)
-  Methylprednisolone, n (%) 84c 3c 
-  Plasma exchange, n (%) 1c 1/23 (4%) 
-  None, n (%) 17/189 (9%) 2/23 (9%) 
Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neu-
ropathy; CSF, cerebrospinal fluid; IQR, interquartile range; IVIg, intravenous immunoglobulin; NA, not avail-
able.
a All patients fulfilled the current diagnostic criteria for GBS.19 Data were collected prospectively for all 
adults and children enrolled in the studies.40-42 For other children, hospital records were reviewed;
b Other electromyography patterns than AIDP were reported in 6/15 (40%) of children, but not further 
specified;
c Combined treatment together with IVIg.
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M. pneumoniae-specific ELISA
All serum samples were tested for the presence of anti-M. pneumoniae IgM and IgG 
antibodies using a commercially available ELISA (Serion ELISA classic M. pneumoniae, 
Serion GmbH, Würzburg, Germany) according to the manufacturer’s instructions. This 
assay includes M. pneumoniae whole-cell lysate as antigen, enriched for the highly spe-
cific adhesion protein P1. The balanced accuracy for IgM and IgG is declared with 93.4% 
and 97.3%, respectively (Serion GmbH).
Glycolipid ELISA
IgM and IgG antibodies to GM1, GM2, GD1a, GD1b, GQ1b, and GalC (all from Sigma-
Aldrich, Zwijndrecht, The Netherlands) were measured as described previously.20,21 To 
determine anti-GalC antibodies, half-area 96-well plates (Costar, Corning B.V. Life Sci-
ences, Amsterdam, The Netherlands) were coated with 450 pmol of glycolipid per well. 
All sera were diluted 100-fold. The optical densities (ODs) at 490 nm from uncoated wells 
(containing ethanol) were subtracted from the glycolipid-coated wells. Cut-off values 
were either predefined (i.e., a background-subtracted OD of 0.2 for IgG and 0.3 for IgM) 
or obtained by measuring 30 healthy control sera (mean optical density plus three times 
the standard deviation). Positive samples were titrated using two-fold serial dilution 
series starting at a 1:100 dilution. The titer was defined as the reciprocal of the highest 
dilution that resulted in an OD higher than the cut-off value. Antibodies to glycolipid 
complexes were determined as described before22 with the modification that 225 pmol/
well was used for GalC and 75 pmol/well for other glycolipids in half-area plates.
Inhibition ELISA
To determine whether anti-GalC antibodies cross-react with M. pneumoniae, the 
strains M129 (subtype 1 reference strain, ATCC 29342), FH (subtype 2 reference strain, 
ATCC15531), A16, A58, A103, ST (all clinical strains from patients with respiratory tract 
infection), and the strain of the index case were grown in tissue culture flasks at 37°C/5% 
CO2 in SP4 medium (pH 7.8). Before the medium was acidified, M. pneumoniae was 
harvested with a cell scraper, followed by centrifugation (10,000 g for 20 min). Aliquots 
were stored at −80°C until use. Protein concentrations were determined using the 
bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Sera were incubated for 3 
h at 4°C with increasing concentrations of M. pneumoniae antigen mixture 1% BSA in 
PBS, centrifuged, and supernatants were tested for binding to GalC as described above. 
As control, sera were incubated with 1% BSA in PBS alone. To assess the specificity of 
anti-GalC antibodies, C. jejuni lipooligosaccharides (LOS) GB2 and GB19 were used as 
controls as previously described.23
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Statistical analysis
Data were analyzed using the R software environment (version 3.2.1; R Foundation for 
Statistical Computing). The Mann-Whitney U test was used to compare medians, and the 
χ2 test or Fisher’s exact test to compare proportions. The log-rank test and Cox regression 
was used to compare the time to outcome. Two-sided p values <0.05 were considered 
to be statistically significant. Correction for multiple testing was performed using the 
Bonferroni method, separately for analyses within adults and within children.
RESULTS
Index case presentation
A 34-year old woman presented with a 3-day history of progressive weakness of the legs 
with increasing difficulty in climbing stairs without weakness of the arms or sensory 
symptoms. She had complained about fever, cough, and shortness of breath two weeks 
before admission. She received no treatment for the respiratory tract infection. Except for 
migraine, her personal and family medical history was unremarkable.
The patient was in a slightly reduced general condition and coughed, but had no fever 
or other abnormal vital signs (body temperature 37.0°C, respiratory rate 19/min, oxygen 
saturation 95%). Neurological assessment revealed walking difficulty (GBS disability 
score24 3) and weakness of the proximal muscles of both legs (iliopsoas, hamstring, and 
quadriceps; Medical Research Council (MRC) sum score25 4). There were no sensory 
or cranial nerve deficits, ataxia, or weakness of the arms. Areflexia was present in both 
the upper and lower extremities, but plantar reflexes were present on both sides. Nerve 
conduction studies four days after onset of neurological symptoms were unremarkable, 
except for absent H-reflexes for the m. soleus on both sides. White blood cell count and 
C-reactive protein were normal, while the erythrocyte sedimentation rate was elevated 
with 71 mm/h. Cerebrospinal fluid (CSF) analysis revealed a mild pleocytosis with 39 
white blood cells/μl and a slightly raised protein concentration (0.53 g/l), which is com-
patible with the diagnosis of GBS.19 No chest radiograph was performed.
M. pneumoniae was cultured from a pharyngeal swab of the patient at presentation 
(Figure 2A). Typing of M. pneumoniae by multiple-locus variable-number tandem repeat 
analysis26 revealed a subtype 1 strain. Anti-M. pneumoniae serum IgM, IgG, and IgA 
antibodies were 145, 14, 150 U/ml at presentation and 74, 34, 12 U/ml after 3 months, 
respectively (norm IgM ≤17, IgG ≤30, and IgA ≤14 U/ml) (Figure 2B). There was no 
intrathecal production of these anti-M. pneumoniae antibodies. Serum anti-glycolipid 
antibodies were found exclusively against GalC of both IgM (ΔOD 490 nm: 1.6) and IgG 
(0.5) isotypes (Figure 2C). Anti-GalC antibodies were absorbed by incubation with M. 
pneumoniae, most strongly by the cultured isolate, but not by C. jejuni LOS (Figure 2D).
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The patient was treated with a standard single course of IVIg of 0.4 g/kg for 5 days. 
Notably, the IVIg brand administered to the patient as well as 3 other IVIg brands did 
not contain anti-GalC antibodies (IgG or IgM; 4 different lot numbers of each IVIg brand 
tested, data not shown). Additionally, the patient received codeine cough suppressant at 
admission. No respiratory symptoms were reported during hospitalization. During the 
first two days, the muscle weakness progressed slightly with additional involvement of 
both arms. Thereafter, the patient improved and was discharged home after 4 weeks, with 
remaining muscle weakness of the triceps (MRC sum score 4/4), finger extensor (4.5/5), 
iliopsoas (4/4), and hamstring (4/4). Reflexes remained absent in the arms and legs. At 
discharge, anti-GalC IgM and IgG were hardly detectable. At a 3-month follow up, the 
neurological exam was normal, but the patient complained about slight muscle ache in 
the arms and legs.
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Figure 2. An M. pneumoniae culture-positive GBS case.
(A) Scanning electron microscopy picture of the M. pneumoniae strain cultured from respiratory specimen 
of the index case. (B) Serum IgM, IgG, and IgA antibody levels (U/ml) at indicated time points. The dotted 
lines represent the cut-off for IgM (17 U/ml), IgG (30 U/ml), and IgA (14 U/ml). (C) Kinetics of serum anti-
GalC IgM and IgG at indicated time points, with length of hospital stay (gray shaded) and IVIg treatment 
(black bar). (D) Cross-reactivity of anti-GalC IgM assessed by incubating anti-GalC reactive serum samples 
of the index case at inclusion with 25 μg/ml of the specific M. pneumoniae isolate (arrow), as well as other 
M. pneumoniae strains (M129, FH, A16, A58, A103, ST) and C. jejuni lipooligosaccharides (GB2 and GB19). 
The mean is shown as percentage of control (incubation of serum samples without antigen) of two rep-
resentative experiments. Abbreviations: GalC, galactocerebroside; Ig, immunoglobulin; IVIg, intravenous 
immunoglobulin; LOS, lipooligosaccharides; MP, M. pneumoniae; OD, optical density.
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Increased frequency of antibodies against M. pneumoniae in children with GBS 
compared to adults
This case prompted us to investigate the frequency of IgM and IgG antibodies against M. 
pneumoniae in adult and pediatric GBS and appropriate controls. To this end, all cohorts 
were tested with the same M. pneumoniae-specific ELISA. Anti-M. pneumoniae IgM 
antibodies were demonstrated in 3% (5/189) of the adults and 21% (5/24) of the children 
with GBS, compared to none (0/104, p=0.16) in the adult healthy controls (HC) and 7% 
(24/339, p=0.03) in the pediatric HC (Table 3 and Figure 3). Anti-M. pneumoniae IgG 
antibodies were found in 34% (64/189) of the adult and 58% (14/24) of the pediatric 
GBS patients, in contrast to 12% (12/104, p<0.0001) of the adult HC and 19% (64/339, 
p<0.0001) of the pediatric HC. A positive serology was significantly more frequent in 
pediatric GBS patients than in adult GBS patients for both IgM (p=0.0005) and IgG 
(p=0.03). Children with non-infectious neurological diseases (neurologic controls, NC) 
had positive anti-M. pneumoniae IgM and IgG antibodies in 19% (7/36, p=1.00) and 39% 
(14/36, p=0.19), respectively. Of note, the enrollment of this control group from January 
to May 2012 coincided with the peak of a nationwide M. pneumoniae epidemic (personal 
communication, Adam Meijer, Institute for Public Health and the Environment (RIVM), 
The Netherlands27,28). Of the GBS patients who were positive for anti-M. pneumoniae 
IgM, all adults and 60% of the children were also positive for the IgG isotype. The median 
level of anti-M. pneumoniae IgM and IgG antibodies was higher in the GBS cohorts com-
pared to controls, although significance was reached only for IgG in adults (p<0.0001) 
(Figure 3).
Table 3. Anti-M. pneumoniae serum antibodies in GBS patients and controls.
Adults Adult GBS Adult HC
(n=189) (n=104) OR (95% CI) p1
Anti-MP IgM+ 5 (3%) 0 (0%) NA 0.16
Anti-MP IgG+ 64 (34%) 12 (12%) 3.9 (1.9–8.4) 0.00002*
Anti-MP IgM+IgG+ 5 (3%) 0 (0%) NA 0.16
Children Pediatric
GBS
Pediatric
HC
Pediatric
NC
(n=24) (n=339) OR (95% CI) p1 (n=36) OR (95% CI) p2
Anti-MP IgM+ 5 (21%) 24 (7%) 3.4 (0.9–10.7) 0.03 7 (19%) 1.1 (0.2–4.7) 1.00
Anti-MP IgG+ 14 (58%) 64 (19%) 6.0 (2.3–15.8) 0.00005* 14 (39%) 2.2 (0.7–7.2) 0.19
Anti-MP IgM+IgG+ 3 (13%) 21 (6%) 2.2 (0.4–8.1) 0.20 7 (19%) 0.6 (0.1–3.0) 0.72
Abbreviations: CI, confidence interval; HC, healthy controls; Ig, immunoglobulin; MP, M. pneumoniae; NA, 
not available; NC, neurologic controls; OR, odds ratio.
All patients were tested with the Serion ELISA classic M. pneumoniae (Serion GmbH, Würzburg, Germany). 
The differences between GBS and control groups are indicated by Fisher’s exact test; p1: p value for GBS vs. 
HC; p2: p value for GBS vs. NC. *Significant p values after correcting for multiple testing by the Bonferroni 
method.
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These data suggest that there is an association of a positive IgM and IgG serology for M. 
pneumoniae and GBS both in adult and pediatric patients, and that a positive serology is 
much more frequent in children with GBS than in adults.
Anti-GalC antibodies are more frequent in pediatric than adult GBS and are 
associated with better outcome in adults and children
We determined next IgM and IgG antibodies to the glycolipids GM1, GM2, GD1a, GD1b, 
GQ1b, and GalC in the GBS cohorts by ELISA. Anti-glycolipid serum antibodies against 
any type of glycolipid were found in 33% (n=62) of adults and 42% (n=10) of children 
with GBS (Table 4). Antibodies were found of both isotypes IgM and IgG. The most 
frequent type was anti-GM1 in adult GBS, and anti-GalC in pediatric GBS.
2
4
8
16
32
64
128
256
512
1024
2
4
8
16
32
64
128
256
512
1024
2
4
8
16
32
64
128
256
512
1024
2
4
8
16
32
64
128
256
512
1024
An
ti-
M
P 
Ig
G
 (U
/m
l)
2
4
8
16
32
64
128
256
512
1024
2
4
8
16
32
64
128
256
512
1024
An
ti-
M
P 
Ig
M
 (U
/m
l)
Adults Children
Adult GBS
(n=189)
Adult HC
(n=104)
An
ti-
M
P 
Ig
M
 (U
/m
l)
An
ti-
M
P 
Ig
G
 (U
/m
l)
Adult GBS
(n=189)
Adult HC
(n=104)
Pediatric GBS
(n=24)
Pediatric HC
(n=339)
Pediatric NC
(n=36)
Pediatric GBS
(n=24)
Pediatric HC
(n=339)
Pediatric NC
(n=36)
p<0.0001
p<0.0001
A B
3% 0% 21% 7% 19%
34% 12% 58% 19% 39%
Positive:
Positive:
Positive:
Positive:
Figure 3. Anti-M. pneumoniae serum antibody levels in GBS patients and controls.
Serum IgM and IgG antibody levels (U/ml) are compared between adult GBS (A), pediatric GBS (B), and con-
trols. The horizontal lines represent the median. The light gray area assigns positive levels above the cut-off 
of the test (IgM: 17 U/ml for adults and children, IgG: 15 U/ml for children and 30 U/ml for adults) and the 
dark gray area levels below the lower limits of quantification (IgM: 5 U/ml, IgG: 3 U/ml; note that samples be-
low these limits are not indicated in the graphs) as indicated by the manufacturer (Serion GmbH, Würzburg, 
Germany). Proportions of positives are indicated on top of each graph. Significant differences in propor-
tions of positives between GBS patients and controls after correcting for multiple testing by the Bonferroni 
method are indicated with the corresponding p value (Fisher’s exact test). Abbreviations: GBS, Guillain-
Barré syndrome; HC, healthy controls; Ig, immunoglobulin; MP, M. pneumoniae; NC, neurologic controls.
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Anti-GalC antibodies (IgM and/or IgG) were present in serum of 4% (7/189) adults and 
25% (6/24) children with GBS (p=0.001). In these anti-GalC-positive patients, antibodies 
against other glycolipids were only present in one adult (anti-GM1 and anti-GD1b) and 
one child (anti-GQ1b). No antibodies were found against complexes of two glycolipids22 
instead of a single glycolipid (data not shown).
The median age for anti-GalC-positive and –negative GBS patients was 45 years (inter-
quartile range [IQR] 26–51) and 55 years (IQR 38–66, p=0.11) in the adult cohort, and 14 
years (IQR 13–16) and 10 years (IQR 9–14, p=0.22) in the pediatric cohort, respectively. 
There was no gender predominance within these groups. Anti-GalC-positive GBS patients 
presented with intriguing clinical characteristics: anti-GalC-positive adult GBS patients 
more often reported preceding respiratory symptoms (86%) than did patients without 
anti-GalC (35%, p=0.02). In addition, in adults, anti-GalC-positive GBS patients tended 
to have more cranial nerve involvement than anti-GalC-negative patients (71% vs. 33%, 
p=0.08). In children, we did not detect significant differences between anti-GalC-positive 
and –negative groups, most likely because the group sizes were too small. The presence of 
anti-GalC antibodies was not associated with electrophysiological subtypes. In general, 
the outcome was better for children than adults. In children, no deaths occurred and all 
were able to walk unaided within 4 months (median 2 weeks). There were no significant 
differences in treatment regimens between anti-GalC-positive and –negative adults (IVIg, 
86% vs. 91%; IVIg + methylprednisolone, 29% vs. 45%; plasma exchange, 0% vs. 1%) and 
children (80% vs. 83%; 20% vs. 11%; 0% vs. 6%). GBS patients with anti-GalC antibodies 
showed a trend for a better outcome compared to anti-GalC negative patients (Table 5).
Table 4. Anti-glycolipid serum antibodies in GBS patients.
Adult GBS Pediatric GBS
p(n=189) IgM IgG (n=24) IgM IgG
Anti-GalC 7 (4%) 2 6 6 (25%) 4 3 0.001*
Anti-GM1 32 (17%) 24 21 4 (17%) 4 4 1.00
Anti-GM2 16 (8%) 4 13 0 (0%) NA NA 0.23
Anti-GD1a 10 (5%) 1 9 0 (0%) NA NA 0.61
Anti-GD1b 17 (14%a) 4 16 2 (8%) 2 2 0.74
Anti-GQ1b 7 (4%) 2 5 1 (4%) NA 1 1.00
Total 89 37 70 13 10 10
Patients with ≥1 antibody 62 (33%) 10 (42%) 0.49
Patients with ≥2 antibodies 19 (10%) 3 (13%) 0.73
Abbreviations: GalC, galactocerebroside; GBS, Guillain-Barré syndrome; GD1a, ganglioside disialo 1a; GD1b, 
ganglioside disialo 1b; GM1, ganglioside monosialo 1; GM2, ganglioside monosialo 2; GQ1b, ganglioside 
quadrosialo 1b; Ig, immunoglobulin; NA, not available.
The differences between adult and pediatric GBS are indicated by Fisher’s exact test. *Significant p values 
after correcting for multiple testing by the Bonferroni method.
a Anti-GD1b antibodies were tested only in 122 (65%) of 189 adult GBS patients.
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Anti-GalC antibodies are related to M. pneumoniae infections in GBS and are 
specifically absorbed dose-dependent by several M. pneumoniae strains
Next, we looked at the putative association between anti-GalC and anti-M. pneumoniae 
antibodies. Serological evidence for a recent M. pneumoniae infection was more often 
found in GBS patients with anti-GalC antibodies than in patients without anti-GalC anti-
bodies, which was the case for both anti-M. pneumoniae isotypes IgM and IgG (Table 6). 
In fact, there was no such relation between other anti-glycolipid antibodies and anti-M. 
pneumoniae antibodies (Figure 4). Further, there was also no relation between anti-GalC 
antibodies and a positive C. jejuni serology (data not shown).
Table 5. Outcome analysis of GBS patients with or without anti-GalC antibodies.
Adult GBS Pediatric GBS
Anti-GalC+ Anti-GalC- Anti-GalC+ Anti-GalC-
(n=7) (n=182) p (n=6) (n=18) p
Time to reach the ability 
to walk unaided (weeks), 
median (IQR)
3.0 (2.0–10.0) 5.0 (2.0–14.0) 0.33a 1.6 (0.9–2.3) 2.6 (1.2–5.8) 0.18a
Poor outcome
(GBS disability score >2 at 
6 months),45 n (%)
0/7 (0) 30/178b (17) 0.51c 0/6 (0) 0/18 (0) NA
Deaths, n (%) 0/7 (0) 7/182 (4) 1.00c 0/6 (0) 0/18 (0) NA
Abbreviations: GBS, Guillain-Barré syndrome; GalC, galactocerebroside; IQR, interquartile range; NA, not 
available.
a Log-rank test. Survival analysis combined for adults and children after adjustment for age by Cox regres-
sion: p=0.22; b GBS disability score at 6 months was available only for 178 (98%) of 182 anti-GalC- adult GBS 
patients; c χ2 test.
Table 6. Anti-M. pneumoniae antibodies in GBS patients with or without anti-GalC antibodies.
GBS Anti-GalC+ Anti-GalC-
Anti-MP IgM+ 6/13 (46%) 4/200 (2%) <0.00001*
-  Adults 3/7 2/182 0.0003*
-  Children 3/6 2/18 0.08
Anti-MP IgG+ 11/13 (85%) 67/200 (34%) 0.0004*
-  Adults 5/7 59/182 0.05
-  Children 6/6 8/18 0.02
Anti-MP IgM+IgG+ 6/13 (46%) 2/200 (1%) <0.00001*
-  Adults 3/7 2/182 0.0003*
-  Children 3/6 0/18 0.01*
Abbreviations: GalC, galactocerebroside; GBS, Guillain-Barré syndrome; Ig, immunoglobulin; MP, M. pneu-
moniae.
The differences between anti-GalC+ and anti-GalC- GBS are indicated by Fisher’s exact test. *Significant p 
values after correcting for multiple testing by the Bonferroni method.
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To demonstrate cross-reactivity of anti-GalC antibodies found in adult and pediatric 
GBS with M. pneumoniae, patient sera were first incubated with increasing antigen con-
centrations (1.66, 6.25, and 25 μg/ml) of M. pneumoniae subtype 1 (M129) and subtype 2 
(FH) reference strains, as well as with four clinical strains from patients with respiratory 
tract infection. The supernatants were subsequently tested for the presence of anti-GalC 
antibodies by ELISA. Anti-GalC antibodies were absorbed in a dose-dependent manner 
by M. pneumoniae (Figure 5). The absorption was more effective for anti-GalC IgG than 
IgM by all M. pneumoniae strains. In a subset of patient sera, the M. pneumoniae FH 
strain showed less effective absorption of IgG compared to the other strains. Anti-GalC 
antibodies were not absorbed by C. jejuni LOS (GB2 and GB19; data not shown).
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Figure 4. Distribution of anti-glycolipid serum antibodies in adult and pediatric GBS in relation to a positive 
M. pneumoniae serology.
In total, 89 anti-glycolipid antibodies were detected in the 189 adult GBS cases (A and B) and 13 in the 24 
pediatric GBS cases (C and D). M. pneumoniae positivity (MP+) indicates positive for specific IgM and/or IgG 
(both isotypes have been associated with GBS). Each segment is provided with the target glycolipid anti-
gen and the correspondent absolute number of detected anti-glycolipid antibodies. Anti-GD1b antibodies 
were tested only in 122 of 189 adult GBS patients. Abbreviations: GalC, galactocerebroside; GBS, Guillain-
Barré syndrome; GD1a, ganglioside disialo 1a; GD1b, ganglioside disialo 1b; GM1, ganglioside monosialo 1; 
GM2, ganglioside monosialo 2; GQ1b, ganglioside quadrosialo 1b; Ig, immunoglobulin; MP, M. pneumoniae.
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Anti-GalC IgG but not IgM antibodies are strongly associated with GBS 
following M. pneumoniae infection
To determine whether anti-GalC antibodies were specifically associated with the occur-
rence of neurological symptoms in GBS, we also tested patients without neurological 
symptoms (non-neurologic controls, NNC) and patients with non-infectious neurologic 
diseases (NC) for the presence of anti-GalC antibodies (Table 1).
Anti-GalC antibodies could be detected in 10 patients of the pediatric NNC, of which all 
had a positive M. pneumoniae serology (anti-M. pneumoniae IgM n=8, IgG n=8). These pa-
tients accounted for 18% (10/56) of the control children with positive anti-M. pneumoniae 
antibodies. Anti-GalC antibodies were not detected in the adult NNC and pediatric NC.
Interestingly, all these anti-GalC-positive control children had exclusively anti-GalC 
antibodies of the isotype IgM. There was no difference for this isotype between M. 
pneumoniae-positive GBS and control patients (p=0.87). These findings were supported 
by retesting samples of previously reported anti-M. pneumoniae IgM-positive control 
patients without neurological symptoms,10 in which we found anti-GalC antibodies in 
38% (6/16) of the patients (5 children and 1 adult). In fact, the majority (83%, 5/6) of 
these control patients also had only anti-GalC IgM in serum.
In contrast, serum anti-GalC IgG were specifically associated with GBS. We found 
anti-GalC IgG only in M. pneumoniae-positive GBS patients, but not in M. pneumoniae-
positive control patients (p=0.006) (Figure 6). In addition, anti-GalC IgG was also more 
common in M. pneumoniae-positive GBS than M. pneumoniae-negative GBS (p=0.03).
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Figure 5. Absorption of serum anti-GalC IgM and IgG antibodies by different M. pneumoniae strains.
Cross-reactivity of anti-GalC IgM (A) and anti-GalC IgG (B) with M. pneumoniae was assessed by incubat-
ing anti-GalC reactive serum samples with increasing doses of different M. pneumoniae strains, i.e., M129 
(subtype 1 reference strain), FH (subtype 2 reference strain), A16, A58, A103, and ST (all clinical strains from 
patients with respiratory tract infection). Anti-GalC antibody concentrations remained unaffected with C. 
jejuni lipooligosaccharides (GB2 and GB19; data not shown). Data shown are the means as percentage of 
control (incubation of serum samples without antigen) and are derived from two GBS patient serum sam-
ples for each isotype. Abbreviations: GalC, galactocerebroside; Ig, immunoglobulin; MP, M. pneumoniae.
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These data demonstrate that M. pneumoniae elicits anti-GalC antibodies in a certain 
proportion of patients, predominantly in children, and suggest that anti-GalC IgG, but 
not IgM, is critical for the development of GBS following M. pneumoniae infection.
DISCUSSION
The role of the respiratory pathogen M. pneumoniae in GBS was previously reported to be 
unclear. This was mainly due to the variable frequency with which anti-M. pneumoniae 
antibodies were detected in GBS patients and the presence of anti-GalC antibodies in 
controls. However, in this study, we demonstrate that there is a strong association be-
tween preceding M. pneumoniae infections and the development of GBS.
We found that the highly variable frequency of a positive anti-M. pneumoniae IgM 
serology among GBS patients is related to the age of investigated patients. The higher 
frequency of anti-M. pneumoniae IgM in children than adults (21% vs. 3%) is in line with 
the higher incidence of M. pneumoniae infections in children.3 This is also reflected by 
the relatively high seroprevalence in healthy controls of children in contrast to adults (7% 
vs. 0%). The prevalence fluctuated significantly between year and season of sampling,29 
which was suggested to be related to the known cyclic epidemic pattern of M. pneumoniae 
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Figure 6. Anti-GalC isotype distribution and antibody titers in GBS patients and controls.
M. pneumoniae (MP+) indicates positive for specific IgM and/or IgG (both isotypes have been associated 
with GBS). Some patients have both IgM and IgG antibodies against GalC and are represented by two data 
points in the graph. Differences in proportions are indicated with the corresponding p value (χ2 test). Ab-
breviations: GalC, galactocerebroside; GBS, Guillain-Barré syndrome; Ig, immunoglobulin; MP, M. pneumoni-
ae; NNC, non-neurologic controls.
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infections that occurs at intervals of 3–7 years, in addition to a background endemic 
pattern.30 In fact, the increased frequency of anti-M. pneumoniae IgM in our pediatric 
controls with neurologic diseases other than GBS compared to pediatric healthy controls 
(19% vs. 7%) may be explained by its 5-month enrollment during a nationwide epidemic 
peak in European countries from 2010–2012.30 In terms of the epidemic pattern of M. 
pneumoniae infections, we did not observe clusters of GBS cases associated with M. 
pneumoniae over the entire study period in adults and children (data not shown). The 
discrepancy between the high frequency of M. pneumoniae infections and the rarity of 
GBS indicates that probably not all M. pneumoniae strains are similarly effective in induc-
ing GBS and, or, that not all infected individuals are equally susceptible to produce the 
immune response causing GBS.31
The anti-M. pneumoniae IgM and IgG responses in our GBS patients reflect a recent 
activation of the immune system elicited by M. pneumoniae at the respiratory surface, 
whether induced by infection or carriage.5,29 This is essential in the context of GBS where 
specific preceding infections may precipitate an immune response against neural targets. 
An immune response against GalC was detected in 4% of adult GBS and 25% of pediatric 
GBS, where it was the most frequent type of the detected anti-glycolipid antibodies. In 
previous studies, anti-GalC antibodies were reported in 1% (2/136)14 and 12% (16/130)10 
of GBS patients (predominantly adults). The rare detection of antibodies against other 
glycolipids or complexes of glycolipids in anti-GalC-positive GBS patients suggests that 
the presence of anti-GalC antibodies may be pathogenic in those cases. This is supported 
by the kinetics of anti-GalC antibodies in the index case, where decreasing levels cor-
related with clinical improvement. Anti-GalC antibodies indeed caused demyelination 
in vitro16 and in experimental allergic neuritis,17 and have also been associated with 
demyelination in GBS,10 encephalitis,32 and acute disseminated encephalomyelitis.33 In 
the current study, there was no significant difference in demyelinating features between 
anti-GalC-positive and –negative patients possibly because demyelination was the major 
electrophysiological feature.34 In comparison with the anti-GalC-negative GBS patients, 
anti-GalC-positive adults presented more frequently with cranial nerve involvement and 
a better outcome. The better outcome was most probably related to the younger age of the 
anti-GalC-positive patients.35 Although their neurological illness dominated the clinical 
picture, they more frequently reported preceding symptoms of a respiratory tract infec-
tion than controls. This finding was congruent with the clear relation between anti-GalC 
and anti-M. pneumoniae antibodies (IgM and IgG). Although GBS following M. pneu-
moniae infection has been reported also in association with antibodies against GM1,14 we 
did not find a relation between anti-glycolipid antibodies other than anti-GalC with M. 
pneumoniae serology, in both adults and children.
As in our index case, we were able to demonstrate cross-reactivity of anti-GalC 
antibodies with M. pneumoniae in adult and pediatric GBS. This cross-reactivity was 
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more effective for anti-GalC IgG than IgM. The specificity of anti-GalC antibodies was 
demonstrated by a lack of cross-reactivity with C. jejuni LOS. It is unclear, however, why 
the M. pneumoniae FH strain led to less effective absorption in a subset of GBS patients 
compared to the other strains. Differences between M. pneumoniae strains in their gly-
colipid structures (GalC-like structure) may be responsible for the observed less effective 
absorption.36
Until now, it has been difficult to explain the presence of anti-GalC antibodies in 
individuals with M. pneumoniae infection without neurological symptoms.14 Anti-GalC 
antibodies were previously detected in the serum of 8% (1/12)14, 18% (6/33)18, and 25% 
(8/32)12 of patients with M. pneumoniae infection without neurological disease. Indeed, 
we also detected anti-GalC antibodies in 18% of our non-neurologic control patients 
who were positive for anti-M. pneumoniae antibodies. Interestingly, all these patients 
were children, and most surprisingly, all exclusively had antibodies against GalC of the 
isotype IgM. These findings were confirmed by retesting other previously found M. 
pneumoniae-positive controls without neurological symptoms,10 where the vast majority 
of anti-GalC-positive patients were also children and again exclusively had anti-GalC IgM 
antibodies. Of note, such anti-GalC IgM+IgG- patients without neurological symptoms 
already had an isotype class switch to anti-M. pneumoniae IgG antibodies in 80% of the 
cases (8/10), which suggested that GalC-specific B cells did not switch as opposed to M. 
pneumoniae protein-specific B cells. The amount and variety of isotypes within a B cell 
pool is determined by the priming condition,37 and glycolipids and proteins have already 
been shown to elicit different isotype responses during helminth infections.38 Thus, one 
might speculate that the anti-GalC class switch to IgG is causing GBS. We indeed found 
anti-GalC IgG specifically associated with GBS, and anti-GalC IgG was also present in the 
vast majority of other anti-GalC-positive GBS cases.10,11,13 Further, our results are in line 
with the study of Susuki et al.,14 who also found that the anti-GalC antibodies in controls 
were of the IgM isotype, whereas in patients with GBS, these antibodies were of the IgG 
isotype. In fact, an unregulated class switch has been shown to favor the onset of autoim-
mune disorders, such as systemic lupus erythematosus.39 We therefore propose that an 
aberrant class switch of GalC-specific B cells to IgG may be critical for the development 
of GBS. Apart from a class switch and the titer of isotypes, also the physiological activ-
ity (fine specificity and affinity) of anti-GalC antibodies and its ability to penetrate the 
inflamed blood-nerve barrier may play a role in GBS.
There are several limitations of our study. First, different control cohorts were used to 
compare the presence of anti-M. pneumoniae and anti-GalC antibodies in GBS. Second, 
control cohorts were tested only for anti-GalC but not for other anti-glycolipid antibodies. 
Third, treatment modalities were systematically assessed for IVIg, methylprednisolone, or 
plasma exchange,40-42 but not for antibiotics. We thus cannot consider with certainty that 
indeed no antibiotics were administered that may have influenced the outcome. However, 
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it is well-known that M. pneumoniae respiratory tract infection can be self-limiting43 or 
respond to anti-inflammatory treatment,44 which was also shown by the full recovery of 
the index case without antibiotic treatment.
In conclusion, this study demonstrates a strong relation between M. pneumoniae infec-
tion and GBS, more frequently in children than adults, and that anti-GalC IgG, but not 
IgM, is associated with GBS. These results suggest that the development of anti-GalC IgG 
is a critical step in the pathogenesis of GBS after an infection with M. pneumoniae.
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ABSTRACT
Mycoplasma pneumoniae triggers Guillain-Barré syndrome (GBS) and elicits anti-
galactocerebroside (GalC) antibodies. Specifically anti-GalC immunoglobulin (Ig) G is 
associated with M. pneumoniae-GBS, possibly because of its better ability to cross the 
blood-nerve barrier (BNB). We here investigated cerebrospinal fluid (CSF) for the pres-
ence of anti-GalC in GBS. Intrathecal anti-GalC was found in 46% of M. pneumoniae-
GBS patients (n=6/13), in contrast to 16% of GBS controls (n=4/25) and 0% of non-GBS 
controls (n=0/7). The antibodies most likely originated from increased BNB permeability 
and/or intrathecal synthesis. Intrathecal anti-GalC IgG was specifically associated with 
M. pneumoniae-GBS, further supporting that anti-GalC IgG contributes to the patho-
genesis of GBS.
HIGHLIGHTS
– Although GBS is a peripheral neuropathy anti-GalC antibodies are found in CSF.
– Intrathecal anti-GalC IgG is specifically associated with M. pneumoniae-GBS.
– Anti-GalC IgG in CSF may be derived from blood and related to increased BNB 
permeability.
– In one patient with additional central nervous system involvement, anti-GalC IgG 
most likely derived from intrathecal synthesis.
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INTRODUCTION
Guillain-Barré syndrome (GBS) is a post-infectious immune-mediated peripheral neu-
ropathy.1 We previously showed that M. pneumoniae is associated with GBS2,3 and found 
evidence for a recent M. pneumoniae infection by serology in 3% of adults and 21% of 
children with GBS.3 M. pneumoniae elicits antibodies against galactocerebroside (GalC),4 
one of the major glycolipids of both the peripheral and central nervous system (CNS).5 
Anti-GalC antibodies have been demonstrated to cross-react with M. pneumoniae an-
tigens in adult and pediatric GBS,3 and to cause demyelination in vitro6 and in rabbits 
immunized with GalC.7
A recent intriguing finding was that specifically anti-GalC immunoglobulin (Ig) 
G was associated with GBS after this type of infection.3 A possible hypothesis for this 
observation may be the better ability of anti-GalC IgG to cross the inflamed radicular 
blood-nerve barrier (BNB) because of its smaller size than IgM. The nerve roots connect 
the peripheral and CNS, and the intrathecal segment is surrounded by cerebrospinal fluid 
(CSF) and covered by a BNB consisting of elastic root sheath derived from the arach-
noid.8 Based on this hypothesis and given that M. pneumoniae infection can also result in 
GBS spectrum disorders involving the CNS9 we here investigated CSF for the presence of 
anti-GalC antibodies in M. pneumoniae-GBS and different control cohorts.
MATERIALS AND METHODS
Patients
Thirteen M. pneumoniae-GBS patients along with 25 M. pneumoniae-negative GBS con-
trols and 7 non-GBS controls were selected for the study. All GBS patients fulfilled the 
current diagnostic criteria for GBS.10 The M. pneumoniae-GBS patients were selected out 
of GBS patients3 according to the following criteria: (1) positive for anti-M. pneumoniae 
IgM, and/or (2) positive for anti-GalC IgM and/or IgG (these anti-GalC antibodies had 
been shown to be specifically absorbed in a dose-dependent manner by M. pneumoniae), 
and (3) sufficient CSF available for further testing. The control patients were randomly 
selected M. pneumoniae-negative (IgM and IgG) GBS controls11-13 and non-GBS controls 
with other neurological diseases and unknown M. pneumoniae serology. These non-GBS 
controls were patients who underwent a lumbar puncture for routine diagnostics at 
the Department of Neurology, Erasmus MC (Rotterdam, The Netherlands). Except for 
gender and age, no further information about these controls was available. The serum 
and CSF samples were stored at −80°C before testing. Ethical approval was granted by the 
institutional review board of the Erasmus MC (Rotterdam, The Netherlands).
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M. pneumoniae-specific antibodies
Serum anti-M. pneumoniae IgM and IgG antibodies were tested using a commercially 
available ELISA (Serion ELISA classic M. pneumoniae, Serion GmbH, Würzburg, Ger-
many) as previously described.3
Intrathecal antibody synthesis
Intrathecal antibody synthesis was analyzed by calculation of an antibody index of simul-
taneously collected CSF and serum samples. Because of the limited amount of remaining 
CSF in our cohort we used the tetanus toxoid-specific antibody CSF to serum concentra-
tion quotient as previously described14 instead of the albumin concentration quotient15 to 
calculate the intrathecal fraction of M. pneumoniae-specific IgG antibodies.
Anti-GalC antibodies
Sera were diluted 100-fold and previously tested as described.3 CSF was used 1:10. Opti-
cal densities (ODs) at 490 nm from uncoated wells (containing ethanol) were subtracted 
from glycolipid-coated wells. Cut-off values (0.05 for IgG and 0.03 for IgM) were obtained 
by measuring an independent set of 14 control CSF of patients with other neurological 
diseases (mean OD plus 3 times the standard deviation).
Statistical methods
Data were analyzed using the R software environment (version 3.4.1). Mann-Whitney U 
test was used to compare medians, and χ2 test or Fisher’s exact test to compare propor-
tions. Spearman rank correlation was used to evaluate relationships between variables. 
Two-sided p values <0.05 were considered to be statistically significant. Correction for 
multiple testing was performed using the Bonferroni method.
RESULTS
Anti-GalC IgG and/or IgM were detected in CSF in 46% (6/13) of M. pneumoniae-GBS 
patients, i.e., 2 adults and 4 children (Figure 1). Demographic, clinical, and labora-
tory characteristics are shown in Table 1. All 6 patients were tested positive for anti-M. 
pneumoniae serum antibodies, and showed higher anti-M. pneumoniae serum antibody 
levels than the other M. pneumoniae-GBS patients. Among the clinical characteristics, 
M. pneumoniae-GBS patients with intrathecal anti-GalC reported more frequently pain 
(p<0.01). CSF analysis revealed significantly higher protein concentrations (median 1.81 
g/l, interquartile range [IQR] 1.22–1.88). CSF anti-GalC IgG and IgM levels correlated 
with CSF protein concentration (anti-GalC IgG: p=0.05; IgM: p<0.00001) and serum 
anti-GalC IgG and IgM antibody titers (anti-GalC IgG: p=0.03; IgM: p=0.03).
Intrathecal antibody synthesis was tested in M. pneumoniae-positive GBS patients by 
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calculation of an antibody index of M. pneumoniae-specific IgG where sufficient CSF was 
available (n=3/6, 50%). Antibody indexes were 0.98, 1.22, and 2.40, respectively (cut-off 
<1.3). These results show that intrathecal antibody synthesis occurred in one patient 
(Figure 1). He was positive for intrathecal anti-GalC IgG, but not IgM. This was also the 
only patient with CNS involvement.
In contrast, 16% of GBS controls had anti-GalC in CSF (4/25, p=0.11). These were all 
adults. No anti-GalC was found in non-GBS controls (57% male, median age 51 years, 
IQR 40–68). The 4 GBS controls with anti-GalC in CSF were all tested negative for anti-
GalC in serum, and exclusively had intrathecal anti-GalC IgM. They also differed from 
the other GBS controls by a significantly higher CSF protein concentration (median 2.33 
g/l, IQR 1.97–2.46 vs. 0.65, 0.48–0.80; p=0.01). Intrathecal anti-GalC IgG was specifically 
associated with M. pneumoniae-GBS (p=0.02) (Figure 1).
Nerve conduction studies in the 10 patients with the detection of intrathecal anti-GalC 
antibodies (6 M. pneumoniae-GBS patients and 4 GBS controls) included also testing 
of the late electrophysiological responses and/or reflexes (F waves or H reflexes) in 7 
patients, and were found to be abnormal or absent in 86% (6/7).
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Figure 1. Anti-GalC antibodies in CSF of patients with GBS.
CSF anti-GalC antibody isotype and level in M. pneumoniae-GBS (dots) vs. GBS controls (triangles). The 
sample of the patient with intrathecal production of M. pneumoniae-specific antibodies is indicated with 
an asterix (CSF anti-GalC IgG+ and IgM-). Cut-off values (0.05 for IgG and 0.03 for IgM) were obtained by 
measuring an independent set of 14 control CSF of patients with other neurological diseases (mean OD 
plus 3 times the standard deviation) and indicated by a gray dotted line. Three patients have both CSF anti-
GalC IgM and IgG antibodies and are represented by two data points in the graphs. The χ2 test was used to 
compare proportions. Abbreviations: CSF, cerebrospinal fluid; GalC, galactocerebroside; GBS, Guillain-Barré 
syndrome; Ig, immunoglobulin; Mp, M. pneumoniae; OD, optical density.
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Table 1. Demographic, clinical, and laboratory characteristics of M. pneumoniae-GBS patients and GBS controls.
M. pneumoniae-
GBS
CSF anti-GalC+
M. pneumoniae-
GBS
CSF anti-GalC-
GBS controls
(n=6) (n=7) p1 (n=25) p2
Demographic characteristics
Sex (male), n (%) 2 (33%) 5 (71%) ns 10 (40%) ns
Age (years), median (IQR) 14 (13–26) 22 (22–58) ns 46 (33–68) 0.02
Children, n (%) 4 (67%) 1 (14%) ns 3 (12%) 0.02
Characteristics of GBS
-  Pain, n (%) 6 (100%) 4 (57%) ns 8 (32%) 0.01*
-  Sensory disturbances, n (%) 4 (67%) 3 (43%) ns 14 (56%) ns
-  Cranial nerve involvement, n (%) 1 (17%) 4 (57%) ns 11 (44%) ns
-  CNS involvement, n (%) 1 (17%) – ns – ns
-  GBS disability scorea at nadir, 
median (IQR)
4 (3–4) 4 (3–5) ns 4 (3–4) ns
-  Mechanical ventilation, n (%) 1 (17%) 2 (29%) ns 5/23 (22%) ns
Electrophysiology
-  AIDP, n (%) 5/6 (83%) 2/6 (33%) ns 12/21 (57%) ns
-  AMAN, n (%) – – ns – ns 
-  Equivocal, n (%) 1/6 (17%) 3/6 (50%) ns 7/21 (33%) ns 
-  Inexcitable, n (%) – 1/6 (17%) ns 2/21 (10%) ns 
-  Normal, n (%) – – ns – ns 
Laboratory characteristics
-  Serum anti-M. pneumoniae IgM 
(U/ml),b median (IQR)
90 (18–175) 27 (14–88) ns 3 (2–6) <0.001*
-  Serum anti-M. pneumoniae IgG 
(U/ml),c median (IQR)
207 (125–453) 72 (30–197) ns 7 (5–9) 0.004*
-  Time onset weakness to LP (days), 
median (IQR)
6 (4–12) 3 (2–5) ns 3 (2–6) ns
-  CSF protein (g/l), median (IQR) 1.81 (1.22–1.88) 0.46 (0.40–0.48) 0.005* 0.71 (0.49–1.18) nsd
-  CSF white blood cell count/μl, 
median (IQR)
2 (1–4) 5 (2–7) ns 2 (1–2) ns
-  Intrathecal M. pneumoniae-specific 
antibody synthesis, n (%)
1/3 (33%) NA – NA –
Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neu-
ropathy; CNS, central nervous system; CSF, cerebrospinal fluid; GalC, galactocerebroside, IQR, interquartile 
range; LP, lumbar puncture; NA; not available; ns, not significant. The differences between groups are indi-
cated by Fisher’s exact test (proportions) or Mann-Whitney U test (medians); p1: p value for M. pneumoniae-
GBS CSF anti-GalC+ vs. M. pneumoniae-GBS CSF anti-GalC-; p2: p value for M. pneumoniae-GBS CSF anti-
GalC+ vs. GBS controls. *Significant p values after correcting for multiple testing by the Bonferroni method. 
a GBS disability score: 0=healthy; 1=minor symptoms and capable of running; 2=able to walk 10 m or more 
without assistance but unable to run; 3=able to walk 10 m across an open space with help; 4=bedridden or 
wheelchair-bound; 5=requiring assisted ventilation for at least part of the day; and 6=death; b Cut-off: 17 U/
ml for children and adults; c Cut-off: 15 U/ml for children and 30 U/ml for adults; d p=0.01 excluding the GBS 
controls with detection of intrathecal anti-GalC IgM (n=4).
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DISCUSSION
Here, we demonstrate the presence of intrathecal anti-GalC antibodies in a considerable 
proportion of GBS cases. Possible explanations for the presence of anti-GalC in CSF may 
be dysfunction of the BNB,8,16 endocytosis at the neuromuscular junction with delivery 
to the spinal cord and brainstem,17 or intrathecal synthesis.16
In M. pneumoniae-GBS patients with anti-GalC in CSF, intrathecal antibody synthesis 
was demonstrated in one case by calculation of an antibody index of M. pneumoniae-
specific antibodies, which proves CNS infection.16,18 Notably, this was the only case with 
CNS involvement.
In the other M. pneumoniae-GBS patients anti-GalC in CSF most likely originated from 
the peripheral blood caused by an increased permeability of the radicular BNB since 
CSF anti-GalC levels correlated with CSF protein concentrations and serum anti-GalC 
titers. These antibodies may be induced by M. pneumoniae infection outside the CNS 
and entrance of these antibodies to the CSF is probably made possible after breakdown 
of the radicular BNB. The role of intrathecal anti-GalC antibodies in the pathogenesis 
of GBS is unknown but they may affect the nerve roots. This is supported by a signifi-
cantly increased CSF protein concentration in those M. pneumoniae-GBS patients with 
intrathecal anti-GalC antibodies, even in the first few days of the clinical course, which 
is characteristic for involvement of nerve roots as a result of BNB dysfunction.8 Nerve 
conduction studies in the patients with intrathecal anti-GalC antibodies also showed 
abnormal late electrophysiological responses and/or reflexes (F waves or H reflexes), 
providing further evidence for the dysfunction of proximal nerve roots.19,20
Notably, all 6 M. pneumoniae-GBS patients with anti-GalC in CSF complained about 
pain. Although numbers are small, this finding was significantly more frequent in M. 
pneumoniae-GBS patients than in GBS controls. Pain is a very complex symptom during 
GBS and may be neuropathic or the result of affected nerve roots (radicular pain),13 but 
we lack the clinical information to discriminate these types of pain.
The 4 GBS controls with anti-GalC IgM in CSF were all tested negative for anti-GalC 
in serum. In fact, it is still unclear why serum antibodies to nerve glycolipids are not 
found in all patients with GBS.21 Possible reasons why they are not present anymore in 
the circulation at onset of GBS may be that they are all bound to nerves and/or removed 
from the circulation by uptake at the neuromuscular junctions with delivery to the spinal 
cord and brainstem.17 Notably, all these 4 patients had significantly higher CSF protein 
concentration compared to other GBS controls, which may further suggests that they are 
washed out from the circulation into the CSF by an increased BNB permeability.
Interestingly, intrathecal anti-GalC IgG was specifically associated with M. pneumoniae-
GBS. These findings resemble our previous observation of anti-GalC in serum: We found 
that the anti-GalC antibodies in controls without neurological disease were of the IgM 
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isotype, whereas in patients with GBS, these antibodies were of the IgG isotype.3 These 
observations led to the hypothesis that anti-GalC IgM may represent an epiphenomenon 
in GBS. The fact that we here found anti-GalC IgG also in CSF specifically associated with 
M. pneumoniae-GBS further supports that anti-GalC IgG contributes to the pathogenesis 
of GBS. However, since anti-GalC IgM has also been found in CSF, other properties of 
anti-GalC IgG than the better ability to cross the inflamed radicular BNB may be critical 
for the development of GBS, like isotype titer, physiological activity (fine specificity and 
affinity), and different ability to activate complement.
CONCLUSION
Our observations demonstrate that intrathecal anti-GalC IgG, but not IgM, is associated 
with M. pneumoniae-GBS, and corroborate our hypothesis that the development of anti-
GalC IgG is a critical step in the pathogenesis of GBS after M. pneumoniae infection. The 
finding of an intrathecal production of anti-M. pneumoniae antibodies in a patient with 
GBS and additional CNS symptoms indicates that CNS infection may occur preceding or 
during GBS development and warrants further investigation.
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LETTER TO THE EDITOR
Dear Editor,
We recently presented a case series of seven children who developed severe and compli-
cated Guillain-Barré syndrome (GBS) after infection with M. pneumoniae.1 The disease 
was rapidly progressive and severe: one died, four had clinically defined central nervous 
system (CNS) involvement, and five required mechanical ventilation. Given the often 
relatively benign disease course of GBS after this specific type of infection2 the severe and 
complicated GBS in this series was rather unexpected.
Since we recently demonstrated that pediatric and adult GBS after M. pneumoniae 
infection is associated with antibodies against galactocerebroside (GalC)2 we investigated 
if anti-GalC antibodies were also present in these children with severe GBS.
Sera were tested for IgM and IgG antibodies to GM1, GM2, GD1a, GD1b, GQ1b, and 
GalC (all from Sigma-Aldrich, Zwijndrecht, the Netherlands) as previously described.2-4 
CSF was tested for IgM and IgG to GalC at 1:10 dilution. ODs at 490 nm from uncoated 
wells (containing ethanol) were subtracted from glycolipid-coated wells. Cut-off values 
(0.05 for IgG and 0.03 for IgM) were obtained by measuring 14 CSF samples of patients 
with other neurological diseases (mean OD plus 3 times the standard deviation). Some 
patients had previously been included in other studies.2,5,6
Data were analyzed using the R software environment (version 3.4.1). The χ2 test was 
used to compare proportions. Two-sided p values <0.05 were considered to be statistically 
significant. The study was approved by the Erasmus MC Medical Ethics Board.
Anti-GalC IgG and/or IgM were found in six out of seven patients (86%). Antibodies 
against other glycolipids were present in three of those six (anti-GM1). No antibodies 
were found against complexes of two glycolipids (data not shown).
Since anti-GalC IgG is specifically associated with GBS after M. pneumoniae infection,2 
we next compared the frequency of anti-GalC IgG in severe M. pneumoniae-positive 
pediatric GBS to (1) M. pneumoniae-positive pediatric GBS patients (cohort as previ-
ously described2), who did not fulfill the criteria for severe GBS1 (defined as “less-severe” 
GBS), and (2) M. pneumoniae-negative pediatric GBS.2 The presence of anti-GalC IgG 
was significantly more frequent in serum of severe M. pneumoniae-positive GBS patients 
(43%, n=3/7) than in “less-severe” M. pneumoniae-positive GBS (17%, n=2/12; p=0.04, 
Figure 1) or M. pneumoniae-negative GBS (0%, n=0/8; p=0.03).
Sufficient CSF was available in three patients with severe M. pneumoniae-positive GBS. 
CSF anti-GalC IgG and IgM was found in three (100%) and one (33%), respectively. All 
these three did show signs and symptoms of CNS involvement.
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The increased presence of anti-GalC IgG in severe M. pneumoniae-positive GBS com-
pared to “less-severe” M. pneumoniae-positive GBS may suggest that these antibodies are 
also involved in the development of severe and complicated GBS. Anti-GalC IgG was also 
detected in another recent study in GBS as most frequent anti-glycolipid antibody, identi-
fied in 37%.7 The reason for the poor outcome in our series (one patient died and only 
two patients recovered completely) remains unclear. We2 and Samukawa and coworkers8 
found previously no significant difference in the outcomes between anti-GalC-positive 
and anti-GalC-negative GBS. In both studies, the anti-GalC-negative group consisted of 
different subgroups of GBS patients including Campylobacter jejuni-related anti-GM1-
positive patients who are known to have a poor outcome.9 Here, all comparisons were 
performed within the M. pneumoniae-positive GBS group. Another risk factor for poor 
outcome in GBS is more severe disease at entry.10 The development of GBS may also 
depend on patient-related factors that influence the susceptibility to produce cross-
reactive anti-glycolipid antibodies triggered by infections.11 The differential outcome 
between severe M. pneumoniae-positive GBS patients of our series and “less-severe” M. 
pneumoniae-positive GBS may suggest that our patients were more prone to produce 
a stronger immune response causing GBS. Indeed, the titers of anti-GalC IgG in these 
patients were higher compared to “less-severe” M. pneumoniae-positive GBS. Apart 
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Figure 1. Anti-GalC isotype distribution in children with severe and “less-severe” M. pneumoniae-associated 
GBS.
Serum anti-GalC antibodies were determined in severe M. pneumoniae-positive childhood GBS of the case 
series1 and compared to its presence in “less-severe” M. pneumoniae-positive childhood GBS of our pre-
vious GBS case-control study.2 Mp+ indicates positive for anti-M. pneumoniae IgM ± IgG (both isotypes 
have been associated with GBS2). Differences in proportions are indicated with the corresponding p val-
ue (χ2 test). Abbreviations: GalC, galactocerebroside; GBS, Guillain-Barré syndrome; Ig, immunoglobulin; 
Mp, M. pneumoniae.
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from the role of anti-GalC antibodies, also other host factors may account for distinct 
outcomes in GBS.12,13
Of the seven GBS patients in this series, four had CNS involvement (two were coma-
tose). The relatively frequent CNS involvement in neurological diseases associated with 
M. pneumoniae may be common in children. Kuwahara and coworkers7 observed that 
patients with CNS diseases were younger than those with GBS and variants, and hy-
pothesized that this could possibly be a result of the relatively undeveloped blood-brain 
barrier in children.
In conclusion, the correlation of anti-GalC IgG with a severe and complicated disease 
course and presence in CSF of patients with CNS involvement suggests that these an-
tibodies may contribute to the pathogenesis of severe M. pneumoniae-associated child-
hood GBS.
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THE POSITION OF THE THESIS IN THE FIELD OF PEDIATRIC INFECTIOUS 
DISEASE
Antibiotic resistance is a major health threat worldwide and there is a strong link be-
tween the magnitude of antibiotic prescription and the selection of antibiotic resistant 
pathogens. Tailored prescription of antibiotic treatment is needed to minimize selection 
of antibiotic resistant pathogens. Suspected bacterial pneumonia is the most frequent 
reason to prescribe antibiotics in children.1 Unfortunately, there is so far no single non-
invasive diagnostic tool that establishes the etiology of pneumonia or that can discern 
between carriage and infection (except for blood cultures in e.g. pneumococcal pneumo-
nia, where bacteremia occurs in <5% of the cases). M. pneumoniae is a major bacterial 
cause of CAP in hospitalized children and is even becoming a more important pathogen 
since the introduction of the pneumococcal conjugate vaccine.2-4 In light of the global 
increase in antibiotic resistance of M. pneumoniae,5 the main goal is to clarify the patho-
genesis of this infection (i) to better understand the need and efficacy of antimicrobial 
treatment for this CAP and (ii) to develop diagnostic and therapeutic strategies for M. 
pneumoniae-associated disease. Vaccination may be a promising alternative to antibiot-
ics. However, to develop optimal approaches to vaccination against M. pneumoniae it is 
critical to understand the immune mechanisms that may contribute to protection and/or 
immunopathology. The main objective of this thesis was to determine the role of antibod-
ies to M. pneumoniae in (i) respiratory tract carriage, (ii) pulmonary infection, and (iii) 
extrapulmonary nervous system disease, where an antibody-mediated pathogenesis has 
been suggested. In this chapter, the main findings of our studies are reported and put in 
broader perspective for daily clinical routine and further research.
IMPLICATIONS OF THE RESULTS OF THE THESIS
Antibody responses to M. pneumoniae: protecting against disease
We and others observed that besides causing URTI and LRTI, M. pneumoniae is also car-
ried in the URT of asymptomatic children (Chapter 4).6-10 Carriage is defined as the state 
where a pathogen appears in the normal flora without causing disease,11 and is considered 
a prerequisite for infection.6,12-14 Interestingly, carriage also occurs following symptomatic 
infection.11
We aimed to investigate M. pneumoniae carriage and infection and the role of humoral 
immunity on these microbial stages of pathogenesis. Since this is difficult to study in 
human subjects, we developed a new M. pneumoniae mouse model. Using this M. 
pneumoniae mouse model, we showed that M. pneumoniae was carried in the nose after 
pulmonary infection (Chapter 2). These observations mimic our findings in humans, 
where M. pneumoniae was carried in the URT of children ≥4 months after symptomatic 
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infection (Chapter 4). Our findings are of major importance for clinical practice since 
they show that the mere presence of a putative pathogen in the URT is not indicative for 
(concurrent) respiratory disease. Thus, it is likely that M. pneumoniae PCR-positive chil-
dren with respiratory tract disease receive antibiotics against M. pneumoniae although 
the infection may be caused by other respiratory pathogens, which have been shown to 
co-exist frequently with M. pneumoniae in the respiratory tract.6
We further showed that B cells and antibodies are crucial for M. pneumoniae clearance 
in the lungs of mice. Our serum transfer experiments demonstrated that transferred M. 
pneumoniae-specific serum antibodies enabled B cell-deficient μMT mice to clear pul-
monary M. pneumoniae infection (Chapter 2). These data supported previous findings 
on the essential role of humoral immunity in clearance of M. pneumoniae pulmonary 
infection. Importantly, our observation that M. pneumoniae infections are more severe 
and chronic in μMT mice resemble the findings in patients that suffer from B cell defi-
ciencies,15 such as CVID, XLA, or hypogammaglobulinemia, who have been reported to 
be at increased risk for M. pneumoniae pulmonary disease and/or extrapulmonary mani-
festations, e.g., arthritis.16-20 Thus, it can be speculated that if these patients experience M. 
pneumoniae infections, they may benefit from IVIg treatment, as our data demonstrate 
that administration of serum containing M. pneumoniae-specific IgG protected μMT 
mice from pulmonary M. pneumoniae infections. Notably, we have demonstrated that 
high amounts of M. pneumoniae-specific IgG are present in commercial human IVIg 
preparations (Chapter 10). These data are in line with current guidelines on the manage-
ment of patients with B cell deficiencies, which recommend the administration of IVIg to 
treat and/or prevent respiratory tract diseases.21
However, in contrast to the lungs, M. pneumoniae-specific IgG did not clear carriage 
in the URT. Transfer of WT murine serum, containing M. pneumoniae-specific IgG, 
controlled M. pneumoniae pulmonary infection in the lungs of μMT mice but did not lead 
to a reduction of M. pneumoniae loads in the nose. Unlike M. pneumoniae-specific IgG, 
M. pneumoniae-specific IgA was more abundant in nasal lavage fluid than in BALF of M. 
pneumoniae-infected mice. The induction of IgA ASCs and IgA production in the URT 
affected M. pneumoniae carriage, but did not mediate complete resolution of the bacteria 
(Chapter 2). Notably, it has been shown for S. pneumoniae that higher density of pneumo-
coccal carriage has been associated with increased risk of pneumonia.22 Thus, although the 
induced antibodies do not mediate complete resolution of M. pneumoniae in the URT the 
reduction in bacterial loads may reduce at least the risk for progression to disease by local 
spread along the respiratory tract. Progression to pulmonary disease may be prevented by 
the induction of M. pneumoniae-specific IgG, which cleared M. pneumoniae in the lungs 
of mice. Thus, carriage may not need to be completely resolved considering the fact that 
progression to disease can be prevented by specific antibody responses. These findings are 
of major importance for the current development of M. pneumoniae-targeting vaccines.
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Unlike other bacteria, M. pneumoniae lacks a peptidoglycan layer and is only covered 
with a cell membrane containing immunogenic proteins and lipids (Chapter 3 and 6).23 
Importantly, M. pneumoniae glycolipids exhibit sequence homology with mammalian 
tissues, which may trigger cross-reactive antibodies that target cells of multiple organ 
systems.24 It is therefore of major importance for the development of vaccines against 
M. pneumoniae to know which antigenic membrane structures are targeted by induced 
antibodies. We showed that during M. pneumoniae infection in mice and humans specific 
antibodies arise that are directed against M. pneumoniae-derived proteins and glycolip-
ids (Chapter 3). However, we found that clearance of M. pneumoniae from the lungs 
is predominantly mediated by antibodies reactive with M. pneumoniae proteins. This is 
supported by other studies showing that anti-M. pneumoniae protein antibodies may not 
only clear but also prevent infection: Antibodies of M. pneumoniae-immunized guinea 
pigs targeting recombinant P1 and P30 protein prevented adherence of M. pneumoniae to 
human bronchial epithelial cells in vitro.25 These findings illustrate that vaccine strategies 
against M. pneumoniae should aim to target M. pneumoniae proteins to protect against 
disease. Potential M. pneumoniae vaccine candidates may consist of a recombinant 
peptide of the P1 (RP14)26 and the P3027 adhesion protein, which both induced a strong 
antibody response and reduced pulmonary disease in the animal model (Chapter 1). 
Target groups for such vaccines would include young children without treatment alterna-
tives to macrolides in countries with high MRMP rates and elderly people. The vaccine 
may help to reduce morbidity from pneumonia and secondary complications, as well as 
to reduce horizontal transmission to individuals at high risk for M. pneumoniae infection, 
i.e., patients that suffer from B cell deficiencies as mentioned above.
Antibody responses to M. pneumoniae: triggering disease
Using Btk– mice, we observed that anti-M. pneumoniae glycolipid antibodies seem re-
dundant for clearance of pulmonary M. pneumoniae infection (Chapter 3). We detected 
antibodies against the glycolipid GalC of the isotype IgM in all M. pneumoniae-positive 
pneumonia patients, which demonstrated that the formation of these antibodies is part 
of the physiological immune response to M. pneumoniae. As opposed to anti-GalC IgG, 
which were not found in patients with M. pneumoniae CAP. Notably, it cannot be excluded 
that these seronegative patients may produce anti-GalC IgG that cause neuropathy but, 
after binding to the nerve terminal, are cleared from the circulation and can thus not be 
found in serum.28 However, none of these patients displayed neurologic symptoms. The 
anti-GalC IgM response in these patients may indeed be redundant. These observations 
are in contrast to the findings in patients with M. pneumoniae-associated nervous system 
diseases: We found that anti-GalC IgG, but not IgM, is associated with encephalitis (Chap-
ter 7) and GBS (Chapter 10, 11, and 12). These results suggest that the development of 
anti-GalC IgG is a critical step in the pathogenesis of M. pneumoniae-associated nervous 
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system disease. These findings further support the use of immunomodulators in these 
disorders (corticosteroids and/or IVIg in encephalitis and IVIg in GBS) as recommended 
by current guidelines. Corticosteroids (such as prednisolone) reduce inﬂammation29 and 
IVIg has pleiotropic immune-modulatory effects.30 Importantly, we also showed that 
commercial human IVIg preparations did not contain anti-GalC antibodies (IgG or IgM) 
(Chapter 10).
Antibody responses to M. pneumoniae: role in diagnosis
This thesis determines the role of antibodies and B cells specific for M. pneumoniae in 
respiratory infection and extrapulmonary nervous system disease. Diagnostic tests 
targeting essential steps in the pathogenesis of M. pneumoniae-associated disease as 
mentioned above are illustrated in Figure 1. The detection of M. pneumoniae-specific B 
cell responses can be crucial to diagnose these clinical syndromes. Based on our findings, 
we summarized a new approach for assessment and management of M. pneumoniae-
associated CAP, encephalitis, and GBS in Figure 2, which will be discussed below.
The humoral immune response is highly specific for the infecting pathogen. In M. 
pneumoniae pulmonary infection, the antigen-specific B cell response may be a sensi-
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Figure 1. Diagnostic tests targeting essential steps in the pathogenesis of M. pneumoniae-associated dis-
ease.
Abbreviations: ASC, antibody-secreting cell; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-
linked immunospot; Ig, immunoglobulin; PCR, polymerase chain reaction. © 2018 P.M. Meyer Sauteur
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tive indicator for infection based on our findings in mice that B cell responses are 
important for clearance of M. pneumoniae from the lungs (Chapter 2). However, the 
use of convalescent sera is not helpful in clinical settings, because of the time delay that 
is inevitable when waiting for a titer increase. Notably, a specific B cell response cannot 
only be detected by measuring antibodies with ELISA but also by measuring ASCs with 
an ELISpot. We showed that the specific ASC response is more rapid and shorter lived, 
and thus an optimal target for determining infectious etiology in CAP patients (Chapter 
4). ASCs peaked at disease presentation, around 2–3 weeks following onset of symptoms, 
i.e., 3–6 weeks after exposure. These findings are in line with the clinical observation 
of slow disease progression in M. pneumoniae CAP, where prolonged presence of the 
pathogen likely results in continuous antigen exposure and, hence, immune activation, 
allowing to detect M. pneumoniae-specific ASCs in all M. pneumoniae CAP patients 
within 2–3 weeks of disease onset. So far, the specific IgM ASC ELISpot was the only 
test reliably differentiating M. pneumoniae infection from carriage. The measurement of 
ASCs could therefore potentially serve as a future test for the timely diagnosis of M. pneu-
moniae childhood CAP (Figure 2). Improvement in the early diagnosis of M. pneumoniae 
infection in CAP patients is of paramount importance to initiate effective and tailored 
antimicrobial treatment.
The diagnosis of M. pneumoniae-associated encephalitis is even more challenging. The 
lack of detectable M. pneumoniae DNA in CSF (Chapter 8) suggested a likely immune-
mediated pathogenesis ignited by a respiratory inflammatory process including pneumo-
nia. Also others31 support our finding that pneumonia may be an indicator for the remote 
inflammatory process in such cases. A chest radiograph should therefore be performed in 
encephalitis patients to detect pulmonary infiltrates and to increase the diagnostic likeli-
hood of M. pneumoniae-associated disease. This was recently implemented in the guide-
lines for encephalitis.32 In addition, we detected for the first time intrathecal synthesis 
of M. pneumoniae-specific antibodies in a patient with severe encephalitis (Chapter 5), 
which proves CNS infections. These results are of major clinical importance by estab-
lishing a causal relationship between M. pneumoniae and this severe clinical syndrome. 
Intrathecal antibody synthesis can be detected either by calculation of an antibody index 
or through parallel immunoblotting of simultaneously collected CSF and serum samples 
(Chapter 6). The routine diagnostic work-up of M. pneumoniae-associated encephalitis 
should therefore aim for the detection of M. pneumoniae-specific antibodies (IgM and/
or IgG) in both CSF and serum, in addition to M. pneumoniae-specific PCR in CSF 
(Figure 2). Further, it will be interesting to investigate the specific intrathecal antibody 
response additionally by ELISpot.
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In contrast, in M. pneumoniae-associated GBS, it is of lesser importance to know whether 
or not the detected pathogen is the cause of the infection in this postinfectious immune-
mediated peripheral neuropathy. It is largely about the presence of cross-reactive antibod-
ies, induced by either infection with or carriage of a pathogen,33 that are associated with 
GBS. However, a causative relationship between an infecting pathogen and GBS may be 
achieved (in retrospect) by using paired patient sera in order to detect seroconversion and/
or a 4-fold increase in antibody titers. However, this approach is mostly hindered by the 
administration of IVIg in GBS patients. Interestingly, we also established the etiological 
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Figure 2. Algorithm for assessment and management of CAP and nervous system diseases associated with 
M. pneumoniae infection.
Abbreviations: AI, antibody index; ASC, antibody-secreting cell; CAP, community-acquired pneumonia; CRP, 
C-reactive protein; CSF, cerebrospinal fluid; EEG, electroencephalogram; ELISA, enzyme-linked immuno-
sorbent assay; ELISpot, enzyme-linked immunospot; FUP, follow-up visit; Ig, immunoglobulin; IVIg, intrave-
nous immunoglobulin; NCS, nerve conduction studies; PCR, polymerase chain reaction; WBC, white blood 
cell. © 2018 P.M. Meyer Sauteur
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diagnosis in two GBS patients by the detection of a specific intrathecal antibody synthesis 
against M. pneumoniae (Chapter 9). The autoimmune response in GBS results in injury 
and inflammation at peripheral nerves and nerve roots, which are surrounded by CSF. 
The detection of a specific intrathecal antibody response may therefore be useful as an 
additional diagnostic tool to further establish the infectious diagnosis in GBS (Figure 2).
Antibody responses to M. pneumoniae: role in treatment
Although M. pneumoniae infection is generally mild and self-limiting, patients of every 
age can develop severe pulmonary and/or extrapulmonary disease (Chapter 1). Cur-
rent guidelines suggest empiric macrolide treatment at any age if there is no response 
to first-line β-lactam antibiotics or in the case of very severe disease.34 Because there is 
insufficient evidence about the efficacy of antibiotics in the treatment of M. pneumoniae 
LRTI in children,35 we recommend antibiotic treatment only in children with severe M. 
pneumoniae CAP (Figure 2). In case of no treatment (i.e., not severe CAP as defined in 
Figure 2), patients should also be followed until they have fully recovered, not to miss a 
potential (but rare) progression to more severe disease.
The self-limiting course of M. pneumoniae infection in most cases suggests that the 
immunological response following infection generates inflammatory reactions that 
may cause pulmonary and extrapulmonary symptoms.3 Although the pathogenesis is 
incompletely understood, individuals with severe illness may experience a “hyperim-
mune” response in the lung.36 Importantly, our findings show that B cell immunity may 
not contribute to immunopathology since B cell-deficient μMT mice experienced more 
severe disease and lung pathology. This suggests that other immune reactions apart from 
B cell responses may contribute to disease. And indeed, other animal models indicate 
that the severity of pneumonia is increased by an intact T lymphocyte response. T cell-
depleted hamsters developed less severe pulmonary disease,37 and T cell reconstitution of 
SCID mice increased the severity of disease.38 In humans, the severity of CAP has been 
shown to correlate positively with the size of cutaneous induration following intradermal 
exposition to M. pneumoniae antigens.39 These results suggested a relationship between 
the severity of CAP and the degree of the skin reaction after intradermal application of M. 
pneumoniae antigens, which is caused by a M. pneumoniae-specific type IV delayed-type 
hypersensitivity reaction mediated by specific CD4+ T cells. In fact, the rapid clinical 
improvement following corticosteroid administration in children with severe M. pneu-
moniae CAP40,41 may illustrate the contribution of the immune system to immunopathol-
ogy of M. pneumoniae-associated disease, which may overshadow the direct pathological 
effects of M. pneumoniae on the respiratory tract in some cases. Systematic studies are 
needed to determine also in M. pneumoniae CAP the true benefit of immunomodulators, 
such as corticosteroids and/or IVIg (Figure 2).
Chapter 13
214
CONCLUSIONS
We demonstrated that the infection-induced M. pneumoniae-specific antibody response 
is essential to clear pulmonary M. pneumoniae infection, but has a limited effect on M. 
pneumoniae carriage in the URT. Our data indicate that the humoral response to M. pneu-
moniae-derived glycolipids is redundant for pulmonary clearance of M. pneumoniae. The 
hypothesis that the M. pneumoniae-induced anti-GalC IgG response turns autoimmune 
is not only of importance to understand M. pneumoniae-associated immune-mediated 
diseases, but also to construct M. pneumoniae-targeting vaccines, as based on these find-
ings such vaccines may include M. pneumoniae-derived protein antigens rather than 
lipids thereby avoiding the induction of potential autoimmune anti-glycolipid antibodies.
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SUMMARY
Since the introduction of the pneumococcal conjugate vaccine, M. pneumoniae has been 
reported to be the most common bacterial cause of community-acquired pneumonia 
(CAP) among hospitalized children (Chapter 1). Although M. pneumoniae infections 
are generally mild and self-limiting, patients of every age can develop severe CAP or 
extrapulmonary manifestations. Unlike other bacteria, M. pneumoniae lacks a pepti-
doglycan layer and is therefore naturally resistant to cell wall synthesis inhibitors such 
as β-lactams. M. pneumoniae is only covered by a cell membrane containing antigenic 
protein and glycolipid structures, of which some resemble particular host antigens (mo-
lecular mimicry) bearing the potential to trigger autoimmune disease by cross-reactive 
antibodies. Antibiotics in vitro effective against M. pneumoniae include macrolides, 
tetracyclines, and fluoroquinolones. However, the in vivo efficacy of these antibiotics for 
M. pneumoniae infection is unclear. Macrolides are extensively used worldwide, and this 
has led to alarming macrolide-resistant M. pneumoniae rates.
The main goal of this thesis is to clarify the pathogenesis of this infection to better un-
derstand the need and efficacy of antibiotics for CAP in patients with M. pneumoniae and 
to develop diagnostic and therapeutic strategies for M. pneumoniae-associated disease. 
Vaccination may be a promising alternative to antibiotics. However, to develop optimal 
approaches to vaccination against M. pneumoniae it is critical to define immune mecha-
nisms that may contribute to protection or immunopathology. The studies described 
in this thesis focus on the role of antibodies to M. pneumoniae in protecting against or 
triggering disease.
We hypothesized that antibodies to M. pneumoniae protect against pulmonary infection, 
but trigger extrapulmonary nervous system disease. Specifically, we aimed to determine 
in mice and human the role of antibodies to M. pneumoniae in (i) respiratory tract car-
riage, (ii) pulmonary infection, and (iii) extrapulmonary nervous system disease, where 
an antibody-mediated pathogenesis has been suggested.
Summary of the most important findings in this thesis:
Part 1: Antibody responses to M. pneumoniae – protecting against disease
– A new C57BL/6 mouse model is developed for M. pneumoniae carriage in 
the upper respiratory tract (URT) after infection of the lower respiratory tract 
(LRT) (Chapter 2), similar to humans (Chapter 4);
– Observed differences in immunoglobulin (Ig) compartmentalization (URT: 
IgA; LRT: IgM and IgG) correlate with differences in M. pneumoniae-specific 
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B cell responses between nose- and lung-draining lymphoid tissues (Chapter 
2);
– The infection-induced M. pneumoniae-specific antibody response is essential 
to clear pulmonary M. pneumoniae infection, but has a limited effect on M. 
pneumoniae carriage in the URT (Chapter 2);
– Antibodies reactive with M. pneumoniae are directed against both M. 
pneumoniae-proteins and –glycolipids. Pulmonary clearance is predominantly 
mediated by antibodies reactive with M. pneumoniae-proteins, whereas the 
humoral response to M. pneumoniae-glycolipids seems redundant for bacte-
rial clearance in the LRT (Chapter 3);
– Antibodies and M. pneumoniae DNA in the URT persist for months after 
CAP and its detection cannot differentiate between infection and carriage. 
In contrast, M. pneumoniae-specific IgM antibody-secreting cells (ASCs) are 
detectable in peripheral blood only during CAP. Specific IgM ASC detection 
re-classifies one out of six positive PCR test results, and thus corrects misdiag-
nosis of M. pneumoniae infection in CAP patients, in which the detection of 
M. pneumoniae DNA in pharyngeal samples reflects carriage but not disease-
causing infection in the absence of specific IgM ASCs (Chapter 4);
– M. pneumoniae-specific IgM ASCs can be detected by the here established 
enzyme-linked immunospot (ELISpot) assay. This new test has the potential to 
become the new gold standard to diagnose M. pneumoniae infection in clinical 
care for children with CAP (Chapter 4).
Part 2: Antibody responses to M. pneumoniae – triggering disease
Part 2.1: Encephalitis
– The detection of an intrathecal synthesis of antibodies to M. pneumoniae 
(Chapter 5) and the lack of detectable M. pneumoniae DNA in cerebrospinal 
fluid (CSF) of encephalitis patients (Chapter 8) support an immune-mediated 
pathogenesis in M. pneumoniae-associated encephalitis (Chapter 6);
– Antibodies against M. pneumoniae infection have been found to cross-react 
with the myelin glycolipid galactocerebroside (GalC), one of the major glyco-
lipids of both the peripheral nervous system (PNS) and central nervous system 
(CNS). The presence of anti-glycolipid antibodies targeting GalC in CSF of 
encephalitis patients suggests that these antibodies mediate M. pneumoniae-
associated CNS disease (Chapter 7).
Part 2.2: Guillain-Barré syndrome (GBS)
– M. pneumoniae infection is associated with GBS, more frequently in children 
than adults, and elicits anti-glycolipid antibodies targeting GalC (Chapter 10);
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– Anti-GalC antibodies in adult and pediatric GBS patients cross-react with M. 
pneumoniae (Chapter 10);
– Patients positive for anti-GalC antibodies show more frequent preceding respi-
ratory symptoms, cranial nerve involvement, and a better outcome (Chapter 
10);
– Anti-GalC antibodies are also present in patients with M. pneumoniae in-
fection without neurological symptoms. All these patients are children and 
have antibodies against GalC of the isotype IgM (Chapter 3 and 10). These 
results suggest that the development of anti-GalC IgG is a critical step in the 
pathogenesis of GBS after an infection with M. pneumoniae. We indeed find 
anti-GalC IgG specifically associated with GBS (Chapter 10);
– The presence of anti-GalC IgG antibodies also in CSF of GBS patients (Chap-
ter 11) and in GBS children with additional CNS involvement (Chapter 9 and 
12) corroborate that these antibodies contribute to the pathogenesis of both 
PNS and CNS disease.
The results in this thesis pave the way for improved diagnostic and treatment strategies for 
M. pneumoniae-associated disease. We present an algorithm in the Discussion (Chapter 
13) for the assessment and management of CAP and nervous system diseases associated 
with M. pneumoniae infection. This approach aims to reduce morbidity of pulmonary 
and/or extrapulmonary disease and to tailor treatment to prevent the emergence of 
antibiotic resistance.
Overall, our data are of importance not only to understand M. pneumoniae-associated 
immune-mediated diseases, but also for the development of preventive and therapeutic 
strategies such as M. pneumoniae-targeting vaccines. Based on our findings such vaccines 
may include M. pneumoniae-protein antigens rather than M. pneumoniae-lipids thereby 
avoiding the induction of potential autoimmune anti-glycolipid antibodies.
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SAMENVATTING
Vertaald in het Nederlands door Theo Hoogenboezem
Sinds de invoering van de vaccinatie tegen pneumococcen wordt bij kinderen die van-
wege longontsteking in het ziekenhuis zijn opgenomen M. pneumoniae als belangrijkste 
bacteriële ziekteverwekker gevonden (Hoofdstuk 1). M. pneumoniae-infecties hebben 
over het algemeen een mild verloop en behoeven dan geen verdere behandeling. Onaf-
hankelijk van leeftijd kan zich echter een ernstiger vorm van longontsteking ontwikkelen. 
Hierbij kunnen zich ook niet direct met de luchtwegen verbonden ziekteverschijnselen 
voordoen. In tegenstelling tot andere bacteriën mist M. pneumoniae een celwand waarin 
peptidoglycaan voorkomt. Het vertoont daardoor een natuurlijke resistentie tegen anti-
biotica die de opbouw van de celwand remmen (β-lactamaseremmers). M. pneumoniae 
is daarentegen omhuld door een celmembraan waarin zich eiwitten- en glycolipide-
structuren bevinden. Doordat sommige structuren sterk op die van de mens lijken 
(moleculaire mimicry) kunnen ze potentieel een auto-immuunreactie oproepen door de 
vorming van antilichamen die kruis-reageren. Tot de antibiotica die in vitro werkzaam 
zijn tegen M. pneumoniae behoren macroliden, tetracyclines en fluoroquinolonen. De 
doeltreffendheid in vivo van deze antibiotica tegen M. pneumoniae is niet altijd duidelijk. 
Macroliden worden wereldwijd veelvuldig ingezet tegen M. pneumoniae-infecties. Dit 
heeft geleid tot een alarmerende toename van ongevoeligheid voor deze antibiotica.
Het belangrijkste doel van dit proefschrift is de ontwikkeling en het verloop van M. 
pneumoniae-infecties op te helderen, en op basis van die kennis nieuwe diagnostische en 
therapeutische strategieën voor M. pneumoniae-infecties te ontwikkelen om te komen tot 
een efficiënte inzet van antibiotica bij patiënten met longontsteking, veroorzaakt door M. 
pneumoniae. Vaccinatie lijkt een veelbelovend alternatief voor antibioticagebruik. Voor 
een optimale vaccinatiestrategie tegen M. pneumoniae is het essentieel om immunologi-
sche mechanismen te begrijpen die bijdragen aan bescherming of juist immunopatholo-
gie veroorzaken.
Het beschreven onderzoek in dit proefschrift richt zich op de rol van antilichamen die 
zowel bij muis als mens beschermen tegen door M. pneumoniae veroorzaakte longont-
steking, waarbij deze antilichamen buiten de long, bij de mens ongewenste neurologische 
problemen kunnen veroorzaken.
Samenvatting van de belangrijkste resultaten:
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Deel 1: Antilichaamvorming tegen M. pneumoniae – bescherming tegen 
ziekte
– Een nieuw C57BL/6 muismodel is ontwikkeld voor M. pneumoniae-
dragerschap in de bovenste luchtwegen na een door M. pneumoniae-infectie 
veroorzaakte ontsteking in de lagere luchtwegen (Hoofdstuk 2);
– Het immuunsysteem is gecompartimenteerd. De hoeveelheden specifieke, te-
gen M. pneumoniae gerichte antilichamen van Immunoglobuline A correleren 
met veranderingen in neus-drainerende lymfeklieren. De hoeveelheden van 
immunoglobulines G en M correleren met veranderingen in long-drainerende 
lymfeklieren (Hoofdstuk 2);
– Specifieke antilichamen, opgewekt tijdens een M. pneumoniae-infectie, zijn 
essentieel om een longontsteking van deze bacterie te doen verdwijnen maar 
hebben een beperkt effect op dragerschap in de bovenste luchtweg (neus) 
(Hoofdstuk 2);
– Het opruimen van een door M. pneumoniae veroorzaakte longontsteking komt 
vooral tot stand door antilichamen gericht tegen eiwitten van M. pneumoniae. 
De humorale respons, veroorzaakt door antilichamen gericht tegen glycolipi-
den van het membraan van deze bacterie, speelt hierbij een veel geringere rol 
(Hoofdstuk 3);
– Maanden na een doorgemaakte infectie met M. pneumoniae kan het DNA 
van de bacterie nog in de bovenste luchtwegen worden aangetoond, evenals 
gevormde antilichamen in het serum. Dit maakt het moeilijk onderscheid te 
maken tussen infectie en dragerschap. M. pneumoniae-specifieke, Immuno-
globuline (Ig) M producerende cellen (ASCs) zijn in bloed alleen aan te tonen 
tijdens een infectie. Aantonen van deze specifieke IgM producerende ASCs 
her-classificeert een van de zes positieve PCR testresultaten als echte infectie 
en corrigeert daarmee vijf onterechte, als infectie aangemerkte diagnoses tot 
dragerschap (Hoofdstuk 4);
– De enzyme-linked immunospot (ELISpot) meting, die zijn waarde inmiddels 
heeft bewezen bij de detectie van perifere, specifiek tegen M. pneumoniae 
gerichte, IgM producerende ASCs zou de gouden standaard kunnen worden 
voor de diagnose M. pneumoniae-infectie, bij in het ziekenhuis opgenomen 
kinderen met longontsteking (Hoofdstuk 4).
Deel 2: Door antilichaamvorming tegen M. pneumoniae veroorzaakte ziekten
Deel 2.1: Encefalitis
– Het aantonen van antilichamen gericht tegen M. pneumoniae (Hoofdstuk 
5) in combinatie met niet detecteerbare hoeveelheden M. pneumoniae-DNA 
in hersenvocht van patiënten met encefalitis (Hoofdstuk 8) steunen een 
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betrokkenheid van het immuunsysteem bij het ontstaan en verloop van deze 
aandoening (Hoofdstuk 6);
– Antilichamen tegen M. pneumoniae kruis-reageren met het myeline glycolipid 
Galactocerebroside (GalC), een van de belangrijkste glycolipiden van zowel 
het perifere- als het centrale zenuwstelsel. Aanwezigheid van antilichamen 
gericht tegen het glycolipide GalC in hersenvocht doen vermoeden dat deze 
antilichamen betrokken zijn bij M. pneumoniae-geassocieerde ziekten van het 
centraal zenuwstelsel (Hoofdstuk 7).
Deel 2.2: Guillain-Barré Syndrome (GBS)
– Het GBS is vaker bij kinderen dan bij volwassenen een gevolg van een vooraf-
gaande infectie met M. pneumoniae. Dit komt dan door antilichaamvorming 
gericht tegen glycolipid GalC (Hoofdstuk 10);
– Antilichamen, gevonden in serum van volwassenen en kinderen, gericht tegen 
GalC, reageren met M. pneumoniae (Hoofdstuk 10);
– Patiënten die eerder klachten zoals longontsteking hebben doorgemaakt en 
die positief scoren op de aanwezigheid van anti-GalC antilichamen hebben 
vaker klachten van het zenuwstelsel die de hersenen betreffen maar ook een 
gunstiger klinisch beloop van de ziekte (Hoofdstuk 10);
– Patienten die een M. pneumoniae infectie hebben doorgemaakt, echter zonder 
bijkomende neurologische symptomen, hebben in hun serum ook anti-GalC 
antilichamen. Bij al deze pediatrische patienten worden antilichamen tegen 
GalC gevonden van de IgM-klasse (Hoofdstuk 3 en 10). Dit suggereert dat 
de vorming van anti-GalC antilichamen van de IgG-klasse een kritieke stap 
is bij de pathogenese van het Guillain-Barré Syndroom na een doorgemaakte 
infectie met M. pneumoniae. Wij hebben vastgesteld dat aanwezigheid van 
anti-GalC van de IgG-klasse specifiek geassocieerd is met GBS (Hoofdstuk 
10);
– De aanwezigheid van anti-GalC antilichamen van de Immunoglobuline G 
klasse in hersenvocht bij patiënten met het GBS (Hoofdstuk 11) en bij GBS 
kinderen met betrokkenheid van het centraal zenuwstelsel (Hoofdstuk 9 en 
12) bevestigt de bijdrage van deze antilichamen aan het beloop van de ziekte 
van zowel het perifere als het centrale zenuwstelsel.
De resultaten in dit proefschrift maken de weg vrij voor verbeterde diagnostiek en 
behandelstrategieën voor aandoeningen waarbij M. pneumoniae betrokken is. Wij pre-
senteren een algoritme voor het vaststellen en de bewaking van zowel longontsteking als 
aandoeningen van het zenuwstelsel waar een M. pneumoniae-infectie bij betrokken is 
(Hoofdstuk 13). Deze benadering beoogt een verbeterd eindresultaat van de ziekte door 
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behandeling op maat van zowel longontstekingen als aandoeningen waar de long niet bij 
betrokken is, om antibiotica-ongevoeligheid te voorkomen.
De in dit proefschrift beschreven resultaten zijn niet alleen van belang voor het begrip 
van M. pneumoniae-infecties, maar ook voor de ontwikkeling van M. pneumoniae-
vaccins. Afgaand op onze bevindingen zouden deze vaccins vooral moeten bestaan uit 
eiwit-antigenen van M. pneumoniae en niet uit lipiden van deze bacterie, om potentiële 
autoimmuunreacties te voorkomen.
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ZUSAMMENFASSUNG
Mit Auszügen aus Medienmitteilungen der Universität Zürich vom 01.10.2016 und 21.11.2017 
(www.media.uzh.ch/de/medienmitteilungen)
Mykoplasmen (Mycoplasma pneumoniae) zählen zu den häufigsten Erregern der bakteri-
ellen Lungenentzündung (Pneumonie) beim Kind. Die weltweite Einführung der Impfung 
gegen Pneumokokken, den Hauptvertreter der bakteriellen Pneumonie, hat dazu geführt, 
dass M. pneumoniae mittlerweile der häufigste nachgewiesene bakterielle Erreger der 
ambulant erworbenen Pneumonie (community-acquired pneumonia, CAP) in den USA 
ist (Kapitel 1). Eine Impfung gegen M. pneumoniae gibt es bis jetzt nicht. Obwohl eine 
Infektion mit M. pneumoniae vorwiegend mild und selbstlimitierend verläuft, können in 
jeder Altersgruppe schwere Pneumonien auftreten sowie verschiedene andere Organsys-
teme betroffen sein (z.B. Nervensystem, Haut, Blutgefässsystem und Verdauungstrakt). Im 
Gegensatz zu anderen Bakterien besitzen Mykoplasmen keine Zellwand. Sie sind daher 
natürlich resistent gegen die bei der Pneumonie primär eingesetzten Penicillin-Antibio-
tika, welche die Zellwandsynthese hemmen. Anstatt einer Zellwand hat M. pneumoniae 
nur eine Zellhülle, welche aus vielen Eiweiss- und Fettstoffen besteht. Den Mykoplasmen 
ist eigen, dass gewisse dieser Eiweiss- und Fettstoffe grosse Ähnlichkeit mit körpereigenen 
Strukturen haben (z.B. mit den Nervenscheiden). Diese Fremdstoffe (Antigene) von M. 
pneumoniae können daher im Körper die Bildung von Antikörpern gegen sich selbst 
bewirken. Antibiotika, welche das Wachstum von Mykoplasmen in vitro (im Reagenzglas) 
hemmen, sind Makrolide, Tetrazykline und Fluorochinolone. Jedoch ist bis anhin unklar, 
ob diese Antibiotika auch in vivo (im Körper) den Krankheitsverlauf positiv beeinflussen. 
Trotzdem werden v.a. Makrolide sehr häufig eingesetzt, was zu einer weltweit alarmieren-
den Zunahme von Antibiotikaresistenzen geführt hat. In gewissen Weltregionen gibt es 
daher für Kleinkinder oft keine geeigneten Antibiotika mehr gegen Mykoplasmen.
Das Ziel dieser Arbeit ist es, die Krankheitsentstehung dieser Infektion besser zu ver-
stehen, damit man in Zukunft den Nutzen einer Antibiotikatherapie für diese Pneumonie 
besser evaluieren und weitere diagnostische und therapeutische Strategien gegen M. 
pneumoniae entwickeln kann. Die Entwicklung spezifischer Impfstoffe könnte bei der 
Bekämpfung der Mykoplasmen eine vielversprechende Alternative zu den Antibiotika 
sein. Eine erfolgreiche Impfstoffentwicklung setzt jedoch voraus, dass man die Reak-
tionen des Immunsystems als Antwort auf einen Erreger, welcher ganz oder teilweise 
im Impfstoff enthalten ist, bestmöglich versteht; d.h. ob die durch Impfung und/oder 
Infektion ausgelöste Immunreaktion schützt (Verhinderung der Krankheit) oder sogar 
selbst zur Krankheit beitragen kann (Entzündungsreaktion, Autoimmunkrankheit). Die 
Studien dieser Arbeit widmen sich der Rolle der Antikörper als Teil der Immunantwort 
gegen M. pneumoniae mit der Frage: Verhindern oder verursachen diese Antikörper 
Mykoplasmen-bedingte Krankheiten?
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Hypothese: Wir nehmen an, dass Antikörper gegen M. pneumoniae vor einer Pneumo-
nie schützen, jedoch bestimmte Krankheiten des Nervensystems auslösen können. Im 
Speziellen möchten wir die Rolle dieser gegen M. pneumoniae gerichteten Antikörper 
untersuchen hinsichtlich (i) Besiedlung im Nasen-Rachen-Raum (Kolonisation), (ii) In-
fektion in der Lunge (Pneumonie), und (iii) M. pneumoniae-assoziierten neurologischen 
Erkrankungen wie Enzephalitis und Guillain-Barré-Syndrom (GBS), bei welchen eine 
Antikörper-vermittelte Autoimmunantwort vermutet wird.
Zusammenfassung der wichtigsten Ergebnisse dieser Arbeit:
Teil 1: Antikörper gegen M. pneumoniae – Schutz vor Krankheit
– Spezifische Immunzellen, sogenannte B-Zellen, sind für die Heilung der 
Infektion essentiell. Die von ihnen produzierten Antikörper eliminieren 
die Mykoplasmen in der Lunge. Hingegen bleiben die Bakterien im Nasen-
Rachen-Raum wochenlang bestehen. Bakterien wurden mit einem Fluo-
reszenzstoff kultiviert und dadurch erstmals während der Infektion visuell 
in der Lunge und den oberen Atemwegen verfolgt. Die Ergebnisse am neu 
entwickelten Mausmodell (C57BL/6-Mäuse) bestätigen klinische Beobach-
tungen bei Kindern, deren obere Atemwege im Anschluss an eine Infektion 
mit Mykoplasmen besiedelt blieben (Kapitel 2 und 4);
– Die Immunabwehr nach der Infektion unterscheidet sich wesentlich zwischen 
unteren Atemwegen (Lunge) und oberen Atemwegen (Nasen-Rachen-Raum): 
In der Lunge hat es mehr sogenannte IgM- und IgG-Antikörper sowie eine 
deutliche Zunahme und Aktivierung von B-Zellen in den lokalen Lymphkno-
ten – wodurch die Erreger innerhalb von Wochen zerstört werden. Im Gegen-
satz dazu hat es in den oberen Atemwegen IgA-Antikörper, keine Aktivierung 
von B-Zellen und demzufolge eine Persistenz des Erregers. Experimente mit 
Mäusen ohne B-Zellen liefern letztlich den Beweis, dass die in die Mäuse 
transferierten Antikörper die Bakterien in der Lunge effektiv zerstören, diese 
aber den Erreger in den oberen Atemwegen nicht eliminieren können (Kapitel 
2);
– Die Antikörperreaktion richtet sich gegen Eiweiss- und Fettstoffe der Zellhülle 
von M. pneumoniae. Antikörper, welche die Mykoplasmen in der Lunge eli-
minieren, sind gegen Eiweissstoffe gerichtet. Hingegen scheinen diejenigen 
gegen Fettstoffe nicht notwendig zu sein für die Heilung der Infektion (Kapitel 
3);
– Der Nachweis von spezifischen Antikörpern im Blut und M. pneumoniae in 
den oberen Atemwegen erlaubt es nicht zu unterscheiden, ob die Mykoplas-
men den Nasen-Rachen-Raum, also die Pforte zur Lunge, lediglich besiedeln 
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(Kolonisation) oder ob sie die Ursache der Pneumonie sind (Infektion). Der 
Nachweis spezifischer B-Zellen, welche die Antikörper produzieren (antibo-
dy-secreting cells, ASCs), ist hingegen ein effizienter diagnostischer Indikator 
einer Infektion mit Mykoplasmen – im Unterschied zu einer Kolonisation, bei 
der keine solchen B-Zellen im Blut des Patienten vorhanden sind (Kapitel 4);
– Diese spezifischen B-Zellen (ASCs) können mit einem eigens entwickelten 
Test (enzyme-linked immunospot assay, ELISpot) zuverlässig nachgewiesen 
werden. Dieser Test könnte in der Zukunft als neuer Standard (“Goldstan-
dard”) für die Diagnose der Mykoplasmen-Pneumonie verwendet werden 
(Kapitel 4).
Teil 2: Antikörper gegen M. pneumoniae – Auslöser der Krankheit
Teil 2.1: Enzephalitis
– Mykoplasmen sind nicht nur verantwortlich für Atemwegsinfektionen, 
sondern können bei Betroffenen auch zu Hirnentzündung (Enzephalitis) 
und Nervenerkrankung mit Empfindungsstörungen und Lähmungserschei-
nungen (GBS) führen. Verantwortlich dafür sind Antikörper, die nicht nur 
die Bakterien, sondern gleichzeitig die Hülle der körpereigenen Nervenzellen 
angreifen. Die grosse Ähnlichkeit von Fettstoffstrukturen der Zellhülle von M. 
pneumoniae mit körpereigenen Strukturen der Nervenscheiden führt dazu, 
dass sich die Immunabwehr sowohl gegen die Mykoplasmen als auch gegen 
die umhüllende Myelinschicht von Nervenbahnen richtet. Dabei handelt es 
sich um Antikörper, die ein bestimmtes Zucker-Fett-Molekül der Zellhülle 
von Mykoplasmen erkennen. Diese Antikörper binden gleichzeitig an Galac-
tocerebrosid (GalC), einer der häufigsten Bausteine im menschlichen Myelin. 
Diese fettreiche Substanz stellt die elektrische Leitfähigkeit der Nervenfasern 
im peripheren Nervensystem (PNS) und zentralen Nervensystem (ZNS) sicher. 
Wird sie zerstört, kommt es zu Lähmungen und Empfindungsstörungen (PNS) 
bzw. Bewusstseinseinschränkung (ZNS). Der Nachweis von Antikörpern 
gegen M. pneumoniae und gegen GalC in der Gehirn-Rückenmarksflüssigkeit 
(Liquor) bei Patienten mit Mykoplasmen-Pneumonie, welche im Verlauf eine 
Enzephalitis entwickeln, lässt einen Antikörper-vermittelten Krankheitspro-
zess (Autoimmunkrankheit) der zugrundeliegenden Enzephalitis vermuten 
(Kapitel 5–8).
Teil 2.2: Guillain-Barré-Syndrom (GBS)
– M. pneumoniae löst die Autoimmunkrankheit GBS aus, häufiger bei Kindern 
als bei Erwachsenen. Das GBS ist eine akute lebensbedrohliche Erkrankung 
der Nerven des PNS, die zu Lähmungen, Schwäche und Empfindungsstörun-
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gen an Armen und Beinen führt. Uns gelingt es erstmals, Mykoplasmen von 
einem GBS-Patienten im Labor zu kultivieren (Kapitel 10);
– Bereits zuvor wurden bei GBS-Patienten vereinzelt Antikörper gegen GalC 
nachgewiesen. Auch bei diesem Patienten finden sich solche, und ihre Kon-
zentration im Blut korreliert mit dem Krankheitsverlauf. Tatsächlich reagieren 
die Antikörper gegen GalC in immunologischen Tests am stärksten mit dem 
vom Patienten entnommenen und im Labor kultivierten Bakterienstamm. 
Auch weitere Mykoplasmen-Stämme reagieren, wenn auch schwächer, wohin-
gegen andere Bakterienarten nicht erkannt werden. Somit ist der Nachweis der 
Kreuzreaktivität des Anti-GalC-Antikörpers erbracht (Kapitel 10);
– Interessanterweise finden sich Anti-GalC-Antikörper auch bei Patienten ohne 
GBS, die kurz zuvor mit Mykoplasmen infiziert wurden. Allerdings sind diese 
ausschliesslich vom Antikörper-Isotyp M (Immunglobulin M, IgM), der im 
Verlauf einer Immun antwort am frühesten gebildete Typ (Kapitel 3 und 10). 
Die Anti-GalC-Antikörper bei GBS-Patienten sind dagegen vom Typ IgG 
(Kapitel 10). Dieser Wechsel des Antikörper-Typs könnte für die Entstehung 
von GBS mitverantwortlich sein;
– Diese Vermutung wird bekräftigt durch den Nachweis von ebendiesen Anti-
GalC-Antikörper vom Typ IgG im Liquor von GBS-Patienten (Kapitel 11) 
und Liquor von GBS-Kindern mit zusätzlich ZNS-Symptomen (Kapitel 9 und 
12).
Die Resultate dieser Arbeit bahnen den Weg für verbesserte diagnostische und therapeu-
tische Strategien für Erkrankungen verursacht durch M. pneumoniae. In der Diskussion 
(Kapitel 13) präsentieren wir einen Algorithmus für die klinische Beurteilung und 
das Management von Patienten mit Mykoplasmen-Pneumonien und Patienten mit M. 
pneumoniae-assoziierter Enzephalitis oder GBS. Kranke Kinder erhalten damit künftig 
eine gezielte und optimal wirksame antibiotische Therapie gegen die ursächlichen Bak-
terien. Als positiver Nebeneffekt wird zudem der Resistenzentwicklung von Bakterien 
entgegengewirkt.
Die Resultate können weiter helfen, spezifische Impfstoffe zu entwickeln, die das Immun-
system auf die Abwehr vorbereiten und eine Infektion verhindern würden. Basierend auf 
den Ergebnissen dieser Arbeit sollte ein solcher Impfstoff Eiweiss- und nicht Fettstoffe 
enthalten, damit sich die Immunabwehr ausschliesslich gegen die Mykoplasmen jedoch 
nicht gegen die umhüllende Myelinschicht von Nervenbahnen richtet.
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